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General Introduction
Tuberculosis (TB) is a major public health problem and  the second killer worldwide due 
to a single infectious agent. It is caused by bacteria from the Mycobacterium tuberculosis 
complex (tuberculosis, africanum, bovis, microtii, canetii and bovis BCG). More than 80% of all 
TB patients live in sub–Saharan Africa and Asia. In 2010, a worldwide incidence of 8.8 million 
individuals with active TB were registered and an estimated 1.4 million people died. The 
incidence of active TB  is slowly declining and the TB death rate dropped 40% between 1990 
and 2010.1  
Many countries worldwide, however, increasingly struggle with Non-Tuberculous Myco-
bacteria (NTM), especially those countries with declining incidence of TB.2,3  Next to M. 
tuberculosis complex, NTM are the second disease entity within the genus Mycobacterium. 
Other clinically relevant mycobacteria are Mycobacterium leprae which causes  leprosy and 
M. ulcerans, causing Buruli ulcer.  
This introduction discusses general, diagnostic and treatment  principles of TB and NTM 
diseases. We subsequently shift our focus to the Dutch situation for both disease entities.
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Tuberculosis 
A historical perspective and pathogenesis 
TB is an ancient disease, as has been demonstrated by studies  in which mycobacterial DNA 
was  isolated from mummies (±2050-500 B.C) by spoligotyping.4   The TB discovered in early 
mummies is a bovine form, proving TB has accompanied mankind since it started domesti-
cating cattle.  In 1882 Robert Koch identified the main causative organism, Mycobacterium 
tuberculosis.  In TB, bacteria are spread by airborne micro-droplets from an infectious 
patient. Transmission occurs when a second person inhales these infected droplets. After in-
halation, the bacteria are phagocytosed by macrophages in the alveoli. Provided there is an 
adequate  immune response, the bacteria are subsequently encapsulated and remain in the 
body in a low metabolic, dormant state (latent tuberculosis infection). Progression to active 
disease occurs in 5-10% of infected individuals. In 50% of these progressive cases, the disease 
develops within the first two years after infection (primary TB). Primary disease is most 
likely to occur in infants and children before 5 years of age, patients with advanced HIV 
infection or those using tumor necrosis factor (TNF) antagonists. Yet the remainder flares 
up years and years later when immune status is impaired due to ageing, malignant disease, 
immune suppressant drugs and other conditions (secondary or reactivated TB). 
Clinical presentations
TB has many appearances and may affect every organ of the human body, except hair and 
nails. The lungs are not only the portal of entry for M. tuberculosis, but they are the organ 
most likely involved clinically by the microbe (>50% of cases).5   Patients with TB may display 
widely variable symptoms. Typical respiratory complaints are productive cough, chest pain, 
hemoptysis, shortness of breath and hoarseness. Constitutional symptoms consists of mal-
aise, weakness, fever, night sweats and anorexia. Some patients, mainly the patients with 
pulmonary TB or disseminated TB, can be extremely ill, whereas others with paucibacillary 
TB tend to have only mild symptoms.
Diagnosis
Until now a definite diagnosis of TB is only made by the gold standard  (positive culture of 
Mycobacterium tuberculosis complex). The (sum of) Tuberculin Skin Test (TST), interferon 
gamma release assays (IGRA), Ziehl Neelsen staining of acid fast bacilli and Polymerase 
Chain Reaction (PCR) of M. tuberculosis complex give an indication in the direction of TB but 
are only supportive to the diagnosis. In case of  pulmonary TB with large cavities, culturing 
M. tuberculosis complex is not too difficult. In extrapulmonary or pediatric TB the diagnosis 
already becomes more challenging. Furthermore, diagnosing TB in a HIV positive patient 
with a low CD4 leukocyte count can be quite problematic at times. 
For a long time, the World Health Organization (WHO) propagated  diagnosing tuberculo-
sis in endemic regions with smear microscopy and (if available) radiography. In the era of 
raising incidences of drug resistant TB worldwide this is no longer sufficient, as we need the 
mycobacterial strain from culture to perform drug susceptibility testing. 
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Knowing that in 2009 only 12% of the estimated 250,000 prevalent multi drug resistant TB 
cases could be identified, we may call this WHO policy outdated now.6  Internationally, es-
pecially in endemic regions, there is an urgent need for mycobacterial culturing facilities and 
adequate trained personnel. The recent introduction of the GeneXpert® in 2010 was a big 
step towards possible fast and accurate diagnosis of probable drug resistant tuberculosis,  
yet the high price of this PCR-based diagnostic method is still an issue to overcome, espe-
cially for the resource-limited settings where drug resistant TB is most prevalent.
Treatment of tuberculosis: history, current treatment and optimization of treatment
Improved socio-economic conditions during the industrialization period in the last century 
lowered the incidence of tuberculosis. Effective treatment, however, did not exist until the 
forties of the previous century. Resting, adequate nutrition and fresh air in TB sanatoria 
could actually cure a quarter of the TB patients, another 25% developed a chronic form of TB 
and the rest died of TB. Collapsing the lung in order to cure tuberculosis was the last major 
thrust of clinicians before the modern era of chemotherapy.  The first antituberculosis drugs 
on the market were streptomycin and para aminosalicylic acid (PAS).7  
Soon after the introduction of these drugs it became evident that monotherapy was readily 
inducing drug resistance and the concept of combined drug therapy for TB was born.8
From 1952 isoniazid was introduced and combination therapy of streptomycin in the first 3-6 
months together with isoniazid and PAS resulted in cure rates of 90-95%. Unfortunately, it 
required up to 24 months of continuous treatment to achieve this goal.7,9  With the introduc-
tion of rifampicin and pyrazinamide, success rates of 95-97% were reached in the registration 
studies7,9 and the shortened treatment duration from 12 to 6 months in 1993 was considered 
a big leap forward. 
Although this treatment regimen is theoretically still highly effective, in practice global 
treatment success rates are only 86% on average.6 Current TB treatment needs optimization 
as its long duration, adverse events and suboptimal pharmacokinetics lead to treatment 
failures, relapses and emergence of drug resistance and as a result: ongoing transmission in 
practice.10 
From a classical clinical pharmacological perspective, pharmacokinetics and pharmacody-
namics determine the eventual effect of TB drugs. The relation between the actual drug 
dose taken and the (time course of) plasma drug concentrations achieved is described by 
the pharmacokinetics of the drugs. 
The plasma concentrations are related to treatment outcome (including problems of sub-
optimal response, emergence of resistance and adverse events) as determined by phar-
macodynamics. Therefore, plasma drug concentrations are an important intermediary link 
between the dose administered and the desirable and undesirable effects. 
From the schematic interplay between adherence, pharmacokinetics and pharmacodynam-
ics in figure 1 it can be easily understood that factors such as suboptimal treatment regi-
mens, non adherence, low plasma drug concentrations and resulting drug resistance, alone 
or in a combination, form threats for effective treatment. 
Other co-factors influencing treatment outcome are for example the localization and exten-
siveness of disease or HIV infection.  On itself, HIV infection also raises the lifelong incidence 
rates of TB. Drug resistance, merely a manmade problem, is a result of the administration of 
inadequate regimens and/or non-adherence to therapy together with the spontaneous 
mutation capacity of mycobacteria during treatment.11 Iseman referred so aptly to the devel-
opment of drug resistance by his article titled: “Extensively drug-resistant Mycobacterium 
tuberculosis:  Charles Darwin would understand”.12
Figure 1. 
From this schematic interplay we can also understand that shortening treatment regimens 
may be a key to improve treatment success rates.13  Shortening TB treatment by optimizing 
rifampicin pharmacokinetics resulting in faster culture conversion to shorten TB treatment 
has been propagated since 200311,14-16 and is currently subject of clinical trials. With rifampicin 
we seem to be at the lower end of the dose response curve and we also know from pharma-
cokinetic studies in the last two decades that many TB patients have low serum concentra-
tions.
 At the introduction of rifampicin to the market issues as high costs, feared toxicity and the 
urgent need for an effective sterilizing regimen led to the choice of  600 mg of rifampicin.14,16 
Unfortunately, data regarding both the pharmacokinetics and pharmacodynamics of TB 
drugs are limited. Clinical trials of higher dosages of rifampicin are currently underway but 
to perform dose finding studies first, then tolerability and toxicity studies and lastly large 
phase III trials it will take quite some time before appropriate proof will be available. [clinical 
trials.gov Identifier: NCT01392911 /NC T00760149].
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1
“The clinical pharmacological view 
of TB treatment”
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As illustrated above  diagnostics and treatment both need to be optimized and much work 
has to be done to achieve the Stop TB partnership goal of reducing the global incidence of 
active tuberculosis to less than one per million population per year in the year of 2050.17
However, tuberculosis research is complicated due to long duration of treatment, the lack 
of surrogate markers for response, a follow up relapse detection period of at least one year 
and the lack of well equipped research sites in endemic regions. 
The current problem of rapidly expanding multi-drug-resistant tuberculosis understand-
ably distracts researchers’ attention from drug susceptible TB to the development of new 
drugs for drug resistant TB. However, limiting TB transmission by offering optimized first 
line therapy schemes in terms of treatment duration might prove to be  more effective to 
control the epidemic.18
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Non-Tuberculous Mycobacterial Pulmonary diseases
A historical perspective and pathogenesis 
In the last decades, the incidence of NTM infections is increasing worldwide due to factors 
including improved detection methods, advancing age, increasing incidence of COPD, wide-
spread use of antibiotics and immunomodulating drugs, and greater awareness of clinicians 
that these pathogens are able to cause serious disease in humans.2,19-20
After the discovery of the main culprit in tuberculosis pathogenesis, ‘mycobacteria other 
than M. tuberculosis’ were subsequently discovered from animals and the environment, 
especially in water and soil.21 Likewise, these mycobacteria can be detected microscopically 
with Ziehl Neelsen and auramine staining as well as TB. Macroscopically, they exhibit dif-
ferent growth patterns from M. tuberculosis complex.  NTM were first classified in 1959 by 
Runyon, into four groups on the basis of growth rates and pigmentation under the influence 
of light.22 This classification is summarized in table 1. 
The route of infection is by ingestion (food) or inhalation (shower). NTM infections are not 
transmissible from person to person. Dormancy, as in TB, is not known for NTM infections.
Group Characteristics Clinically most important species
I Slow growth; pigmentation after exposure to light M. kansasii, M. szulgai, M. simiae
II Slow growth; pigmentation without light exposure M. xenopi, M.gordonae, M. scrofulaceum
III Slow growth; no pigmentation M. avium, M.intracellulare, M. malmoense
IV Rapid growers M. abcessus, M. fortuitum, M.chelonae
Table 1.  Classification of Non Tuberculous Mycobacteria
Clinical presentations
With this classification microbiology laboratories were now able to identify different spe-
cies of NTM and this resulted in the characterization and distinction of clinically relevant 
diseases. Manten was the first to focus on the issue of clinical relevance of NTM in The Neth-
erlands in 1965.23  TB resembling pulmonary NTM disease by M. kansasii, cervical lymphadeni-
tis  in children by M. scrofulaceum, skin disease by M. marinum (fish tank granuloma) were 
commonly found diseases.2 Either systemic (HIV infection) or local (bronchiectasis, coal 
miners lung) defects of the immune system are facilitating the growth of NTM’s causing 
clinically relevant disease. 
Pulmonary NTM disease can present radiologically with cavities, nodules and bronchiectasis 
but also as a hypersensitivity pneumonitis with diffuse infiltrates and nodules and a mo-
saic pattern on CT scan.24-25  The clinical course of NTM is generally more prolonged than 
in TB and patients present with cough, fatigue, fever and weight loss, depending on the 
underlying lung disease and NTM species. Extra pulmonary NTM disease is rare, except for 
lymphadenitis caused by M. scrofulaceum or M. avium in children below 6 years of age.26 
Dissiminated extra pulmonary NTM disease generally affects immunocompromised patients 
(HIV or after organ transplant). The above described NTM disease is mainly caused by slowly 
growing NTM. Rapid growers (especially M. abcessus) cause difficult to treat eye and ear 
disease as well as pulmonary disease in patients with cystic fibrosis.27-30 
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Diagnosis
Contrary to TB, it is possible to encounter NTM bacilli from sputum (coincidental presence 
in the respiratory tract or due to contamination of the sample during collection) on one or 
more occasions without clinical significance.2  This makes positive NTM cultures difficult to 
interpret for many clinicians. To diagnose clinically relevant NTM disease it is necessary to 
collect clinical data, perform radiological tests, grow microbiological cultures and subse-
quently have the NTM strain determined. 
To differentiate  clinically relevant from non clinically relevant NTM disease, the American 
Thoracic Society (ATS) has published criteria to aid in this diagnostic process.2  These criteria 
are a combination of clinical and radiological features together with microbiological data. In 
The Netherlands, these criteria are increasingly adopted by clinicians. 
Table 2:  Summary of the American Thoracic Society diagnostic criteria2 for pulmonary NTM  
 infections
Clinical
1. Pulmonary symptoms, nodular or cavitary disease on chest radiograph, or an HRCT scan that shows 
 multi focal bronchiectasis with multiple small nodules. 
 And
2. Appropriate exclusion of other diagnoses. 
Microbiological
1.         Positive culture results from at least two separate expectorated sputum samples.
2.         Positive culture results from at least one bronchial wash or lavage.
3.         Transbronchial or other lung biopsy with mycobacterial histopathologic features    
            and positive culture for NTM or biopsy showing mycobacterial histhopathologic    
            features and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either    
            infrequently encountered or that usually represent environmental contamination.
5.         Patients who are suspected of having NTM lung disease but who do not meet the diagnostic 
            criteria should be followed until the diagnosis is firmly established or excluded.
6.         Making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, 
            which is a decision based on potential risks and benefits of therapy for individual patients.
Patients who meet these criteria are likely to have true pulmonary NTM disease; their NTM isolates can be considered 
clinically relevant.
15
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Treatment of NTM disease: history, current treatment and optimization of  treatment
In the first years after the discovery of the NTM as causative organism of disease it was 
thought that surgery was the only treatment option.23  Observational studies of NTM dis-
ease treated with drugs formed the basis for the few randomized controlled trials conduct-
ed so far. The first prospective trial of treatment of M. kansasii infections was published in 
1994 by the British Thoracic Society (BTS).31 
In the same period, studies of macrolide based multi-drug therapy for M. avium infections 
were published. Together with the experience from dissiminated M. avium infections in HIV 
infected patients we learned that NTM disease is curable with multidrug regimens consist-
ing of rifamycins, ethambutol and macrolides33  although consensus about the most favour-
able treatment regimen is still not reached due to conflicting results of important random-
ized controlled trials. Especially the benefit of macrolides for treatment of pulmonary NTM 
disease in non-HIV infected individuals remains controversial.2,33
Further studies are needed, especially in NTM disease caused by species other than M. 
avium complex and M. kansasii, which are mostly even harder to treat.27,34-35  
In TB the sequence of adherence to drug treatment, pharmacokinetics and pharmacody-
namics has been subject to several studies so far. In NTM disease there are only a few, 
though important, publications from Wallace36 and Peloquin37  which unfortunately never 
resulted in a reevaluation of dosing strategies until now. 
Considering the available evidence so far we feel it calls for optimized dosing regimens in 
NTM disease as we understand from the studies in TB patients that suboptimal plasma con-
centrations may lead to treatment failure and relapses.11  Considering all the above it always 
remains important to emphasize that the decision to institute drug therapy in NTM disease 
should be based on the evaluation of potential risks and benefits for the individual.2
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TB referral centers in The Netherlands
From the introduction of effective drugs along with an excellent public health protocol of 
contact tracing and screening of immigrants, The Netherlands has decreased incidences of 
tuberculosis to an average of 6.5 : 100,000 person/year in 201038  Only Scandinavian coun-
tries and the United States of America have comparatively low incidences. 
In native Dutch individuals, the incidence is even lower: immigrants show much higher 
incidences of tuberculosis. In The Netherlands, 1000 cases of active tuberculosis emerge 
every year, of which 50% are diagnosed by pulmonary diseases specialists, 25% by the public 
health TB doctors and the rest by infectious disease specialists and others. The low inci-
dence undoubtedly is a very exciting development. Yet this declining incidence also means 
progressively less exposure of doctors to tuberculosis, leading to more doctor’s delay, more 
difficulties in diagnosing TB (especially in smear negative and extrapulmonary TB) and sub-
sequently increasing morbidity and possibly higher transmission rates in the community.39
For this reason, the Dutch tuberculosis foundation (KNCV) has introduced the National 
Tuberculosis Consultants in 1983. These pulmonary disease specialists can be consulted by 
colleagues in case of difficulties in diagnosing or treating tuberculosis. The four consultants 
work in the two national referral centers for tuberculosis (Dekkerswald, Groesbeek/ Beat-
rixoord, Haren) where complex tuberculosis patients can be hospitalized for treatment or in 
case of necessity of (forced)  isolation. 
In practice, individuals with HIV infection, multi or extensive drug resistant tuberculosis, 
toxic drug reactions, severe co-morbidity, substance abuse, psychiatric disorders or home-
lessness are hospitalized for some time during treatment. Also patients with complex NTM 
disease are increasingly hospitalized in these TB referral centers as their prevalence among 
the largest patient population of a respiratory disease specialist (i.e. COPD patients) is 
increasing and clinically relevant disease necessitating drug treatment may lead to serious 
morbidity. In general, hospitalization rates in both referral centers have increased signifi-
cantly in the last few years (rapport KNCV 2010). 
Nowadays, around 200 patients are hospitalized in a referral centre each year. Having all 
possible study techniques and of course the financial means to offer patients the most 
optimal treatment under supervised circumstances we are able to perform epidemiological, 
diagnostic and pharmacological studies in these institutes at an academic level.
17
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Aims and outline of this thesis
This thesis covers a range of subjects related to TB and NTM disease. By addressing epidemi-
ological, diagnostic and pharmacological issues both in tuberculosis and NTM lung disease, 
we provide an overview of activities in a tuberculosis referral centre in The Netherlands. 
Chapter 2 and 3 are devoted to epidemiological aspects of TB and clinical characteristics of 
the patients involved.  Chapter 2 describes the population of TB referral centre Dekkerswald 
in the period 2000-2005. After this study we hospitalized, in a short period, three female 
native Dutch immunocompromised patients with TB caused by M. bovis in Dekkerswald. We 
became interested in the current prevalence and characteristics of M. bovis TB. 
Chapter 3 describes these cases together with the current epidemiology and characteristics 
of patients with M. bovis in The Netherlands. 
Chapter 4 has its focus on TB diagnostics. With data provided from the Netherlands Tuber-
culosis Registry we investigated all cases from 2007-2009 that were not culture confirmed. 
We investigated how and where diagnosis was made, why culture result was negative or 
why culture was not performed. We classified these non-culture confirmed diagnoses in 
‘no’, ‘possible’, ‘probable’, and ‘confirmed’ TB, according to the European Centre of preven-
tion and Disease Control (ECDC)  TB case definitions for the accuracy of the diagnoses. 
Chapter 5, also focusing on diagnostics, is a study of spinal TB diagnoses. We investigated 
whether a decreasing TB incidence leads to increase of diagnostic delays in The Netherlands 
in the period 2000 to 2011. We studied patient records at the public municipal TB services 
and compared results with data provided from the Netherlands Tuberculosis Registry. We 
describe current epidemiology and characteristics of patients with spinal TB.
After diagnostics we switched to pharmacokinetics of TB and NTM treatment. Chapter 6 
describes the pharmacokinetics of TB patients admitted to tertiary referral TB centers in The 
Netherlands and compares results with data from the literature. We assessed with linear re-
gression analysis the sampling points correlating best with the area under the concentration 
versus time curve (exposure). This may enable more convenient yet sufficiently accurate 
estimation of exposure in future drug trials and in patient care. Chapter 7 focuses on the 
pharmacokinetics of patients in Dekkerswald suffering from a recurrent TB. 
These patients all suffered from a cavitary TB and showed absorption problems due to 
alcohol abuse, gastric surgery in the past and diabetes mellitus. We performed dose adjust-
ments based on plasma concentration measurements (Therapeutic Drug Monitoring) and 
evaluated its effect on treatment outcome and adverse events.  In chapter 8, the pharma-
cokinetics of drugs in NTM pulmonary disease were evaluated. 
We studied the interactions between rifampicin, ethambutol, isoniazid, moxifloxacin, 
azithromycin and clarithromycin. 
Finally, in chapter 9, the summary and general discussion, the results of the studies de-
scribed are summarized. Subsequently the implications from our studies for future TB care 
and prevention, as well as possible future research directions are discussed. 
Chapter 1
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Abstract
Objective: to describe the patient population in Dekkerswald, Nijmegen, one of two tuber-
culosis (TB) centres in The Netherlands. 
Design: descriptive, retrospective study.
Method: examination of medical records for all TB patients hospitalized between 2000 and 
2005, including demographic, social, clinical and follow-up data.
Results: data from 166 patients were analysed. Tertiary referrals accounted for 98% of 
all hospitalisations. Most patients (68%) were referred for clinical reasons, and 32% were 
referred for social reasons. Drug resistance was encountered in 23% of patients; 9% had 
multidrug-resistant TB. Ten percent of patients were seropositive for HIV. Toxicity and side 
effects of treatment often led to changes in treatment (40%). Patients had pulmonary TB 
(59%), extrapulmonary TB (23%) or both (17%). Overall, 141 patients (85%) completed treat-
ment. The TB-related mortality rate was 5%.
Conclusion: in Dekkerswald, there is a selected patient population that is characterised by 
drug-resistance, comorbidity, side-effects, extrapulmonary disease and social issues. Due to 
the low prevalence of TB in The Netherlands, knowledge and experience regarding complex 
types of TB are limited. Centralisation of patient care is important to preserve and optimise 
this expertise
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Introduction
Tuberculosis (TB) is an infectious disease and until the mid-1980s its incidence in the Neth-
erlands gradually decreased and was mainly limited to risk groups. Since 1987 the incidence 
increased as a consequence of immigration.1 This effect has also been observed in other Eu-
ropean countries.2-5 Other determinants of the rising incidence, which persisted until 1994, 
were international travel for work and tourism and HIV infections.6-7 After 1994 the number 
of new cases fell to 8 per 100,000 inhabitants (about 1100 cases) per year.1,6
In The Netherlands, TB patients are mostly treated by a pulmonologist (52%), a public health 
physician active in the area of tuberculosis control (24%), or an internal medicine specialist 
(12%).1 Patients with a complex form of TB or with complications in the disease progression 
are often referred to a centre. In the practice guideline ‘Medical treatment of tuberculosis 
2005’ contacting a tuberculosis expert is advised for certain forms of TB.8
The University Centre for Chronic Diseases Dekkerswald is part of University Medical Centre 
Nijmegen. Dekkerswald is one of the two TB centres still active in The Netherlands; the 
other is Beatrixoord in Haren. 
Dekkerswald also has clinical and outpatients departments for general pulmonary diseases. 
The Dutch TB centres focus not just on the treatment of patients with complex forms of TB 
and the problems associated with this, but are also active in preventing the spread of the 
disease, in education, in providing consultancy and advice to support other professional 
practitioners, and in carrying out scientific research.9 Problems in the areas of resistance, 
medication, comorbidity, surgical interventions and treatment compliance are taken care of 
with an interdisciplinary approach. However, whether this approach leads to higher treat-
ment success rates is not known.
Data from TB patients and treatment outcomes from Dutch TB centres have not been 
published previously, although in 2000 outcomes concerning multi drug resistant TB were 
reported from the two centres.  In this article we describe the population of TB patients in 
Dekkerswald, admitted during the period 2000-2005, to provide insight to demographic, 
clinical and social characteristics.
Patients and Methods
From all patient records admitted at least two days in the period 2000-2005, demographic 
and clinical data were registered, as equally the reason for referral, resistance patterns and 
follow-up. A distinction was drawn between pulmonary TB, extrapulmonary TB, which 
included pleural tuberculosis, and combined pulmonary and extra pulmonary TB. The 
National Institute for Public Health and the Environment (RIVM) performed determination, 
genotyping and susceptibility tests.
‘Mono-drug resistance’ was defined as resistance against just one anti-TB drug and ‘poly-
drug resistance’ as resistance against at least two drugs other than isoniazid and rifampicin. 
‘Multi-drug resistance’ was defined as resistance towards at least isoniazid and rifampicin. 
Patients of foreign origin were defined as patients not born in The Netherlands.
A serious adverse effect was defined as each reaction that resulted in the suspension of the 
treatment with one or more anti-TB drugs or other medication, except for analgesics.
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Hepatotoxicity was defined as an increase in the serum transaminase activity (aspartate 
aminotransferase (ASAT) or alanine aminotransferase (ALAT)) above 50 U/l and severe 
hepatotoxicity as transaminase values above 500 U/l. Inflammatory immune-reconstitution 
syndrome in HIV-positive patients was defined as a paradoxical deterioration of pre-existent 
infectious diseases after the start of highly active antiretroviral therapy (HAART). Compari-
sons between groups were assessed using the chi-squared test.
Results
A total of 166 patients were included in the study. Table 1 provides general and demographic 
details of the study population, classified according to land of origin. The population con-
sisted of 37 different nationalities; 14% (n=23) were from Surinam, Turkey or Morocco. 
Referral. Severe hepatotoxicity was the principal reason for referral (n=18) followed by 
delayed response to treatment (n = 17), surgical interventions mainly for spondylodiscitis 
(n=12), combined HIV-TB infection (n=11), resistance problems (n=11) and need for isolation 
(n=9). Social reasons for referral included homelessness and substance abuse.
Table 1.  Characteristics of 166 tuberculosis (TB) patients admitted to Dekkerswald, 
 Nijmegen in the period 2000-2005.
*      Resistant to just one anti-TB drug
**    Resistant to at least two drugs other than isoniazid and rifampicin
***  Resistant to at least isoniazid and rifampicin
Origin
Netherlands (n=50) Abroad (n=116) Total (%) N = 166
Gender
Male 35 80 115 (69)
Female 15 36 51 (31)
Mean age in years (limits) 56.3 (15-90) 34.2 (16-74) 40.8 (16-90)
Referral indication
Clinical reason 33 80 113 (68)
Social reason 17 36 53 (32)
Referred by
Other hospital 29 69 98 (59)
Municipal health service 11 30 41 (25)
General Practitioner 2 3 5 (3)
Radboud UMC 6 12 18 (11)
Other 1 0 1 (1)
Via outpatients clinic Dekkerswald 1 2 3 (2)
Sensitivity; no. strains (n=49) (n=116) (n=165)
Normal 42 73 115 (69.7)
Mono-drug resistant* 2 14 16 (9.7)
Poly-drug resistant** 0 5 5 (3.0)
Multi-drug resistant*** 0 14 14 (8.5)
Unknown 5 10 15 (9.1)
HIV (n=49) (n=114) (n=163)
Positive 3 14 17 (10)
Negative 24 77 101 (62)
Not tested 22 23 45 (28)
Diagnosis
Pulmonary TB 39 59 98 (59)
Extrapulmonary TB 5 34 39 (23)
Pulmonary and extrapulmonary TB 6 23 29 (17)
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Anti-tuberculosis drugs resistance 
For 93% of the patients (n=155) TB diagnosis was confirmed with a positive culture result 
(the gold standard); for 11 patients this was not possible. In these non-culture confirmed TB 
cases clinical and radiological response to treatment was observed.
Resistance patterns were determined for 150 strains; in five cases the data were missing in 
the medical files. Thirty-five strains (23%) had an abnormal drug susceptibility. Resistance 
against isoniazid (n=18), rifampicin (n=15) and streptomycin (n=20) were the most frequent. 
Of the resistant strains, 94% (33/35) were isolated from patients of foreign origin (p<0.0001). 
Seventeen patients had previous TB treatment in their case history. Nine of them had an 
abnormal resistance pattern and two had multi-drug resistant TB. Poly-drug resistant TB oc-
curred more frequent in patients who underwent previous treatment. Three patients who 
had previous treatment a reactivation could be established because DNA fingerprints con-
curred with those of the earlier episode. For the other 14 patients these data were missing.
HIV and TB. Equal numbers of Dutch and foreign patients were not tested for HIV. This was 
mainly the case in patients with a negative test result in the past or older patients with a 
lower prior chance of HIV infection. 
Immune reconstitution syndrome only occurred in those patients who started HAART dur-
ing the first 2 months of the TB treatment (8/17).  
Adverse effects. Table 2 shows the adverse effects that occurred in the study population. 
Sixty-six (40%) of the patients were treated with second-line anti-TB drugs due to adverse 
effects or resistance. In 53 patients one or more of these drugs became a permanent part of 
the treatment. 
The most prescribed were amikacin, levofloxacin and moxifloxacin. Fourteen HIV-positive 
patients (82%) experienced adverse effects during treatment, mainly hepatotoxicity. Almost 
60% of them (n=10) had therapy changes as a result of adverse effects and interactions. 
Extrapulmonary TB. Foreign born patients presented significantly more with extrapulmo-
nary TB (p <0.01). In particular, patients from African countries (p <0.02) and Eastern Medi-
terranean regions (p <0.001) had more extrapulmonary TB. For many patients it concerned 
more than one extrapulmonary localisation, as illustrated in Table 3. 
In our population, HIV-positive patients did not present significantly more extrapulmonary 
TB than HIV-negative patients.  
Admission period. The median admission period for the total population was 10.1 weeks 
(limits 0.6 - 38.1). There was no significant difference in duration of admission between 
patients who were admitted for clinical or social reasons or between patients of Dutch or 
foreign origin. 
HIV patients, however, were admitted longer (median 15.7 weeks; limits 10.1 - 28.0) than HIV-
negative patients (median 10.6 weeks; limits 0.6-38.1 weeks). Treatment success. Hundred 
and forty one patients (85%) completed treatment (TB patients are only officially considered 
cured if no reactivation has occurred after 2 years). In six percent of the cases (n=10) no 
data concerning treatment completion after discharge from hospital were found. TB-related 
mortality was 5% (n=8).
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Adverse effect n (%)
None 77 (46)
Unknown 3 (2)
Hepatotoxicity 64 (39)
Skin reactions 7 (4)
Neurotoxicity 5 (3)
Arthritis/gout 4 (2)
Ototoxicity 2 (1)
Eye disorders 1 (1)
Isoniazid fever 1 (1)
Allergic response 1 (1)
Drug fever 1 (1)
Total 166 (100)
Table 2.  Adverse effects of anti-tuberculosis drugs in 166 tuberculosis patients admitted to  
 Dekkerswald, Nijmegen, during the period 2000-2005
Discussion
In this era of a gradually decreasing TB incidence, patient care appears to be increasingly 
concentrated in specialised centres. Dekkerswald is one of these centers and wishes to 
retain this expertise in the future. The patient population is characterised by complexity 
as a consequence of (multi)drug resistance, or HIV co-infection, adverse effects, extra 
pulmonary TB and social problems. Despite this complexity, the interdisciplinary approach is 
leading to high treatment success rates in our study population.
Virtually the entire population was referred from other hospitals and from municipal health 
services. The 3 patients from the population who were admitted via our own outpatients 
clinic are typical of the number of patients that present to the average pulmonologist in The 
Netherlands. 7 
Table 3.  Extrapulmonary TB localisations in 68 of 166 tuberculosis patients admitted to   
 Dekkerswald during the period 2000-2005.
Extra pulmonary localisation* n (%)
Lymphnode 25 (28)
Spine 16 (18)
Pleura 11 (13)
Central nervous system 9 (10)
Miliary tuberculosis 8 (9)
Gastro-intestinal localisation 5 (6)
Musculoskeletal localisation 2 (2)
Pericardium 2 (2)
Urogenital tract 2 (2)
Ear Nose Throat area 1 (1)
Hepatobiliary area 1 (1)
Total 88 (100)
*More than one localisation could occur per patient 
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Resistance problems are an important reason for referral to Dekkerswald. Multi 
drugresistant TB is a very rare phenomenon in the Netherlands (1-2% per year, which is 
equivalent to 10-12 cases per year).7 In the study population, however, multi drugresistance 
was far more prevalent. Interestingly 85% of the multi drugresistant TB patients had good 
treatment outcome. This is high compared to the European and international figures9-14 and 
illustrates the importance of treating multi drugresistance in specialized centres.12,15-16 
A concomitant infection with HIV and TB is also rare in the Netherlands (n = 60; 5% of 
the total number of TBC patients in the Netherlands/year).7 In the study population 
this percentage was ten percent. Not all patients were tested for HIV although that is 
recommended as standard policy. The patient group described was complex due to the 
large number of adverse effects, interactions and immune reconstitution syndrome. This 
was translated in a longer median admission period. 
The low incidence of TB in The Netherlands leads to decreasing experience of treating 
physicians with toxicity and adverse effects of treatment. The occurrence of adverse effects 
therefore often results in consultation of our centre. A proportion of these patients are 
subsequently referred to Dekkerswald due to the complexity of their case, the expected 
longer admission period or the use of second-line anti-TB drugs. Hepatotoxicity is the most 
frequent adverse effect. The definition of hepatotoxicity of transaminase level increases > 
50 U/l appears to be very strict. For an asymptomatic transaminase increase up to maximum 
of 5 times the reference value, no adjustment of the medication policy is, in principle, 
necessary.17 Only if a rise in the transaminase level is accompanied by symptoms or is 
greater than 5 times the reference value, there is an indication for temporarily suspending 
the administration of the medication.18 Recently, a high risk of hepatotoxicity was described 
for HIV-positive patients.19 In our study population, patients with HIV co-infection also 
experienced relatively more hepatotoxicity. 
The presence of extrapulmonary TB within the population described did not deviate 
from that of the Dutch population in general. In recent years this has been about 40%.20-21 
Patients of foreign origin more often have extrapulmonary TB;20,22 this was also seen in the 
study population.  In recent years there has been an increase in the prevalence of bone 
and joint TB in The Netherlands within the group of extrapulmonary TB.23 This increase is 
5-7% and is mainly visible in older (> 65 years) Dutch patients.7 Due to a possible indication 
for surgical treatment in the case of spondylodiscitis24 this was often a reason for referral 
to Dekkerswald. Social factors are an important reason for referral to our centre. Illegal 
immigrants, prisoners, alcohol and drug addicts, and the homeless often need intensive 
supervision to complete treatment. In these groups the chances of not completing 
treatment are higher with consequently an increased risk of recurrent TB or acquired 
resistance.25-26 
An interdisciplinary team of nurses, a social worker, dietician, activities supervisor, pastoral 
care worker and a physiotherapist supervise these patients intensively. Within the study 
population no difference was seen in treatment result or admission period between 
patients with a clinical or a social reason for admission. 
Treatment results, based on percentages of completed treatments, were slightly higher in 
our centre than the national average (86% versus 84%)(7). The mortality was the same(7). 
In view of the complexity and comorbidity within our population a lower success rate or a 
higher mortality could be expected.
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In conclusion, the population of TB patients admitted to Dekkerswald had good treatment 
results despite the complexity and diversity of the population. In view of the number of 
admissions to our centre a need would appear to have been met. 
The sanatoria might have disappeared from the Netherlands27,27 but TB will never disappear 
completely. Especially with decreasing incidence there is an ongoing need for TB referral 
centres where knowledge and experience can be maintained due to the concentration of 
patient care, consultations, education and research. Furthermore the current international 
threat of extensive drugresistant TB poses a challenge to Dutch healthcare with respect to 
anticipation of prevention and treatment.
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Abstract
In the Netherlands, 1.4% of the tuberculosis (TB) cases is caused by Mycobacterium bovis. 
After we admitted three patients with M. bovis infections in our reference hospital we 
conducted a retrospective analysis of all M. bovis disease in the Netherlands during 1993-
2007. We analysed data from 231 patients for clinical, demographic, treatment and outcome 
characteristics and for risk factors.
Most patients were native Dutch (n=138; 59.7%), or Moroccan (n=54; 23.4%). Disease was 
mainly extrapulmonary (n=136; 58.9%). Although 95 patients had pulmonary disease, 
person-to-person transmission did not occur, as shown by structural DNA fingerprinting 
analysis. Lymph node TB was more likely to develop in women (p< 0,0001), whereas 
pulmonary M. bovis disease developed more frequently in men (p< 0,0001).  Diagnosis 
was accurate but delayed and led to inadequate treatment in 26% of the cases, in terms of 
content and duration. Proportion of deaths from M. bovis disease was higher than that for 
M. tuberculosis disease.
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Introduction
Mycobacterium bovis disease was common in the Western world in the era before 
pasteurization of milk products. In 1938, the percentage of M. bovis disease among all 
patients with tuberculosis (TB) was 9% in Amsterdam and 11% in the rest of The Netherlands. 
In 1940, pasteurization became obligatory and in 1952, the percentage of M. bovis disease 
had dropped to 1.5-2.0% in Amsterdam.1-2 From 1945 to the mid-1960s, M. bovis was gradually 
eradicated in livestock in The Netherlands. Nevertheless, during 1973-1975 around 2.5% of 
the human TB cases in The Netherlands were still caused by M. bovis.3
Since 1993, only ten cases of M. bovis infections have occurred in livestock in The 
Netherlands. All were caused by infected livestock that have been imported (D. Bakker, 
personal communication). Because most M.bovis infections are contracted through the oral 
route, extrapulmonary manifestations were primarily observed. Diagnosing extrapulmonary 
TB is generally difficult, and as the prevalence of TB has declined, the experience of 
physicians in diagnosing this specific infectious disease has also decreased, and therefore 
the time to diagnosis has increased.4-5   The difficulties in the diagnosis and treatment 
of M. bovis infections in 3 female patients in the University Centre for Chronic Diseases 
Dekkerswald prompted the present study. To investigate the magnitude of M. bovis 
infections in persons in The Netherlands, we conducted a retrospective study of patients 
with M. bovis infections and describe the epidemiologic, clinical and bacteriologic findings. 
Materials and Methods
We retrieved data from two databases; one at the National Institute for Public Health and 
the Environment (RIVM), Bilthoven, The Netherlands, which contains the bacteriologic 
information of all M. tuberculosis complex isolates in the Netherlands. The other is the 
Netherlands Tuberculosis Register (NTR), an anonymous case register held by KNCV 
Tuberculosis Foundation in The Hague, The Netherlands. 
This database is based on a voluntary registration, but contains data of virtually all TB 
patients in The Netherlands.  The patients in the NTR database have been registered by 
their physicians. This register holds basic information on demographic, clinical and some 
bacteriologic data. Death is registered as TB-related or not-TB-related without further 
explanation. Treatment and treatment outcome are registered without further details. 
Exact treatment length could be determined because length was registered in 2 different 
categories. Therefore, we could categorize treatment length in 6 groups, namely <3 
months, 4 -5 months, 6 months, 7-9 months, 10-12 months and > 12 months.
We selected all M. bovis cases that occurred during 1993 - 2007. By using these two 
databases we had information on bacteriologic and clinical factors, demographic 
data, risk factors, as well as treatment and outcome. We used the RIVM database for 
the bacteriologic data and localization of the infections and the NTR database for the 
demographic and clinical data, including treatment outcome. 
To distinguish M. bovis caprae and M. bovis bovis cases, we reviewed available IS6110 
restriction fragment length polymorphism (RFLP), spoligotyping and pyrazinamide 
susceptibility data of all M. bovis isolates analysed in this study.6-7
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Because IS6110 RFLP typing of all M. tuberculosis complex isolates is routinely performed in 
the Netherlands, we also analyzed information on possible interhuman transmission of 
M. bovis.  Associations between localisation of infection in the patient, geographic 
distribution, ethnicity, etc. were evaluated on basis of information from both databases 
by using the Χ2 test. Mortality rates were evaluated by using the NTR database and were 
correlated with the demographic and clinical data.
Case reports
         Patient 1
A 73 year old female patient sought treatment for non-productive cough and 
dyspnoea. Medical history included severe rheumatoid arthritis, for which 
she had received treatment with anti-Tumor Necrosis Factor-α (anti-TNF-α) 
treatment for 1 year. High resolution Computed Tomography (CT) imaging of 
the thorax showed micronodular lesions in both lungs. CT imaging of the brain 
indicated several cerebral nodular lesions, suspected to be tuberculomas. 
Culture of broncho alveolar lavage fluid yielded M. bovis. The patient was 
treated with isoniazid (H), rifampin (R), ethambutol (E). Moxifloxacin and 
steroids were added, because of the high penetration level through the 
blood-brain barrier and to compensate for the absence of pyrazinamide in the 
treatment regimen. 
 
Patient 2
An 84 year old female patient with a medical history of myelodysplastic 
syndrome and diabetes mellitus type 2 sought treatment for a traumatic 
leg wound that did not heal, and her condition gradually progressed to 
generalized skin lesions. She was referred to the dermatologist in our 
hospital. Culture of a skin biopsy grew M. bovis. The patient had lesions on her 
tongue, typical for TB (see Figure 1), and in her larynx and lungs. The patient’s 
condition resolved after 9 months of treatment with isoniazid, rifampicin and 
ethambutol. Contact tracing showed no human transmission.
Figure 1.  Mycobacterium bovis lesion  of  
 the tongue of patient 2.
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Patient 3
An 87 year old female patient with severe rheumatoid arthritis sought 
treatment for weight loss, cough, night sweats and dyspnoea one year after 
starting anti-TNF-α treatment. Radiologic imaging showed a single nodular 
lesion of the lung parenchyma and pleural fluid. Culture of a broncho alveolar 
lavage specimen yielded M. bovis. The patient received isoniazid, ethambutol 
and moxifloxacin for 18 months because she had an intolerance for rifampicin. 
No contact tracing was performed.
Results
During 1993-2007, a total of 16,059 patients were registered in the NTR with culture-proven 
tuberculosis; 231 (1.4%) patients were registered with M. bovis infection8 (Figure 2).The 
number of patients with M.bovis infection born outside The Netherlands (foreign born) 
showed an increase in the proportion from 35.1% to 46.3% in the last five years of the study 
period (Figure 3). 
Over time, the percentage of patients with M. bovis TB who live in major cities increased 
from 33.3% to 41.8%, with an accompanying decline elsewhere in The Netherlands. No 
relation was found between outbreaks in livestock and human disease.
Figure 2.  Mycobacterium tuberculosis and M. bovis infections, The Netherlands,   
   1993-2007. Data derived from the National Institute for Public Health and the  
   Environment (RIVM) database.
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Figure 3.   Percentage of Mycobacterium bovis infections in foreign born persons  and   
   total number of M. bovis infections, The Netherlands, 1993-2007.  Data derived 
   from the National Institute for Public Health and the Environment (RIVM)   
   database.
Among patients with M. bovis disease, a significant difference in mean age was noted 
among those born in The Netherlands and immigrants. In native Dutch persons with M. 
bovis disease,  the median age was 64.8 years whereas among immigrants with M. bovis 
disease the median age was 38.6 years (Figure 4). 
We observed 58 cases in young foreign-born patients and 16 cases in young Dutch patients 
(< 40 years). Five Dutch patients had a general risk factor for contracting M. tuberculosis 
complex disease (one drug addiction, one alcohol addiction and three not specified risk 
factors) and 44 foreign-born had 1 or 2 general risk factors (32 immigrants, 8 fugitive status, 
3 illegal immigrants, and 1 TB-contact, 1 in criminal detention, 1 not specified risk factor). 
Figure 4. Number of Mycobacterium bovis infections, according to patient age and 
  origin, The Netherlands, 1993-2007. Data derived from the NTR database.
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Most of the patients were native Dutch (138 out of 231; 59.7%). Most foreign-born patients 
came from Morocco (54 out of 93; 58.0%). The other immigrants had other places of origin: 
Europe (n= 6; 6.5%), Africa (n= 15; 16.1%), Asia (n= 9; 9.7%), and South America (n= 3; 3.2%)
(Table 1). A distinction between native Dutch and second generation Dutch immigrants 
could not be made.
Bovine tuberculosis mainly had appeared as extrapulmonary disease; 136 (58.9%) of 231 
had extrapulmonary disease alone,  68 (29.4%) of 231 had pulmonary M. bovis disease and 
27 (11.7%) of 231 had both pulmonary and extrapulmonary disease. A significant difference 
between men and women was found in terms of localization of disease. In women lymph 
node TB was more likely to develop, mainly located in the cervical region (p<0,0001); men 
more often had pulmonary M. bovis disease(p<0,0001). This finding was seen in all age 
groups in both Dutch and foreign-born patients (Table 1).
Bovine tuberculosis Netherlands Foreign-born Total
Sex
Male 56 (40.6%) 49 (52.7%) 105 (45.5%)
Female 82 (59.4%) 44 (47.3%) 126 (54.5%)
Male Female Male Female
Age
0-60 13 22 45 35 115 (49.7%)
60+ 43 60 4 9 116 (50.3%)
Localisation
Pulmonary tuberculosis 26 22† 25 7‡ 80   (34.6%)
Respiratory tract 5 8 5 1 19   (8.2%)
Menigeal and CNS 2 4 0 0 6     (2.5%)
Intestinal tract 0 5 3 5 13   (5.6%)
Bone and joint TB 4 5 2 1 12   (5.2%)
Urogenital tract 4 4 3 2 13   (5.6%)
Other organs (f.e.: lymph node) 5 24* 9 21∫ 59   (25.5%)
Miliary TB 6 3 0 2 11   (4.8%)
Unknown 4 7 2 5 18   (7.8%)
Table 1.   Clinical and demographic data derived from the NTR database
Foreign-born patients originate from European countries (n= 6), Africa (n= 69), Asia (n= 9), 
South America (n= 3), and Unknown (n= 6)
† p=0.018
‡ p<0.001
* p=0.004
∫ p= 0.002
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Several treatment schedules were used for our study population; 157 of 231 patients 
received a combination of isoniazid (H), rifampin (R), ethambutol (E) and pyrazinamide (Z) 
or another pyrazinamide containing antibiotic combination. Treatment with pyrazinamide-
containing regimens had no negative effect on treatment outcome.
According to World Health Organization (WHO) standards, a regimen of isoniazid and 
rifampicin of 9 months and ethambutol for 2 months is indicated for treating M. bovis 
disease. In our study population, 113 (52%) of 217 patients were cured and completed 
treatment according to the WHO standard. Thirty seven (17%) of 217 patients were 
considered cured with an insufficient treatment schedule, duration or both. 
For 14 patients, outcome data were not available. No significant associations were found no 
significant associations between insufficient treatment and particular disease localizations 
or outcome.  An anonymous questionnaire distributed to the physicians who were caring 
for the patients at the time of the disease (34 sent and 24 returned) showed that most of 
the physicians followed the Dutch TB guidelines, which are based on the WHO standard. A 
problem these colleagues faced was the lag of time between sampling and the results of 
culture, identification and drug susceptibility test results, which sometimes took as long as 
4 months. Treatment outcomes comparisons for Dutch and foreign-born patients in The 
Netherlands are shown in table 2. 
The overall proportion of deaths for the infection itself was 5.2% for M.bovis disease and 
the proportion of deaths associated with non-TB-related causes (e.g. cardiac disease and 
haematological malignancy) for patients with M. bovis was 14.7%. 
Bovine tuberculose
Netherlands Foreign-born
Tretment result
Treatment 
completed
Cause of death
Other
Treatment 
completed
Cause of death
OtherTB 
related
NonTB
related
TB 
related
NonTB
related
Total n (%)
85
(61.6)
10 (7.2) 28 (20.3)
15 
(10.9)
66
(71.0)
2
(2.1)
6
(6.5)
19 
(20.4)
Age
0-60 25 1 3 6 59 2 3 16
60+ 60 9 25 9 7 0 3 3
Sex
Male 33 3 18 2 35 0 3 11
Female 52 7 10 13 31 2 3 8
Localisation
Pulmonary 26 2 9 3 21 0 2 5
Extrapulmonary 52 5 11 10 44 0 3 11
Pulmonary and 
Extrapulmonary
7 3 8 2 1 2 1 3
Table 2.   Treatment result according to age, sex and localisation of disease in Dutch and   
 foreign-born patients as recorded in the NTR database.
Other: treatment not completed and treatment continued elsewhere
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An analysis of the overall mortality from bovine TB according to sex, age, ethnicity and 
disease localization is shown in table 3. A correlation was found between death and age 
> 60 years, Dutch nationality, and miliary disease . When dividing death in the categories 
of TB-related and non-TB-related, only high age was statistically significant between the 
groups;  all other variables were not significant (Table 4). Cause and rate of death differed 
between sexes; among women, death was more often related to M. bovis TB;  in men, 
the overall mortality rate was higher, although these differences were not statistically 
significant. 
Mortality p-value
Sex 0.31
Age >60 years < 0.0001
Dutch nationality 0.001
Disease localisation (miliairy TB) < 0.0001
* X2-test
Table 3. Correlation of overall mortality with demographic variables* 
Table 4. Correlation of TB related and non-TB related mortality with demographic variables*
Mortality p-value
Sex 0.58
Age >60 years 0.03
Dutch nationality 0.91
Disease localisation (miliairy TB) 0.49
*X2-test
Discussion
Bovine tuberculosis comprised 1.4% of all TB cases in The Netherlands during 1993-2007 
This finding is comparable to those of studies in other countries where control and 
corresponding control efforts of M. bovis TB in livestock are present.9-11
During 1993-1997, mainly elderly Dutch persons were found to have bovine TB;  later (1998-
2007) the infections were divided more equally between the native Dutch and immigrants 
(Figure 3).  M. bovis TB in the population of The Netherlands shows an age-curve with 
double peaks. The younger patients were mostly foreign-born or first-  and second-
generation immigrants, who may have (frequently) travelled back to their country of origin 
or contracted an oral M. bovis infection before coming to the Netherlands. 
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These patients more often had extrapulmonary M. bovis disease mainly affected the cervical 
or abdominal lymph nodes. Ingestion of non-pasteurised dairy products is the most likely 
route of infection.12-13  The 12 Dutch patients, ages 20 - 40 years, may have been in contact 
with non-pasteurised food while travelling to developing countries, because the chance of 
contracting a M. bovis infection in The Netherlands is considered low.
The second age-peak contains elderly native-born Dutch persons. This result is most 
likely a birth-cohort effect because these persons most probably had a late endogenous 
reactivation of latent M. bovis infection contracted in the era before pasteurization of 
milk was introduced and while M. bovis infection in livestock was still highly prevalent in 
The Netherlands. Spoligotyping of their isolates showed a single typical pattern, which 
is considered the old predominant cattle-endemic strain of the Netherlands.14  This 
epidemiological trend is also seen in other European countries including Norway, Sweden 
and Belgium.9-10
Endogenous reactivation of M. bovis infections in elderly patients follows impairment 
of immunity from hematological causes, immune modulation by medication including 
anti-TNF-α treatment, other comorbidity or immunosenescence. As the use of anti-TNF-α 
treatment rises, due to increasing indications in rheumatologic and gastrointestinal 
diseases, mycobacterial disease will likely become more common.15  Two of the patients 
we described had negative tuberculin skin test (for M. tuberculosis complex) and chest 
radiograph results, and therefore did not receive isoniazid prophylaxis before the received 
anti-TNF-α treatment. 
This result calls into question the efficacy of the screening protocol used in the Netherlands 
to evaluate patients before they receive anti-TNF-α treatment. Of note, reactivations of 
latent TB usually occur in the first 3-4 months of anti-TNF therapy,15 although in our 2 
M. bovis patients, reactivation occurred after 1 year. This long-term reactivation of diseases 
has been previously observed16-17 and raises questions involving the role of the bacteriologic 
virulence factor in the pace of the reactivations. 
In the Netherlands, the largest 2 immigrant populations are from Turkey and Morocco 
(378,330 and 341,528 respectively).18 A high occurrence of M. bovis disease was observed in 
Moroccan patients, whereas, to our surprise, M. bovis disease was rare in Turkish patients. 
Both populations come from agricultural areas where pasteurization of dairy products is not 
common. Popular raw milk cheeses in Morocco (‘jben’) and Turkey (kasar, tulum) have been 
found to contain Listeria and/or Brucella species, in as many as 8,2% of the samples tested.19-
20  In both studies cheeses were not tested for M. bovis. 
However, M. bovis can survive in raw milk cheese and cause an infection after it is eaten, 
as was described recently in a cluster of infections resulting from consumption of fresh 
Mexican cheese in New York and San Diego.12-13,21 Besides consumption of fresh cheese and 
unpasteurized milk, consumption of raw or undercooked meat is also a possible route of 
oral transmission.10,22-23   
More women than men were infected by M. bovis, contrary to the epidemiology of M. 
tuberculosis. Other studies about M. bovis do not show this result.9,11
This difference could be an age-related effect for Dutch patients, however, one can also see
this difference in the Moroccan patient population (data not shown).  Notably,  we also 
found a difference in disease localization between men and women.  
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More cervical lymph node TB, which was not correlated with age, was diagnosed  for 
female patients. Female sex has in general been considered a risk factor for M. tuberculosis 
extrapulmonary TB.24-26  However,  this finding has not been described for M. bovis TB. 
Various explanations have been given for this gender difference in TB. One possible 
explanation could be a difference in the immunity to M. tuberculosis complex infection. 
Several studies have been conducted in humans to compare the immune response in both 
sexes. Differences in reaction among others in TNF and interleukin-10 production have been 
found.27-28  Another explanation for this finding may be related to the route of infection. 
Men could be more likely to become infected through the tracheal route by aerosols from 
diseased cattle, whereas women become infected by ingesting M. bovis while preparing or 
consuming contaminated food. Lastly, smoking has also been identified as a risk factor for 
pulmonary TB,25 which (assuming a higher percentage of smokers are men) could explain  
the difference we found in our study that men have more pulmonary M. bovis disease than 
women. Unfortunately, we could not retrieve smoking status from the databases. 
The geographic distribution of bovine tuberculosis in The Netherlands showed a 
proportional increase in M. bovis infections in the major cities in the Western part of the 
Netherlands during 1993-2007. This finding probably reflects the population demographics 
of The Netherlands where most persons live in and between the major cities, but also by 
the fact that immigrants mainly live in the major cities and that the elderly persons who 
contracted bovine TB in the pre-pasteurisation era are undergoing a natural decline in 
health.  We showed that, in 37 (17.1%) of 217 patients, treatment of M. bovis disease was 
not compliant with international guidelines. Although all M. tuberculosis complex isolates 
in The Netherlands undergo drug susceptibility testing, apparently the results do not 
reach clinicians. Recognition of M. bovis as the causative agent of TB does not in itself 
lead to the conclusion that adjustment of the therapy is required; many physicians only 
make adjustments after receiving the results of drug susceptibility testing, which usually 
arrive quite late because of the slow growth of M. bovis. Moreover, the quick molecular 
identification of cultured M. bovis still implies a culture delay of about 4 weeks. Better 
education of physicians and increasing future application of molecular identification of 
M. bovis directly in clinical samples, i.e. sputum or lymph node aspirates, is therefore 
needed.  The overall mortality among patients with M. bovis disease was higher (19.9%) than 
the overall mortality among patients with M. tuberculosis disease (4.4%) in The Netherlands. 
The mortality rates during 1993-2007 were 5.2% for M. bovis disease versus 1.9% for M. 
tuberculosis disease. This result is probably related to the higher prevalence of miliary and 
central nervous system localization in M. bovis disease. Death rates from other, non-TB-
related, causes for patients with M. bovis were 14.7% compared to 2.5% for M. tuberculosis8 
infection.  Subgroup analysis of M. bovis showed that the proportion of deaths was higher 
among Dutch than in foreign-born patients, but this result most likely correlates with age 
and impairment of immunity.10-11,29  We cannot explain the unexpected trend in lower survival 
of female patients after an episode of M. bovis disease. Previous studies have shown that 
male sex is a risk factor for unsuccessful treatment,30-31 but the numbers in our study were 
too small to draw any firm conclusions.
This study had limitations; the analysis of the results was hampered by the relatively 
low number of foreign born patients (n=93) and the heterogeneous nature of the study 
population. 
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Therefore, only data concerning patients from Morocco (n=54) could be analysed 
separately, and differences with the Dutch case-patients were found in terms of age, 
mortality rate and primary localization of disease. 
Another limitation is that a distinction could not be made between native Dutch and 
second- generation immigrants born in The Netherlands. This lack of distinction implies that 
some patients have roots in a foreign country where the risk for M. bovis TB could be higher. 
In conclusion, the incidence of M. bovis in the Netherlands is comparable to that in other 
countries in which control programs for M. bovis are enforced. Gender differences in clinical 
presentation and mortality rates were found in our cohort of patients. The disease now 
mainly infects immigrants from Morocco and elderly Dutch citizens. Anti-TNF-α treatment is 
an emerging cause of endogenous reactivation of M. bovis disease in elderly Dutch patients, 
as occurred in 2 of the recent bovine TB cases described in this article; reactivation may be 
slower than for M. tuberculosis.
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Abstract
Introduction. From 2007-2009, the proportion of culture confirmed tuberculosis (TB) cases 
among all notified TB cases decreased in The Netherlands from 72 to 66 percent. 
Objective.We assessed  the accuracy of registration of culture results in the TB register 
and studied the characteristics of patients notified with non-culture confirmed TB and the 
quality of TB diagnosis. 
Methods. Patient records of all 950 patients notified with non-culture confirmed TB in 
the period 2007-2009 were reviewed at the Public Municipal Health Services (PMHS), 
whereafter hospitals and laboratories were contacted to obtain missing information 
on diagnostic tests. These data were compared to the information in the Netherlands 
Tuberculosis Registry (NTR). Cases were classified according to the TB case definition of the 
European Centre for Disease prevention and Control (ECDC) as; ‘no’, ’possible’, ’probable’ or 
’confirmed’ TB. 
Results. Laboratory confirmation data of (191/3171=) 6%  of notified TB cases in the NTR were 
incorrect or incomplete. The overall percentage of culture confirmed cases was corrected 
from 70% to 71%. In total 63% of non-culture confirmed cases were extrapulmonary TB. A 
total of 42% of non-culture confirmed TB diagnoses were established with other laboratory 
evidence such as positive Polymerase Chain Reaction or positive Ziehl Neelsen staining, or 
histology suggestive of TB. In total 164 out of 516 (32%) of the non-culture confirmed cases 
represented early diagnosis of extra pulmonary TB due to active case finding by physicians 
of PMHS, and no culture was attempted. In clinical extra pulmonary cases culture was 
not done because biopsy material was not suitable for culture anymore. After correction, 
according to the ECDC case definition classification, 56% of non-culture confirmed cases was 
classified as ‘possible TB’, 35% as ‘probable TB’, and 6.8% as ‘confirmed TB’. Thirteen cases 
could not be classified due to missing data.  
Conclusion. The overall culture confirmation rate changed from 70 to 71% after correction of 
incorrect or missing data. TB patients with non-culture confirmed disease were more often 
those with paucibacillary disease and children. Most ‘possible’ TB cases were those with 
a high likelihood of infection, diagnosed through active case finding by physicians of the 
PMHS. ‘Probable’ TB cases were mostly diagnosed in the hospital, culture was attempted in 
60% of the cases but remained negative. In 31% of the cases the body material was retrieved, 
but delivered in the wrong condition to be cultured.
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Introduction
Culture of Mycobacterium tuberculosis is considered the gold standard in the diagnosis of 
tuberculosis (TB), confirming a presumptive diagnosis on the basis of a variety of clinical 
symptoms.1 In the era of emerging drug resistance, culture is increasingly important to 
facilitate drug susceptibility testing (DST) in order to verify and adjust treatment. In The 
Netherlands, country wide culture and DST in the last decades have contributed to low 
relapse rates.2
In case of pulmonary TB, especially if characterized by large cavities, the diagnosis is 
generally robust and confirmed by culture.3 
In a proportion of TB diagnoses, especially  in (children with) extra pulmonary TB (ETB) and 
in HIV co-infected patients, culture confirmation is lacking.4-5 TB diagnosis is often more 
challenging in those cases, due to poor accessibility of the TB lesions and a low bacterial 
load.3,5-8 The overall impression of clinical symptoms, Ziehl Neelsen (ZN) or Auramine 
fluorescence microscopy, polymerase chain reaction (PCR) targeting M. tuberculosis 
complex, X-ray and other radiological imaging methods, histological examination, results 
of tuberculin skin testing (TST), interferon gamma release assay (IGRA), and ultimately 
response to TB treatment all provide some degree of confirmation of the diagnosis, but are 
not always conclusive.3,9 
In The Netherlands, the number of TB cases is declining, as there were 1612 notified cases 
in 1995, 1443 in 2000 and 1007 in 2011 with a notification rate in 2011 of 6 per 100 000 
population. At the same time the proportion of ETB cases is increasing,  as 56% of the cases 
are exclusively PTB, and 44% involve ETB.10
Physicians of the Public Municipal Health Services (PMHS) diagnose approximately 20% of 
TB cases through active case finding. Other patients are diagnosed by hospital affiliated 
physicians, i.e. pulmonologists, internal medicine specialists and pediatricians. TB is a 
notifiable disease to be reported to the PMHS by the diagnosing physician and the medical 
microbiologist. The PMHS subsequently submit data to the central web based NTR. A TB 
case in the NTR is a patient diagnosed with TB after culture confirmation or with a suspicion 
of active TB with an indication for treatment. Surveillance data and in particular the 
proportion of culture confirmed cases are based on this register. 
From 2007-2009, the proportion of culture confirmed TB cases among all notified TB cases 
decreased in The Netherlands from 72 to 66 percent, while in the period 2000-2006 72-76% 
of all TB cases were culture confirmed.10 Especially in ETB, culture confirmation decreased 
significantly in the last ten years; from 70 to 54%.  In 2008 an international review committee 
assessed the quality of the TB control program in the Netherlands. The committee 
specifically expressed a concern about the comparatively low and declining rate of culture 
confirmation of notified TB cases. The team recommended to study whether these findings 
could be related to a decreasing quality in diagnosis linked to loss of expertise in a country 
with a declining TB epidemic. 
The objective of this study was to determine the characteristics of non-culture confirmed TB 
cases, to assess the accuracy of registration of culture results and TB diagnosis in the NTR 
and to assess the quality of diagnosis in non-culture confirmed TB cases.
Methods
A retrospective, descriptive study was performed of the notified non-culture confirmed 
TB cases in the NTR in the period 2007-2009. We classified the cases into 3 groupings; 1: no 
culture performed, 2: culture result negative, and 3: unknown whether culture had been 
performed or results remained unknown. Medical records at the PMHS of all cases in groups 
1 and 3 were reviewed and a sample of 15% of the culture negative cases. The selection 
of the latter group concerned adults from four different PMHS with the largest group of 
patients. When indicated, physicians in the hospital or microbiological laboratories were 
contacted in order to obtain missing information. In case of failure to obtain sufficient 
information, this was registered as ‘missing data’. Basic demographic data, and more 
detailed information on who diagnosed the TB case, symptoms, presentation of TB, co-
morbidity, methods applied to diagnose TB, reasons for negative culture results or the lack 
of culture result in the NTR were all recorded. 
We re-classified the cases based on the additional information retrieved from the patients 
files; group A: not culture performed, B: culture negative, C: culture positive, and D: 
unknown whether culture had been performed or unknown result, to enable comparison 
with the original NTR data. 
Subsequently,  based on the final laboratory information cases were classified according to 
the TB case definition of the European Centre for Disease prevention and Control (ECDC).11  
‘Confirmed TB’ was defined as cases with positive M. tuberculosis cultures or having both 
positive ZN as well as positive PCR results. ‘Probable TB’ were those who had, in addition 
to signs, symptoms and/ or radiological findings consistent with active TB, a positive ZN 
staining or detection of M. tuberculosis complex in DNA or RNA amplification or granulomas 
in histology. ‘Possible TB’ was defined as signs, symptoms and/or radiological findings 
consistent with active TB in any site and a clinician’s decision to treat the person with a full 
course of anti-tuberculosis therapy. ‘No TB’ was defined as registered incorrectly in the NTR. 
All statistical analysis was performed in SPSS version 18.0.
Results  
Characteristics of total population registered in the NTR during the period 2007-2009: Of 3171 
notified TB patients 70% had culture confirmed (n=2221) TB  and 33.7% had ETB.  Individuals 
of Somalian nationality, by far the largest group of immigrants with TB in recent years, 
showed a deviating ratio of 54.2% ETB compared to the whole population and had a slightly 
lower overall percentage of culture confirmed TB diagnoses (67.9%). 
Children aged 0-14 years accounted for 5% (n=158) of the total population. Twenty two 
percent (36/158) had culture proven TB and 63% (99/158) were diagnosed during contact 
tracing. Less than 4% of the notified cases were HIV infected (n=114), 24% were HIV negative 
(n=755) and the rest had an unknown HIV status. Eighty percent had culture proven TB and 
10% was culture negative. 
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Characteristics of notified  cases with non-culture confirmed TB: Of non-culture confirmed 
TB cases (n = 950) 57.1% had ETB, 294 were classified in group 1, 477 in group 2 and 179 in 
group 3. In total 516 files were studied (285 group 1, 65 /477 (14%) group 2, 166 group 3). 
Twenty-two cases were excluded due to wrong diagnosis (n = 12), latent TB infections (n = 
7), double registry (n = 1) and missing files (n = 2). 
Table 1 shows the characteristics of the non-culture confirmed TB cases after studying and 
re-classifying the patient records at PMHS. In group 3 the highest incidence of erroneous 
registries was found. After studying the patient records, only 16% of the patients remained 
with unknown results. Of these cases 25 out of 29 (86%) were diagnosed by a pulmonologist 
and only one (3.4%) by a physician of the municipal TB control service.
In 17.8% of cases children aged 0-14 years were involved. PTB accounted for 37.4% and ETB 
for 62.6% of cases. Thirty cases were treated for TB in the past, the majority (16; 53.3%) 
was cultured but resulted negative, 11 (36.7%) were not cultured. In nine of these formerly 
treated cases, no material was obtained in the procedure at the PMHS and in two cases 
material was delivered in the laboratory in wrong conditions. TB physicians from the PMHS 
diagnosed 139 patients (48%) of the cases in group 1. Forty-one percent of these diagnoses 
(119/290) were “early diagnoses” from screening risk groups and contact investigations, of 
which 66 were children.
Next to the physicians at the PMHS, pulmonologists and specialists in internal medicine 
accounted for respectively 113 (39%) and 25 (9%) of the diagnoses established without 
culture results (group A). In 44 out of 113 cases (38.9%) the pulmonologist did not perform 
Mycobacterium cultures (of which in total 32 cases of uveitis), in five patients material was 
not obtained, and from ten patients the sample never arrived in the laboratory. As a final 
group of physicians, pediatricians diagnosed 7 out of 84 children with TB in group A. In five 
of these cases they did not perform cultures. 
Positive histology for TB was indicated in 147 (28.5%) and positive PCR in 53 (10.2%) of non-
culture confirmed TB cases in the study group. From all patients with incorrectly delivered 
materials (n=71), 56 showed granulomas with 21 cases with positive PCR, 9 negative PCR and 
26 not performed. No patients had negative histology and positive PCR. A total of 42% of 
diagnoses were established with other supportive evidence than culture (data not shown in 
table 1).
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Table 1. Main characteristics of cases after re-classification into groups A-D
*absolute numbers  and row percentages
¶ other co-morbidities: diabetes mellitus, malignancy, renal insufficiency and immune suppressive drugs.
Patient characteristics*
Culture result Total
Group A
‘no culture
performed’
(n=290)
Group B
‘culture 
negative’
(n=184)
Group C
‘culture 
positive’
(n=13)
Group D
‘unknown 
result’
(n=29) (n=516)
Ag
e 
gr
ou
ps
0-14 
15-44
45-64
>65
84 (91.3)
121 (49.6)
50 (47.2) 
35 (47.3)
7 (7.6)
102 (41.8)
44 (41.5)
31 (41.9)
0 (0)
6 (2.5)
6 (5.7)
1 (1.4) 
1 (1.1)
15 (6.1)
6 (5.7)
7 (9.5)
92 (100)
244 (100)
106 (100)
74 (100)
Co
-
m
m
or
bi
di
ty
 
HIV positive
Other¶ 
5 (41.7)
29 (38.7)
6 (50)
35 (46.7)
1(8.3) 
5 (6.7)
0 (0)
6 (8.0)
12(100)
75(100)
ty
pe
 o
f 
TB PTB
ETB
P + E
68 (48.2)
209 (64.7)
13 (25)
65 (46.1)
89 (27.6)
30 (57.7)
4 (2.8)
5 (1.5)
4 (7.6)
4 (2.8)
20 (6.2)
5 (9.6)
141(100)
323 (100)
52(100)
TB
 s
ta
tu
s New
Previously treated
Unknown 
255 (59.6)
11 (36.7)
24 (41.4)
149 (34.8)
16 (53.3)
19 (32.8)
7 (1.6)
1 (3.3)
5 (8.6)
17 (4.0)
2 (6.7)
10 (17.2)
428 (100)
30 (100)
58 (100)
re
as
on
 o
f 
di
ag
no
si
s Active case finding
Passive case finding
Unknown 
119 (72.6)
153 (47.5)
18 (60.0)
43 (26.2)
130 (40.4)
11 (36.7)
2 (1.2)
11 (3.4)
0 (0)
0 (0)
28 (8.7)
1 (3.3)
164 (100)
322 (100)
30 (100)
D
ia
gn
os
in
g 
ph
ys
ic
ia
n
PMHS
Pulmonologist
Other clinicians
Missing 
139 (75.5)
113 (44.1)
37 (51.4)
1 (25)
43 (23.4)
112 (43.8)
29 (40.3)
0
1 (0.5)
9 (3.5)
3 (4.2)
0
1 (0.5)
22 (8.6)
3 (4.2)
3 (75)
184 (100)
256 (100)
72 (100)
4 (100)
H
is
to
lo
gy
Characteristic TB
Negative for TB
Not done/ result 
unknown
72 (49.0)
2 (22.2)
216 (60.3)
63 (42.9)
6 (66.7)
115 (32.1)
3 (2.0)
0 (0)
10 (2.8)
9 (6.1)
1 (11.1)
17 (4.7)
147 (100)
9 (100)
358 (100)
PC
R
Positive
Negative
Not done/ result 
unknown
28 (53.8)
15 (31.3)
247 (63.7)
18 (34.6)
31 (64.6)
134 (34.5)
5 (9.6)
0 (0)
2 (0.5)
1 (1.9)
2 (4.2)
5 (1.3)
52 (100)
48 (100)
388 (100)
Cu
ltu
re
 
Not sampled
No material obtained
Material not to lab
Wrong condition
Missing 
184
17
12
71
6
184 
17
12
71
6
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Validity of the Netherlands tuberculosis registry:  In table 2 the accuracy of registry in the NTR 
is showed.  Of the cases in group 1, 2 and 3 respectively 87%, 91% and 10% were registered 
correct in the NTR.  Overall, only 5.6% (29/516) of the cases remained with unknown culture 
results or diagnostics after the study. Of culture positive cases 12/13 (92%) were diagnosed 
in the hospital. Almost all of these results could be easily extracted from the PMHS patient 
record. The exact reason why they did not feature in the NTR did not become clear in our 
study. These 13 culture positive cases modify the overall percentage of culture confirmation 
in the NTR from 70.0 to 70.9%. Laboratory confirmation data of 6% (191/3171) of notified 
TB cases in the NTR were incorrect or incomplete. As 91% of the random sample of the 
culture negative group were registered adequately, a total of 60% ((477:100X91) + 30 + 95 
= 559/928) of the non-culture confirmed TB cases may be assumed truly culture negative 
during 2007-2009. The reasons why cultures were negative could not be extracted from the 
patient files and it was not possible to obtain this information from the clinicians or medical 
microbiologists.
From the culture negative cases ‘group 2’; 477 minus 65 (random sample) cases were not 
studied. As a result we did not validate 13% of all cases from 2007-2009.
Table 2. Accuracy of national tuberculosis registry of non-culture confirmed TB cases
NTR data After re-classification: group A-D
G
ro
up
 1
 n
=
 2
85
Group A ‘no culture performed’  n = 248 (87%)
Group B ‘culture negative’  n =  30 (11%)
Group C ‘culture positive’ n = 1 (0.3%)
Group D ‘unknown result/unknown whether culture performed’ n = 6 (2.1%)
G
ro
up
 2
 n
=
65
/ 
47
7 Group A ‘no culture performed’  n = 1 (1.5%)
Group B ‘culture negative’  n = 59 (91%)
Group C ‘culture positive’ n = 0 (0%)
Group D ‘unknown result/unknown whether culture performed’ n = 5 (7.7%)
G
ro
up
 3
 n
=
 1
79
Group A ‘no culture performed’  n = 41 (22.9%)
Group B ‘culture negative’  n = 95 (53.1%)
Group C ‘culture positive’ n = 12 (6.7)
Group D ‘unknown result/unknown whether culture performed’ n = 18 (10.1%)
Group 1 no culture performed, group 2 culture negative result, group 3 unknown result or unknown if culture 
was performed.
NTR Netherlands tuberculosis registry, PMHS public municipal health service
Group A no culture performed, group B culture negative, group C culture positive, group D unknown result
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Quality of TB diagnosis: According to the ECDC case definition, 55.8% (n=288/516) was 
classified as ‘possible TB’, 34.8% (n=180) as ‘probable TB’, and 6.8% (n=35) as ‘confirmed TB’; 
13 cases were culture confirmed and 22 cases were confirmed as a consequence of the more 
extensive definition of the ECDC comprising  positive ZN and PCR as a regular method to 
diagnose TB.  The reason why culture remained negative in these 22 cases did not become 
clear from our study.
Thirteen cases could not be classified due to missing data. In Table 3 the characteristics of 
the patients in the study population with ‘possible’ and ‘probable’ TB diagnoses are outlined.
From the ‘possible TB’ cases, 139 out of 288 (48%) cases were identified through screening of 
risk groups and contact tracing. Hundred and sixty-nine of the 288 (68%) of the cases were 
diagnosed and treated by a physician of the PMHS.
In the group classified as ‘probable TB’, 63% had ETB, 11% pulmonary and extrapulmonary 
TB localizations (P+E) and 26% had PTB. Culture was negative in 109 out of 180 patients 
(61%). Subsequently, the diagnosis was based on positive results for ZN microscopy of other 
material than sputum (20%), PCR (29%) and/or histology (72%). 
Classification of the cases according to the ECDC case definitions showed that 9.1% 
(288/3171) of all notified TB cases in The Netherlands during 2007-2009 was ‘possible TB’, 
5.7% ‘probable TB’ and 71.9% ‘confirmed TB’. 
Discussion
The current study provides characteristics of a multi ethnic patient population of 950 non-
culture confirmed TB patients in The Netherlands. We found 13 positive culture results in 
the patient records. These positive cases accounted for 2.5% of the cases in the studied 
group and overall culture confirmation of notified cases TB cases in 2007-2009 increased 
only slightly from 70 to 71%. Furthermore, our study shows that although TB diagnosis may 
seem less robust lacking positive culture, 42% of the diagnoses were actually established 
with other supportive laboratory evidence. In clinical ETB culture was mostly not performed 
because biopsy material was put in formalin or no material was obtained during the 
procedure. In total 63% of possible or probable TB cases were ETB cases. Possible TB cases 
were more often children, and diagnosed by PHMS physicians in the context of active case 
finding, and culture was not attempted in these cases. Probable TB cases were more often 
culture negative, diagnosed by clinicians. The reason of not culturing in this group was more 
often wrong preservation of the body materials. 
One third of the non-culture confirmed cases represented cases traced in active case finding 
by physicians of the PMHS.  Active case finding is a policy propagated to interrupt the chain 
of transmission in low incidence countries12 and performed in The Netherlands by the PMHS. 
The presumed likelihood of infection combined with clinical features of active TB do not 
always prompt these TB physicians to seek further culture confirmation through invasive 
procedures. 
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*Response to treatment favorable: clinically and/or  radiologically 
#Other diagnosis excluded: when clear from the medical history or correspondence from the 
hospital
Variable, n= (%)
Possible 
TB
N = 288
(%) Probable TB N = 180 (%)
Diagnosis
PTB 
ETB
P + E
83 
182 
23 
29
63
8
47 
113 
20 
26
63
11
Age groups 
0-14
15-44
45-64
>65
89 
129 
42 
28 
31
45
15
10
2 
92 
49 
37 
1
51
27
21
Foreign born 
No
Yes
Missing
146 
141 
1
51
49
121 
59 6733
Other diagnoses 
excluded#
No
Yes
Missing
214 
71
3
74
25
117 
62 
1
65
34
Culture
Not done
Performed
Unknown
196 
88 
4
68
31
1
70
109
2
39
61
1
Reason not 
cultured 
Not sampled
No material obtained
Not to lab
Wrong conditions
175
11 
5
4
88
6
3
1
4 
4
7
57
6
6
10
79
Diagnosis made 
by
PMHS
Pulmonologist 
Pediatrician
Others
Missing
169
90
7
20
2
59
31
2
7
14
131
3
30
2
8
73
2
17
Active case 
finding
yes
No
Unknown
147
131
10
51
45
4
13
148
19
7
82
11
TB Symptoms
No
Yes
Missing
96
190
2
33
66
0
179 (99)
1
0
99
Radiology
No
Yes
Missing 
60
227
1
21
79
57
122
1
31
68
Response to 
treatment* 
No
Yes
Missing 
35
223
30
12
77
10
43
111
26
24
62
14
Table 3. Characteristics of patients with possible, probable and confirmed TB diagnoses
Their specific professional background may cause some extent of diagnostic bias when 
faced with symptoms resembling active TB or risk groups prone to TB. This policy does not 
comply with the recently published European Union standards for TB care to submit at 
least two sputum specimens for microscopic examination, culture and drug susceptibility 
testing in case of suspicion of PTB. If ETB is suspected, appropriate specimens from the site 
of involvement should be obtained for examination.13  However, this recommendation may 
jeopardize early diagnosis. In contact tracing, especially in young children, early diagnosis 
may considerably prevent morbidity. Moreover, in case of a low bacterial load, as generally 
observed in ETB,6 the results of invasive diagnostics may be disappointing, and frequently 
do not outweigh the patient burden, especially in children. The majority of all ‘possible TB’ 
cases in this study responded favorable to treatment. This parameter is used as a surrogate 
marker for disease confirmation by clinicians in case of high clinical TB suspicion and is used 
after two months of treatment to decide whether to continue treatment or not.14
Over sixty percent of cases classified as ‘probable TB’ were cultured and TB diagnosis was 
based on positive results of other laboratory tests. ZN results of body materials other than 
sputum are not captured in the current national and international surveillance registries. 
Nonetheless, this is important information to assess the quality of diagnosis. 
Unfortunately, in one third of the cases in the ‘probable TB’ group, material was fixated 
in formalin and could not be cultured. Probably they were primarily suspected for a 
malignancy and TB did not feature in the physicians’ differential diagnosis list. This can 
be explained by the declining TB incidence accompanied by a low index of suspicion 
and declining expertise.12 However, in the era of increasing incidence of COPD and Non-
tuberculous mycobacterial lung diseases15-16 it will become increasingly important to 
consider Mycobacterium culture of all surgically resected materials. 
Second, this study showed that 6% of the notified cases in the NTR (191/3171) culture status 
was incorrectly classified. The most common misclassification was ‘culture not done or 
results unknown’, while this information could be retrieved from the hospital or laboratory 
files of the patient. The PMHS collect data for the NTR, not only from patients treated 
by these organizations but also from those treated by other physicians in the covered 
geographic region. Hospital clinicians and laboratories lack awareness about the relevance 
of all laboratory results, including negative results for national TB surveillance.17
The scientific board of respiratory disease specialists in The Netherlands has recently 
adapted the idea of installing TB coordinators in every hospital. Beside clinical tasks and a 
role in prevention of nosocomial transmission, they can also be informed on the importance 
of a correct registration in refresher courses organized by the scientific board on a regular 
basis. Residents in respiratory diseases have four days of compulsory TB education on a 
national basis and their responsibilities concerning NTR data supply should have more 
attention in the future. Standard questionnaires may help the clinicians to supply all the 
necessary information to the PMHS in an efficient way. 
Advanced training of PMHS staff in registration methods may further improve the quality 
of the NTR.  After correction of the notification data, the percentage of culture confirmed 
cases slightly increased to 70.9%. The lower culture confirmation rates in 2007-2009 
compared to earlier periods is  most likely explained by the increase in the proportion of 
cases with ETB  from 38% to 44% in this period.2,10 
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These ETB cases had a low rate of culture confirmation of 58% compared to PTB cases (79%). 
Data registration, surveillance methods, case definitions and clinical practice did not change 
during this period. 
Data concerning laboratory samples exchanges and other errors, or culture contamination 
were studied but could not be extracted systematically from the PMHS patient records, nor 
from the information supplied by the clinicians or laboratories. We conclude the quality of 
diagnosis through culture confirmation in The Netherlands can be considered high among 
PTB patients in comparison with other low incidence countries18 and is comparatively low 
in patients with isolated ETB for reasons mentioned above. In 2010 and 2011, the culture 
confirmation rates among notified TB cases increased again to 74 and 72% respectively, so 
there is no reason to question the quality of microbiology in our laboratories.
Our study has a few limitations. First, we have only validated a small random sample of the 
adult culture negative cases from four different PMHS. We learned however that 91% of the 
results in the NTR of these cases was confirmed in our study. Second limitation is the lack of 
earlier validation studies in our country. We are therefore not able to detect a trend in the 
quality of TB diagnosis in The Netherlands.
Conclusions and recommendations: In terms of the quality of the registered data on culture, 
we found that ‘culture negative’ results were accurate in 91% of the cases, but ‘missing’ 
or ‘unknown results’ could mostly be extracted from the patient files or the laboratory 
registries. However, only few cases did have a positive culture and the overall culture 
confirmation rate did not really change after correction of incorrect or missing data.
In terms of patient characteristics, we found that TB patients with non-culture confirmed 
disease were more often those with paucibacillary disease. 
In terms of the quality of diagnosis we found that  most ‘possible’ TB cases were those with 
a high likelihood of infection, diagnosed through active case finding by physicians of the 
PMHS. In the large majority of cases, no material was retrieved for culture. ‘Probable’ TB 
cases were mostly diagnosed in the hospital, culture was attempted in 60% of the cases but 
remained negative. In 31% of the cases the body material was retrieved, but delivered in the 
wrong condition to be cultured. 
Clinicians in The Netherlands, should be aware of the increasing need to culture biopsy and 
resection material with the increasing incidence of drug resistant TB and NTM infections. 
TB physicians should be aware of the risk of false positive diagnosis of TB disease in active 
case finding even if the likelihood of infection is high. At least 2 attempts to obtain a sputum 
sample or other body material should be made according to the European Standards of TB 
diagnosis, without endangering the opportunity for early diagnosis and treatment.
Increased awareness of hospital clinicians and laboratories to provide information on all 
relevant laboratory diagnostic results will improve registration and surveillance to serve 
TB control. Standard questionnaires may help clinicians to supply all the details needed to 
the PMHS to complete all data for the NTR. Advanced training of PMHS staff may further 
improve quality of the registered data in the NTR.
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Abstract
With declining TB incidences diagnostic delays may increase. We describe the patient and 
clinical characteristics of spinal TB and assessed the course of diagnostic delays from 2000-
2011 in The Netherlands.  Data from the Netherlands Tuberculosis Registry were studied, 
completed with from the patient records at the public municipal health services. 
A total of 274 cases were studied. Median diagnostic delay was five months during 2000-
2011. Sex and age groups were associated with significant differences in diagnostic delay. 
No difference was observed between origin of patients, patients presenting with TB risk 
factors or with neurological symptoms. Typical TB symptoms at presentation lead to 
significantly increased doctors’ delay (typical symptoms 4.0 vs no typical symptoms 2.0 
months, p=0.05). Considering spinal TB diagnosis and act expeditious is necessary to limit 
the time to diagnosis in spinal TB. Refresher courses should be offered both to family 
physicians and clinical specialists in The Netherlands.
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Introduction
Worldwide, tuberculosis (TB) remains a great healthcare problem. In 2010, 8.8 million TB 
cases were registered with 1.45 million deaths.1 TB is the second leading cause of death from 
infectious diseases after HIV/AIDS.2 Extrapulmonary TB accounts for 1-5% of all TB cases. 
In turn, bone- and joint tuberculosis (BJTB) comprises 15-35% of all extrapulmonary TB, of 
which 50 percent is localized in the spine.3-8  Spinal TB was first described by Percivall Pott 
in 1779 (Pott’s Disease).9 Treatment of spinal TB consists of chemotherapy with at least 
isoniazid, rifampicin and pyrazinamide in case the infection is caused by normal susceptible 
M. tuberculosis complex. Six months of treatment is recommended in BJTB by the American, 
British and Dutch TB guidelines.10-13 In selected cases chemotherapy should be combined 
with surgery.7-8,14-15 
In The Netherlands, TB incidence is declining, with 1443 reported cases in 2000 and 1073 in 
2010.16 As a consequence, patient characteristics and clinical symptoms of (extrapulmonary) 
TB become less well known. For this reason TB is no longer high in  the list of differential 
diagnosis and this may lead to prolonged diagnostic delay. 
In this study we aimed to describe the patient- and clinical characteristics  of patients with 
spinal TB and to assess its course of diagnostic delay in The Netherlands from 2000-2011.
Study population and Methods
In The Netherlands TB is a notifiable disease. For this purpose TB cases are registered in the 
Netherlands Tuberculosis Registry (NTR). Detailed information is collected and registered 
on a voluntary basis by the Public Municipal Health Services (PMHS), but contains data 
of virtually all TB patients in The Netherlands. A retrospective, descriptive study was 
conducted based on the NTR data in the period 2000-2011. Patients registered with BJTB 
were selected and all spinal TB cases were evaluated. To study the individual case  records, 
prior permission was needed from the physicians of the PMHS. Basic demographic data, 
clinical presentation, localization in the spine, TB risk factors, diagnostic methods, and 
therapy were recorded. As to diagnostic methods, spinal TB was considered confirmed in 
patients who were diagnosed by culture or by positive ZN as well as PCR results, according 
to the European Centre for Disease Prevention and Control (ECDC) criteria.17 
Patients’ delay was defined as the time from initial onset of symptoms to the first 
consultation to a physician. Doctors’ delay was defined as the time from the first 
consultation to the time of diagnosis. Diagnostic delay was defined as the time from the 
moment symptoms developed to the time diagnosis was established. Time to diagnosis 
is strictly not always entirely delay; we have used this definition to be consistent with the 
use in the general literature.  Statistical analysis was performed in SPSS, version 18.0. Basic 
demographic data, clinical presentation, localization in the spine, TB risk factors, diagnostic 
methods, and therapeutic interventions were presented descriptively. Patients’, doctors’ 
and diagnostic delay were also described using appriopriate measures of central tendency 
and spread considering the non-normal distribution of these delays. Delays subdivided 
according to patient characteristics or possible other determinants were described as we 
were primarily interested in clinically relevant (long) differences in delay.  They were also 
tested using the  Wilcoxon rank sum test, Kruskall Wallis one-way ANOVA or correlation 
analysis (Spearman correlation coefficient) dependent on the determinant and without 
correction for multiple testing. Determinants evaluated were sex, age group, foreign born, 
presence of any risk factors, symptoms, ‘trias of symptoms’ typical for spinal TB,  and 
neurologic deficit at presentation.
Results
From 2000-2011, a total of 14,382 TB patients were registered in the NTR. Seven hundred and 
thirty five had BJTB (735/14,382 (5%)). Fifty percent of these (366/735) were spinal TB. Three 
PMHS did not give permission to study the patient records for various reasons, 15 patient 
records could not be studied due to logistic reasons, and 42 patient records were missing. 
Five patients were wrongly registered in the NTR. A total of two hundred and seventy-four 
patients were evaluated in this study (figure 1).
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Figure 1.     Case selection
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Patients characteristics
Patients characteristics are summarized in table 1. Two hundred and seventy-four patients 
with spinal TB were evaluated, 163 males (59%) and 111 females (41%). 
Table  1.  Patient characteristics 
Clinical symptoms and localization of spinal TB. The most frequent presenting symptom 
was backache (96.7%), followed by weight loss (54.2%), night sweats (39.9%), fever (31.9%), 
limb weakness and numbness (15.8%), isolated limb weakness (11%) or isolated limb 
numbness (5.5%). Seven patients (2.6%) had paraplegia, three patients (1.1%) had tetraplegia. 
80 patients (29%) presented with a combination of backache, weight loss and night sweats. 
Affected spinal sites are summarized in table 2. Nineteen percent of the patients had more 
than one affected site (53/274).  The thoracic spine was affected most (134), followed by 
lumbar (120), cervical (49) and sacral sites (28). 
Treatment
Total
Conservative (%) Surgery (%) Unknown
Involved 
spinal sites
One
More
Unknown
124 (65)
34 (64)
19 (61)
64 (34)
19 (36)
6 (19)
2
0
6
190
53
31
Localization 
in the spine*
Cervical
Thoracic
Lumbar
Sacral
32 (65)
78 (58)
83 (69)
24 (86)
17 (35)
54 (40)
36 (30)
4 (14)
0
2
1
0
49
134
120
28
                       * Total > 274 as 53 patients have more than one affected site
Table 2.  Spinal localizations and treatment
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Figure 2.  Course of the patients delay, 
doctors delay and diagnostic delay 
through the years.
TB risk factors. Seventy-five patients (27%) had risk factors for TB and some had more than 
one. Type 2 Diabetes Mellitus (n=23), known TB contacts (21), pregnancy (14), malignancy 
(11), intravenous drug abuse (n=5), HIV-infection (n=4), BCG-treatment for bladder cancer 
(2), renal failure (2), surgery (2) and alcohol abuse (1) were risk factors found in the studied 
group. 
Diagnostics and treatment. 157 patients initially visited a general physician. From 104 
patients this information could not be retrieved from the patient record. Diagnosis was 
made by specialists in respiratory disease (33.2%), internal medicine (32.1%) and others (34% 
: neurology, (orthopedic-/neuro-) surgery and others. All patients met the clinical criteria 
of TB, defined as signs, symptoms and/or radiological findings consistent with active TB. In 
addition, some had positive acid-fast bacilli detected, or had detection of Mycobacterium 
Tuberculosis (MTB) in nucleic acid or granulomas in histology. Diagnosis was confirmed 
by a positive culture in 196 patients (72%). Sixty-two patients (23%) were treated based on 
clinical and radiological symptoms. Sixteen had positive PCR results or histological evidence 
for TB (5.8%) or histological evidence for TB (4.0%). 171 cases had normal susceptibility for 
all first-line drugs (isoniazid, rifampicin, pyrazinamide and ethambutol). 19 cases had mono-
resistant TB, 6 had multi drugresistant (MDR) TB. In 78 cases drug susceptibility could not 
be determined due to negative cultures or to the fact that no culture was performed. 
Treatment. All patients were treated by a physician with a full (at least 6 months) course 
of anti-TB therapy. 264 patients completed  treatment. 6 patients died before finishing 
treatment, none directly related to TB. 4 patients were lost to follow-up. Patients with 
cervical lesions underwent surgery in 35%, with thoracic lesions in 40%, with lumbar lesions 
in 30% and with sacral lesions in 14% of the cases. Patients presenting with spinal lesions 
localized in one site underwent surgery in 34% (64/190) of the cases. Patients with multiple 
lesions underwent surgery in 36% (19/53) of the cases. 
                                             
Patients’delay, doctors’delay, 
diagnostic delay and its determinants. 
Patients delay could be extracted 
from the patient record in 142 out of 
274 cases (52%). Median patient delay 
was 1.0 month (range 0-72). Patients 
delay showed a slight decrease during 
our study period (figure 2). In 164 out 
of 274 cases (60%) we were able to 
define doctors delay from the patient 
records. Median doctors delay was 
3.0 months (range 0-52). Finally , from 
197 out of 274 patient records(72%) 
we were able to determine diagnostic 
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Deter
minant value
Patients’ delay
Median in months 
(min-max)
Doctors’ delay
Median in months 
(min-max)
Diagnostic delay
Median in months
(min-max)
Sex* M 0.75 (0-37.5) P=0.139
2.25 (0-24)
P=0.052
4.5 (0.25-38.5)
P=0.004
F 1.00 (0-72) 4.00 (0-52) 5.5 (0-76)
Age#
0-34 ys 0.75 (0-9)
P=0.235
2.00 (0-52)
P=0.022
4.5 (0.25-52)
P=0.00635-64 ys 1.00 (0-72) 4.00 (0.25-27) 5.75 (0.75-76)
> 65 ys 1.50 (0-18) 3.25 (0-24) 5.00 (0-25)
Origin*
NL 1.5 (0-12)
P=0.883
2.5 (0-24)
P=0.370
5.0 (0-30)
P=0.665
Fb¶ 1.0 (0-72) 3.0 (0-52) 5.0 (0.25-76)
Risk 
factors*
Yes 1.0 (0-72)
P=0.967
3.0 (0-12.5)
P=0.581
5.0 0.75-46)
P=0.889
No 1.0 (0-37.5) 3.0 (0-52) 5.25 (0-52)
Trias of 
symptoms*
Yes 0.5 (0-35)
P=0.483
4.0 (0-27)
P=0.050
5.50 (0.5-46)
P=0.582
No 1.0 (0-72) 2.0 (0-24) 5.0 (0-76)
Neurol
sympt*
Yes 0.88 (0-18)
P=0.049
3.75 (0.25-24)
P=0.403
4.25 (0.25-24)
P=0.070
No 1.0 (0-72) 2.25 (0-13) 5.5 (0-76)
 *Mann-Whitney test,  #Kruskal Wallis test, ¶Fb = foreign born, Trias of symptoms = night sweats, weight loss     
   and back pain, 
 Neurol sympt = neurological symptoms at presentation
Table 3. Determinants of delay 
Focussing on doctors’ delay, we learn from this table that female sex is associated with a 
clinically relevant longer doctors’ and diagnostic delays (resp. median 2.25 vs 4.0 months 
and 4.5 vs 5.5 months). Another feature is that middle-aged patients (35-64 years) appear 
to show more doctors’ and diagnostic delay than younger patients.  Of note, we did not 
observe an association between the occurrence of risk factors for TB, including origin of 
the patient, neurological symptoms at presentation and doctors’ delay. The typical ‘trias of 
symptoms’ for spinal TB (night sweats, weight loss and backache) was even associated with 
longer doctors’ delay. 
delay. Median delay was 5.0 months (range 0-76). Twenty nine patients had a diagnostic 
delay longer than 12 months. Diagnostic delay appeared to be constant over the years, 
possibly showing a slight decrease in recent years (figure 2). Patient characteristics and 
determinants and their association with patients’delay, doctors’delay and diagnostic delay 
are shown in table 3.
Chapter 5
72
Discussion
In this study we described patient and clinical characteristics of all patients with spinal TB 
in The Netherlands. In addition we assessed patients’, doctors’ and diagnostic delay in this 
population. We found a median diagnostic delay in spinal TB of five months which remained 
constant during the studied period . Sex and age groups were associated with significant 
differences in doctors’ and diagnostic delay. No difference in delays were observed 
between foreign born patients and patients originated from The Netherlands; patients 
with TB risk factors did not have shorter doctors’ or diagnostic delay; and presentation 
with neurological symptoms did not lead to shorter doctors’ delay.  Even more surprisingly, 
typical TB symptoms (back pain, night sweats and weight loss) at presentation lead to 
significantly increased doctors delay.  
Diagnostic delay may lead to increased morbidity, such as kyphotic deformities of the spine, 
eventually leading to cosmetic problems, ventilatory compromise and paralysis as was 
shown in previous studies.3,18-19 Only few studies of diagnostic delay of spinal TB have been 
performed in low incidence countries.5,20-22 Jutte et al. found a mean diagnostic delay of 203 
days for spinal TB22 during 1993-2000. In our study, we found a median diagnostic delay of 
five months, which is hard to compare as we used the more appropriate measure of central 
tendency. Our mean diagnostic delay was 7.9 months, showing a diagnostic delay roughly 
similar to the previous period in The Netherlands. Patients delay seemed to decline during 
2000 to 2011(figure 2). We were unable to determine whether this is by chance or a true 
drop. Whether this decline could be explained by improved accessibility to health care of 
risk groups as immigrants, illegal or substance abusers could not be defined. 
Night sweats and weight loss are symptoms considered classical constitutional symptoms 
for TB but are frequently lacking in patients with (extrapulmonary) spinal TB.  In a patient 
presenting with constitutional symptoms a physician should consider TB as a diagnosis. In 
our study, we found that patients presenting with night sweats, weight loss and back pain 
had clinically relevant longer doctors’ delay than patients not presenting with this ‘trias’. 
Features associated with spinal TB include prolonged symptomatic course, absence of fever 
or chills, spinal angulation, neurological defects, and paraspinous masses. Different regions 
of the spine are preferentially involved in different age groups and usually two vertebrae 
are involved, either contiguous or in a skip fashion. Classically, there is more extensive 
destruction of the ventral portion of the vertebrae, which results in anterior wedging as 
the bone collapses.23 The distinction in imaging studies between TB and other diagnosis as 
malignancies of the spine can be difficult.24 Diagnosis of spinal TB optimally entails recovery 
of the pathogen from the suspected site by (CT guided) needle biopsy showing caseating 
granulomas and yield Mycobacteria on culture. 
Sex and age groups were associated with significant differences in delay. As to the effect 
of age, 30-40% of the Dutch population, between the ages of 45-63 years, visit their family 
physician with complaints of backache.25 Their pain is  mostly attributed to other causes 
than TB and this may explain why patients in our study, aged 45-55 years, had significantly 
longer diagnostic delays. 
The clinically relevant difference of doctors’ and diagnostic delay between men and women 
is striking to occur in a developed country, but already a known phenomenon in developing 
countries with a high incidence of TB. Lower access to diagnosis and treatment,  biological 
difference in incidence, and lower sputum smear sensitivity for women compared to men 
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have been reported as possible explanations in developing countries for the difference in 
diagnostic delay in TB.26-28 In general, sex and gender differences are widely observed in 
medicine and are increasingly recognized as important interventional targets to further 
improve quality of healthcare.29
Foreign born origin and the presence of TB risk factors were not associated with shorter 
delays. This is undesirable and more attention to continuous education should be paid to 
prevent late diagnoses and unnecessary morbidity among patients having typical clinical 
features and characteristics associated with (spinal) TB. Excellent initiatives to increase the 
awareness of family physicians to immigrant diseases in The Netherlands already exist and 
should be promoted continuously.30
This study has limitations. Patients- and doctors delay was registered in the NTR until 
2005. Consequently, the PMHS probably did collect less data on the issue resulting in less 
accurate findings from this year. Besides this data collection issue, the reported duration 
of symptoms is always based on a patients’ recall and interpretation. Recall bias is thus a 
threat to the estimates of patients’ delay. Second, due to the retrospective nature of our 
study, there was many missing data. 
Conclusion
Considering spinal TB diagnosis and act expeditious is necessary to limit the time to 
diagnosis in spinal TB. Refresher courses should be offered both to family physicians and 
clinical specialists in the era of declining TB incidence in order to raise the awareness and 
knowledge of TB. Hospital TB coordinators may play a crucial role in education to maintain 
TB expertise among specialists in their hospitals and participate in clinical decision making in 
difficult diagnostic cases. 
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Abstract 
Therapeutic drug monitoring (TDM) of tuberculosis (TB) drugs currently focuses on peak 
plasma concentrations, yet total exposure (AUC0-24) is probably most relevant to the efficacy 
of these drugs. Therefore we assessed population AUC0-24 data  for all four first-line TB drugs 
and moxifloxacin, and  developed limited sampling strategies to estimate AUC0-24 values 
conveniently. 
AUC0-24 and other pharmacokinetic parameters were determined following intensive 
pharmacokinetic sampling in two Dutch TB referral centers. Best subset selection multiple 
linear regression was performed to derive limited sampling equations. Median percentage 
prediction error and median absolute percentage prediction error were calculated via 
jackknife analysis to evaluate bias and imprecision of the predictions.
Geometric mean AUC0-24 values for rifampicin, isoniazid, pyrazinamide, ethambutol and 
moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 h*mg/L respectively. Limited sampling at 
various fixed sampling points enabled an accurate and precise prediction of AUC0-24 values of 
all drugs separately and simultaneously.  
In the absence of clinically validated target values for AUC0-24, the average AUC0-24 values 
could be used as reference values in TDM. Limited sampling of AUC0-24 is feasible and allows 
for TDM at a larger scale in Europe.
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Introduction
In the European Union and the European Economic Area (EU/EEA) tuberculosis (TB) cure 
rates are frequently disappointing, especially in countries where drug resistant TB now 
poses public health threats.1 The long duration of TB treatment and adverse events often 
lead to non-adherence, which is thought to cause treatment failure, relapse and emergence 
of drug resistance.2 Besides this, several studies on relationships between drug exposure 
and response,3-5  results from the in vitro hollow fibre model,6 and findings from a recent 
meta-analysis,7  point to pharmacokinetic variability as an additional culprit of treatment 
failure and acquired drug resistance. Unfortunately, the determinants associated with the 
variability in drug exposure are not entirely clear and predicting low exposure in TB patients 
remains difficult.8
In this context therapeutic drug monitoring (TDM), i.e. measurement of plasma 
concentrations and individualization of drug dosing based on these measurements, seems 
useful to improve treatment response. Our group and others have previously described that 
TB drugs fulfill several but not all criteria for TDM. Indications for TDM in selected patients 
have been formulated, and experience in clinical practice shows that this tool can be of 
decisive value in individual patients.3,9-12 As a result, the practice of TDM is already accepted 
in some treatment centers, yet it is rejected in others in view of remaining prospective 
evidence to be gathered.  Still, it is surprising that the recently published European 
standards for TB care developed by the European Centre for Disease Prevention and Control 
(ECDC) / European Respiratory Society (ERS) task force did not mention pharmacokinetic 
evaluation as a method of patient-centered approach at all.13
Unfortunately, clinically validated targets for measures of exposure to TB drugs are 
unknown. However, reference ranges for peak plasma concentrations (Cmax) of TB drugs 
have been described in the past, representing the normal concentrations that can be 
expected in adults with standard doses of TB drugs.9 Using these Cmax reference values, TDM 
for TB drugs involves sampling early in the pharmacokinetic curve as a means to ‘catch’ and 
estimate the Cmax concentration in an individual, as described by Peloquin
9  and applied by 
others.10-12 Evolving data however suggest that the total exposure to TB drugs or the ‘area 
under the concentration versus time curve‘ (AUC0-24) is more relevant to the efficacy of the 
first-line TB drugs14-19 and of moxifloxacin, a second line drug that is being evaluated as a 
first-line TB drug.20 Ideally, AUC0-24 is combined with the minimum inhibitory concentration 
(MIC) of the mycobacteria, to yield AUC0-24/MIC that is supposed to best predict response.  
To enable forecasting of drug dosing based on total exposure, reference population 
pharmacokinetic data concerning the AUC0-24 are needed. In addition, a limited (or optimal) 
sampling strategy is required, using a limited number of concentrations measured at 
predefined times after dosing in order to estimate AUC0-24  in an individual.
21 
The alternative of recording a full pharmacokinetic curve is often not feasible in patient 
care, as it implies a significant patient burden, a large time investment to collect samples, 
and high costs. Therefore the objective of this study was to assess the population 
pharmacokinetics of rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin 
in patients from TB referral centres in The Netherlands and to develop limited sampling 
strategies to estimate the  AUC0-24 of these drugs.  
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Methods
Subjects.  The study subjects were TB patients admitted to the two Dutch TB referral 
centres, namely University Medical Centre Nijmegen, Centre for Chronic Diseases 
Dekkerswald, Groesbeek and University Medical Centre Groningen, Tuberculosis 
Centre Beatrixoord, Haren. TB was diagnosed by the gold standard (positive culture of 
Mycobacterium tuberculosis complex). Patients were included if at least 18 years of age 
and they had to provide written informed consent. The study protocol was approved by 
the Ethical Review Board of University Medical Centre Nijmegen, The Netherlands. A local 
feasibility declaration was obtained from University Medical Centre Groningen as required 
by Dutch law.
Design and procedures.  A descriptive pharmacokinetic study was performed. 
Pharmacokinetic parameters were generated using the standard two-stage approach. With 
this approach, individual pharmacokinetic parameters are estimated in the first stage. In 
the second stage, population characteristics of each parameter are derived by obtaining 
measures of central tendency and spread of all the subjects’ individual parameters. 
Patients were recruited consecutively. TB drugs were administered once daily and dosed 
according to the Dutch Society of Pulmonary Diseases and Tuberculosis (NVALT) guidelines 
for medical TB treatment.22 TB drugs were taken simultaneously, under supervision of 
a nurse. All TB drugs were approved and separately formulated. Other (concomitant) 
medication was taken at least four hours after TB drug intake. A full pharmacokinetic curve 
was recorded during the intensive phase of TB treatment after steady state was reached 
(≥ 2 weeks). Patients refrained from food intake from 11.00 p.m. on the day preceding the 
pharmacokinetic assessment until four hours after intake of study medication. Serial venous 
blood samples were collected just prior to, and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0 and 
24.0 hours after witnessed intake of study medication. Plasma was separated immediately, 
frozen to -80°C and transported on dry ice for bio-analysis. 
Bio-analysis. Plasma concentrations of rifampicin, pyrazinamide, ethambutol and 
moxifloxacin were assessed at University Medical Centre Nijmegen, using validated high 
performance liquid chromatography (HPLC) methods as described before.23-24 
Plasma concentrations of isoniazid were determined at the University Medical Centre 
Groningen with a validated method using protein precipitation followed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). This bio-analytical method for 
isoniazid has not been described before and details can be read in the appendix of this 
article.
Pharmacokinetic analysis. Pharmacokinetic analysis was performed with non-
compartmental methods using WinNonLin version 5.0 (Pharsight Corp., Mountain View, 
California) as previously described.23 Most importantly, AUC0-24 was calculated using the 
linear-log trapezoidal rule. If the concentration at 24 h post dose (C24) was below the limit 
of quantitation (for rifampicin and isoniazid) it was calculated using the formula C24= Clast*e
-
β*(24-Tlast), in which β is the first order elimination rate constant and Clast is the last measurable 
concentration sampled at Tmax. β was obtained by least squares linear regression analysis on 
log C versus time, with the absolute slope of the regression line being β/2.303.
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Statistics. Descriptive statistics were calculated for each of the pharmacokinetic 
parameters. For each TB drug, the proportion of patients with Cmax within reference values 
was assessed. Reference Cmax values of the first line TB drugs were as follows: rifampicin 
8-24 mg/L, isoniazid 3-6 mg/L, ethambutol 2-6 mg/L and pyrazinamide 20-50 mg/L9 or ≥35 
mg/L(5). These reference Cmax values are based on data that were compiled from all available 
sources (both healthy volunteers and TB patients) by, amongst others, Holdiness and 
Peloquin.25-26 For moxifloxacin, standard minimum inhibitory concentration (MIC) values of 
0.25 and 0.5 mg/L were used  to estimate the pharmacodynamic indices AUC0-24/MIC and 
Cmax/MIC. These ratios should reach the desired values of 100 and 10, respectively, to achieve 
the greatest bactericidal effect and a decreased probability of resistance, at least when 
moxifloxacin is used against fast-growing Gram negative bacilli.20   
Pharmacokinetic parameters were log transformed before further statistical analyses. 
Comparison of pharmacokinetic parameters between subgroups was performed using the 
independent sample t-test on the log-transformed parameters or the Wilcoxon rank-sum 
test for time to Cmax (Tmax). Correlations between numerical variables were calculated using 
the non-parametric Spearman’s rank correlation coefficient (rho). 
Best subset selection multiple linear regression was performed to derive limited sampling 
equations predictive of the AUC0-24 of individual TB drugs, and for simultaneous prediction 
of the AUC0-24 of rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin. To 
maintain clinical applicability, all models were constrained to include three samples at the 
most, collected within 6h after drug administration. For all subsets containing one, two or 
three samples, we calculated the average adjusted r square and the model with the biggest 
average r square was chosen. In addition, it was evaluated whether the practice of sampling 
at 2h, 4h and 6h post dose in order to ‘catch’ Cmax, as applied in one of our TB referral 
centres, provides an accurate estimation of AUC0-24. 
To assess the predictive performances of the models we calculated residuals for each 
patient based on models fitted to a dataset where that patient was omitted (jackknife 
analysis).27 Potential bias in the predictions was assessed using the median prediction 
error (MPE) and median percentage prediction error (MPPE); for this latter measure, 
residuals were converted to percentages by dividing the residuals by the predicted values. 
Imprecision was assessed using root median squared prediction error (RMSE) and median 
absolute percentage prediction error (MAPE). MPPE and MAPE of <15% were considered 
acceptable.27 All statistical analyses were performed with SPSS for Windows version 
20.0 (SPSS Inc, Chicago, IL) and R version 2.15.2. P values of below 0.05 were considered 
significant. 
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#other co-morbidities are cancer, cardiovascular disease, respiratory diseases
Results
Patients. Forty-one TB patients were included in the study. Patient and treatment 
characteristics are summarized in table 1. Four out of 41 patients were diagnosed with TB 
caused by mycobacteria that were resistant to isoniazid and rifampicin (multi-drug resistant 
TB, MDR-TB). Moxifloxacin was used in patients for MDR-TB (n=12), because of possible MDR-
TB based on treatment history, and in case of intolerance for other TB drugs. Concomitant 
medication was not expected to influence the pharmacokinetics of the TB drugs (data not 
shown). None of the patients had compromised liver or kidney function (defined respectively 
as transaminases ≥ 50 U/L and glomerular filtration rate < 60 ml/min).
Table 1. Patient characteristics  
Characteristic Value
Demographic characteristics
Male, n (%) 32 (78)
 Age, median (IQR) 42 (27)
Body weight (kg), mean (SD) 64.5 (14.6)
Ethnicity, n (%)
Caucasian 12 (29)
Black 13 (32)
Asian 5 (12)
Indian-Afghan 5 (12)
Middle-East 4 (10)
Other / mixed origin 2 (5)
Type of TB
Pulmonary 34
Extrapulmonary 7
Co-morbidity, n(%)
HIV co-infection 3 (7)
Diabetes mellitus 1 (2)
Dose, mg/kg, median (range)
Rifampicin 9.3 (4.7-13.0)
Isoniazid 4.5 (2.3-6.1)
Pyrazinamide 28.7 (11.7-32.5)
Ethambutol 20.3 (15.9-26.0)
Moxifloxacin 7.0 (5.7-9.3)
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Pharmacokinetic 
parameter*
(range)
Rifampicin
N=34
Isoniazid
N=14
Pyrazinamide
N=19
Ethambutol
N = 19
Moxifloxacin
N=12
AUC0-24 (h.mg/L) 41.1
(4.6-118.9)
15.2
(6.1-29.8)
380
(267-679)
23.5
(13.8-86.4)
33.6
(15.2-84.2)
Cmax (mg/L) 9.5
(1.3-24.8)
3.2
(1.3-5.2) 44.5(33.6-60.3)
3.3
(2.0-7.6)
3.3
(2.4-5.8)
Tmax (h) 2.0
(1.0-6.0)
1.3
(1.0-2.5)
1.5
(1.0-2.5)
3.0
(1.0-6.2)
2.0
(1.0-4.0)
Cl/F (L/h) 14.5
(5.0-129.6)
19.8
(10.1-49.3)
4.6
(2.6-6.3)
54.3
(16.2-87.3)
11.9
(4.8-26.3)
Vd/F (L) 39.2
(17.8-379.1)
82.1
(49.3-187.9)
37.0
(27.5-55.2)
723
(249-1651)
142.3
(89.5-270)
t½(h) 1.9
(1.0-4.4)
2.9
(1.7-4.5)
5.9
(3.0-13.8)
9.2
(6.3-16.0)
8.3
(5.4-13.1)
Table 2.  Summary of pharmacokinetic parameters of rifampicin, isoniazid, pyrazinamide,   
 ethambutol  and moxifloxacin
* Geometric mean and range, apart from tmax, for which median and range are displayed.
AUC0-24: area under the concentration versus time curve, Cmax: peak plasma concentration, Tmax: time to peak 
plasma concentration, Cl/F: apparent clearance, Vd/F: apparent volume of distribution, t1/2: elimination half-life. 
Pharmacokinetics of TB drugs. Table 2 displays the pharmacokinetic parameters of rifampicin, 
isoniazid, pyrazinamide, ethambutol and moxifloxacin. Remarkable inter-patient variability in 
total exposure (AUC0-24) was observed for rifampicin (range 4.6-118.9 h*mg/L), isoniazid (6.1-
29.8 h*mg/L), ethambutol (13.8-86.4 h*mg/L) and moxifloxacin (15.2-84.2 h*mg/L). Exposure 
to pyrazinamide showed relatively small inter-patient variability (267-679 h*mg/L). 
One third of patients had low peak plasma concentrations of rifampicin (<8 mg/L, 10/33 
patients) and isoniazid (<3 mg/L, 4/12). Only one patient had a low Cmax of pyrazinamide 
below 35 mg/L but above 20 mg/L. No patients showed low peak plasma concentration of 
ethambutol. Geometric mean values (range) for moxifloxacin AUC0-24/MIC and Cmax/MIC were 
67.2 (30.4-168.4) and 6.6 (4.8-11.6) respectively. Three out of 12 patients had moxifloxacin 
AUC0-24/MIC above 100 based on a fixed MIC of 0.5 mg/L. Based on a fixed MIC of 0.25 mg/L, 
10/12 patients would have moxifloxacin AUC0-24/MIC above 100. 
The geometric mean AUC0-24 of moxifloxacin was 28.1 h*mg/L when combined with rifampicin 
(n=5) compared to 38.1 h*mg/L for moxifloxacin without rifampicin (n=7) (p =0.172).
No clear associations were found between pharmacokinetic parameters and age, gender or 
BMI. Only for rifampicin, there was a trend to lower AUC0-24 with increasing weight (Spearman’s 
rho -0.30, p = 0.08). The number of patients with HIV/AIDS and diabetes mellitus and numbers 
of patients within various ethnic groups were considered too small to test. 
Limited sampling equations. Table 3 shows the best performing one, two and three 
time point equations of all four first-line TB drugs and moxifloxacin separately when 
administered on an empty stomach. For pyrazinamide, ethambutol and moxifloxacin a high 
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adjusted R2 (>0.90) was already reached with only one sample at 6 h post dose, but a set of 
three samples clearly gave the highest adjusted R2 (table 3). For rifampicin, sampling at 1, 4 
and 6 h post dose enabled the best prediction of AUC0-24. For isoniazid, samples at 1, 2.5 and 
6 h post dose were best. Sampling at 0, 2 and 6 h post dose for pyrazinamide; at 0, 2.5 and 
6 h post dose for ethambutol; and at 0, 1.5 and 6 h post dose for moxifloxacin enabled the 
best prediction of exposure (table 3). 
Table 3. Best performing one, two and three sampling point strategies for estimation of AUC
0-24
 
of individual TB  drugs * 
Sampling times Equation Adjusted R2 MPE MPPE % RMSE MAPE%
RI
F
C4 AUC0-24 = -0.86 + 7.16×C4 0.8365 -1.72 -3.63 7.09 16.07
C2,C6 AUC0-24 = 0.57+ 2.68×C2 + 6.98×C6 0.9321 -0.40 -1.08 2.99 8.49
C1,C4,C6
AUC0-24 = -4.71+ 1.74×C1 + 3.76×C4 
+ 4.83×C6
0.9691 -0.13 -0.15 3.44 7.60
IN
H
C3 AUC0-24 = -1.15 + 7.97×C3 0.8886 -0.46 -2.93 1.35 7.27
C4,C6 AUC0-24 = -0.59+ 5.06×C4 + 7.14×C6 0.9638 0.45 3.09 0.84 4.91
C1,C2.5,C6
AUC0-24 = -1.02+ 2.06×C1 + 1.98×C2.5 
+6.03×C6
0.9746 -0.31 -1.70 1.29 7.00
PY
R
C6 AUC0-24 = 41.49 + 13.91×C6 0.9127 -5.13 -1.38 25.00 6.13
C4,C6
AUC0-24 = -30.18+ 5.02×C4 + 
10.14×C6
0.9539 -2.82 -0.56 13.65 3.47
C0,C2,C6
AUC0-24 = -15.42+ 7.71×C0 + 3.55×C2 
+8.66×C6
0.9687 0.40 0.10 12.69 3.56
ET
H
C6 AUC0-24 = 8.16 + 9.98×C6 0.9295 0.10 0.62 3.02 12.80
C0,C6 AUC0-24 = 6.17+ 12.27×C0 + 7.98×C6 0.9597 0.19 1.10 2.00 8.16
C0,C2.5,C6
AUC0-24 = 0.91+ 10.24×C0 + 2.86×C2.5 
+7.45×C6
0.9751 0.59 2.43 1.88 11.04
M
O
XI
C6 AUC0-24 = -2.54 + 16.35 ×C6 0.9608 -0.74 -2.07 3.85 8.94
C0,C2.5 AUC0-24 = 1.40+ 25.04×C0 + 6.84×C2.5 0.9855 0.65 1.98 1.83 4.30
C0,C1.5,C6
AUC0-24 = 1.43+ 16.75×C0 + 2.12×C1.5 
+8.18×C6
0.9935 0.58 2.26 1.45 4.69
* Formulas are based on blood sampling in the first 6 h post dose after administration of drugs on an empty stomach. 
The formulas do not apply to administration of drugs with food.
Abbreviations: RIF = rifampicin, INH = isoniazid, PYR= pyrazinamide, ETH = ethambutol, MOXI = moxifloxacin, 
MPE = median prediction error, MPPE = median percentage prediction error, RMSE = root median squared prediction 
error, MAPE = median absolute percentage prediction error 
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Table 4 shows the best performing one, two and three time point equations for 
simultaneous prediction of exposure to all five drugs based on blood sampling in the first 
6 h. The best limited sampling strategy for the simultaneous prediction of exposure to all 
five drugs involved the time points 1, 4 and 6 h. Sampling at 2, 4 and 6 h post dose, as can be 
applied to ‘catch’ the peak plasma concentrations, also enabled a good prediction of AUC0-24 
for all drugs (table 4). Again, these equations were based on and are applicable for intake of 
TB drugs on an empty stomach. 
Sampling 
times
Equation Adjusted 
R2
MPE MPPE% RMSE MAPE%
RIF C6 AUC0-24 = 12.76 + 9.92×C6 0.6484 0.61 1.96 8.41 17.74
INH C6 AUC0-24 = 5.54 + 9.94×C6 0.6968 -0.27 -1.89 2.60 23.56
PYR C6 AUC0-24 = 41.49 + 13.91×C6 0.9127 -5.13 -1.38 25.00 6.13
ETH C6 AUC0-24 = 8.16 + 9.98×C6 0.9295 0.10 0.62 3.02 12.80
MOXI C6 AUC0-24 = -2.54 +16.35×C6 0.9608 -0.74 -2.07 3.85 8.94
RIF C3, C6 AUC0-24 = -2.14 + 3.63×C3 + 5.91×C6 0.8941 0.09 0.37 6.21 14.32
INH C3, C6 AUC0-24 = -1.06+5.87×C3 + 4.05×C6 0.9467 0.61 5.60 1.93 10.50
PYR C3, C6 AUC0-24 = -40.03 +4.53×C3 + 10.48×C6 0.9505 -5.54 -1.50 11.29 2.73
ETH C3, C6 AUC0-24 = -0.14 + 4.49×C3 + 8.33×C6 0.9496 1.03 5.98 2.97 15.51
MOXI C3, C6 AUC0-24 = -4.75 + 4.16×C3 + 12.11×C6 0.9635 -0.39 -1.24 4.15 10.91
RIF C1,C4,C6 AUC0-24 = -4.71 + 1.74×C1 + 3.76×C4 +4.83×C6 0.9691 -0.13 -0.15 3.44 7.60
INH C1,C4,C6 AUC0-24 = -0.67 + 0.84×C1 + 3.55×C4 +7.60×C6 0.9673 0.03 0.16 1.04 5.24
PYR C1,C4,C6 AUC0-24 = -48.51 + 0.80×C1 + 5.31×C4 +9.20×C6 0.9549 -3.46 -0.80 15.08 3.82
ETH C1,C4,C6 AUC0-24 = 0.37 + 2.23×C1 + 2.26×C4 +8.52×C6 0.9514 1.70 9.18 2.81 13.20
MOXI C1,C4,C6 AUC0-24 = -4.91 + 2.93×C1 - 0.21×C4 +14.52×C6 0.9796 0.39 1.70 2.64 7.57
RIF C2,C4,C6 AUC0-24 = -2.22 + 2.05×C2 + 2.25×C4 +4.93×C6 0.9494 -1.07 -1.85 4.22 9.47
INH C2,C4,C6 AUC0-24 = -1.46 +1.18×C2 + 4.71×C4 +5.51×C6 0.9674 0.46 2.68 1.20 7.30
PYR C2,C4,C6 AUC0-24 = -48.65 + 1.78×C2 + 3.58×C4 +9.90×C6 0.9554 -4.53 -0.90 10.52 2.57
ETH C2,C4,C6 AUC0-24 = -6.34 +5.22×C2 + 2.83×C4 +7.07×C6 0.9632 -0.43 -2.11 1.75 7.43
MOXI C2,C4,C6 AUC0-24 = -4.35 + 3.97×C2 - 6.49×C4 +20.05×C6 0.9659 0.18 0.64 4.40 11.95 
Table 4. Best performing one, two and three sampling point strategies for estimation of AUC
0-24
 
of 5 TB  drugs simultaneously *
* Formulas are based on blood sampling in the first 6 h post dose after administration of drugs on an empty stomach. 
The formulas do not apply to administration of drugs with food.
Abbreviations: RIF = rifampicin, INH = isoniazid, PYR= pyrazinamide, ETH = ethambutol, MOXI = moxifloxacin, 
MPE = median prediction error, MPPE = median percentage prediction error, 
RMSE = root median squared prediction error, MAPE = median absolute percentage prediction error 
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Discussion
The current study first provides steady-state population pharmacokinetic data collected in 
a typical multi-ethnic population of TB patients admitted to TB referral centres in Western-
Europe. In the absence of clinically validated target or cut-off values for AUC0-24, these 
population (average) values for AUC0-24 could be used as reference values in TDM, similar 
to the use of ‘normal’ Cmax values of TB drugs.
9 The reasoning is that these average values 
represent the best case scenario for the standard doses of the drugs. If an individual can 
achieve such concentrations, then it would appear unlikely that low drug exposure is 
the primary reason for suboptimal clinical response, and other explanations should be 
considered.9
Second, this study showed a large inter-individual variability in pharmacokinetics of all 
TB drugs studied, apart from pyrazinamide, which is consistent with data from other 
populations.5,8 Many patients had Cmax of rifampicin or isoniazid below reference values. 
Similarly, reference values for moxifloxacin AUC0-24/MIC and Cmax/MIC ratios were not 
reached in some patients, dependent on the fixed MIC value used. Large inter-individual 
variability in exposure to just one TB drug may already contribute to treatment failure or 
drug resistance,7 whereas multiple low concentrations may further predispose to these 
events. Inter-individual variability in exposure is a reason and actually a prerequisite for TDM 
as a means to individualize drug dosing.
Third, linear regression analyses showed that limiting sampling can be used to make an 
accurate and precise estimation of AUC0-24 values for all first-line TB drugs and moxifloxacin 
separately and simulataneously. With this strategy, the patient burden is significantly 
lowered, and time investment and costs are reduced compared with the intensive (11 
time points) pharmacokinetic evaluation necessary to assess AUC0-24 values as performed 
in this study. Use of two sampling points at t = 3 and 6 h for simultaneous estimation of 
all AUC0-24 values resulted in acceptable R
2 values, yet the predictive performance of the 
two sample points equations was less favourable in terms of median absolute percentage 
prediction error (MAPE, table 4). Three sampling points (at t = 1, 4 and 6 h) resulted in the 
most accurate simultaneous estimation of AUC0-24. We ourselves favour the sampling at t 
= 2, 4 and 6 h post dose, as this allows for estimation of Cmax (which is commonly based on 
sampling at 2h plus 4h or 6 h post dose9,12) as well as estimation of AUC0-24. Alternatively, the 
population pharmacokinetic data from the current study can be used in another approach 
to assess AUC0-24 in the context of TDM, i.e. maximum a posteriori (MAP) Bayesian fitting 
(28). This technique uses the ‘a priori’ population pharmacokinetic parameters, the patient’s 
drug dosing information, and measured plasma concentrations to assess ‘a posteriori’ 
pharmacokinetic parameters of the patient, including the AUC0-24. Use of the population 
parameters in this Bayesian estimation approach requires expertise with specific software, 
but has the advantage that sampling time points do not need to be fixed, as long as exact 
sampling times are known. Either with limited sampling formulas or with MAP Bayesian 
fitting, it seems feasible to evaluate AUC0-24 of TB drugs and to individualize doses in 
patients with a higher a priori risk of treatment failure, relapse rates and emergence of drug 
resistance. Less invasive pharmacokinetic assessment tools may further facilitate TDM of 
TB drugs, especially in children and in remote areas. For example, small blood spots can be 
taken with insulin-type needles, dried on filter paper and sent by regular post mail (Dried 
Blood Spot technique, DBS).29 In addition, saliva could be used as a matrix for TDM.30  
For the near future, it is important to derive clinically validated cut-off values for AUC0-24h 
and Cmax rather than to normalize exposure to population values. In addition, susceptibility 
of mycobacteria (MIC) should be taken into account to optimize AUC0-24h/MIC.  
One limitation of this study relates to its relatively small sample size, typical to a study 
with intensive pharmacokinetic sampling. The average AUC0-24 data proposed as reference 
data for TDM may need to be confirmed in a larger population. Furthermore, we did not 
prospectively validate our limited sampling formulas. Instead we calculated residuals for 
each patient based on models fitted to a dataset where that patient was omitted (jackknife 
analysis), an analysis which is a useful and appropriate approach in cases of small sample 
size.27 Finally, when it comes to the application of the limited sampling equations in TDM, it 
must be considered that accumulating evidence shows an association between exposure 
of single TB drugs in plasma and treatment outcome and emergence of resistance, but the 
exact relationships need further elucidation. 
In summary, low plasma concentrations of pivotal anti TB drugs have recently been 
appointed as an additional culprit of treatment failure and acquired drug resistance. The 
current study provides steady-state data for total exposure (AUC0-24) to first-line TB drugs  
and moxifloxacin. These population AUC0-24h values  could be used as reference  values 
for TDM, a technique which is feasible in the European setting. Limited pharmacokinetic 
sampling at 1, 4 and 6 h or at 2, 4 and 6 h post dose enables an accurate and precise 
simultaneous estimation of AUC0-24 values for all these TB drugs. Evaluation of drug 
exposure with limited sampling and less invasive assessment methods may become an 
important tool in the near future to optimize treatment results and prevent emergence of 
resistance. 
Appendix. Bio-analytical method for isoniazid at University Medical Centre Groningen
Ten microliter of each plasma sample was added to precipitation reagent methanol and 
acetonitrile 4:21 v/v containing the internal standard. The mixture was vortexed, stored at 
-20 °C for about 30 min to promote protein precipitation, and consequently centrifuged. 
From the clear upper layer, 5 microliter was injected on a 100 mm x 2.1 mm C18, 5μm 
analytical column set at 20 °C. The mobile phase consisted of a gradient made from an 
aqueous buffer containing ammonium acetate, acetic acid and trifluoroacetic anhydride, 
water and acetonitrile. The detector was operating in electrospray positive ionization 
mode and performed selected reaction monitoring (SRM) as scanning mode. The mass 
parameters of m/z 138.1        121.1 (collision energy 14eV) were measured with a scan width 
of 0.5 m/z. Accuracy was between 95.6% and 111.3%, depending on the concentration of 
isoniazid. The intra- and inter assay coefficients of variation were less than 10.5% over the 
range of 1.5 to 30 mg/L. The lower limit of quantitation was 0.4 mg/L.
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Abstract
At the University Centre for Chronic Diseases Dekkerswald, a tertiary tuberculosis (TB) 
referral hospital in The Netherlands, Therapeutic Drug Monitoring (TDM) is used in  patients 
in case of relapse TB, when there is delayed response to TB treatment, and when abnormal 
TB drug concentrations are suspected for other reasons. In this article, a case series is 
presented to illustrate the value of individualized TB drug dosing in four patients with low 
TB drug concentrations. Increased doses of the TB drugs, especially of rifampicin, resulted in 
adequate peak plasma concentrations and improved clinical response to treatment in these 
patients, while no adverse events occurred.                
Introduction
First-line treatment of drug susceptible tuberculosis (TB) is highly effective. Nevertheless, a 
number of patients fail to respond to treatment, have relapse TB, or develop drug-resistant 
TB1. Inadequate response to TB treatment results from a complex and poorly understood 
combination of factors that vary from patient to patient2. 
Suboptimal plasma concentrations of first-line TB drugs, in particular of rifampicin 
and isoniazid, are among these factors.3-4 Low plasma concentrations can result from 
malabsorption in patients with human immunodeficiency virus (HIV) infection or 
gastrointestinal tract anomalies, diabetes mellitus (DM) as a concomitant disease, or 
interindividual variability in pharmacokinetics.5-12
Therapeutic Drug Monitoring (TDM), i.e. individualized drug dosing guided by drug plasma 
concentrations,13 could be of help in improving response to drug treatment. So far, TDM has 
been applied to TB treatment in a limited number of centres only.2,10,11,14,15 In our setting, TDM 
was introduced to a selected group of patients in 2006. Here, we present our TDM practice 
and a case series that illustrates the value of using TDM in patients with drug-susceptible TB 
who are suspected to have low TB drug plasma concentrations.
Methods
Setting
The University Centre for Chronic Diseases Dekkerswald is one of two tertiary TB referral 
hospitals in The Netherlands for patients with severe or complex TB disease, co-morbidities 
such as HIV-infection, and drug-resistant TB. 
TB treatment in this centre is in accordance with guidelines of the Dutch Association of 
Physicians for Lung Disease and Tuberculosis (NVALT) and the standard, first-line treatment 
regimen consists of 2 months daily isoniazid (H: 5 mg/kg bodyweight, maximum 300 
mg), rifampicin (R: 450 mg in patients with bodyweight < 50 kg; 600 mg in patients with 
bodyweight > 50 kg), pyrazinamide (Z: 30 mg/kg bodyweight, maximum 2000 mg), and 
ethambutol (E: 15-20 mg/kg bodyweight, maximum 1600 mg), followed by 4 months of daily 
H and R, in separate formulations.16
TDM practice
In our centre, TDM is used in patients with drug-susceptible TB when abnormal TB drug 
concentrations are suspected (e.g. in case of HIV-infection, diabetes, gastrointestinal 
anomalies, malnutrition, or renal or hepatic dysfunction), when there is delayed sputum 
culture conversion (i.e. after more than 8 weeks of treatment), and in case of relapse TB. 
Pharmacokinetic sampling is performed after a minimum of 2 weeks of treatment, when 
steady state concentrations of the first-line TB drugs have been achieved. Samples are 
taken pre-dose (C0), and at 2 h (C2) after drug intake on an empty stomach to estimate 
the peak plasma concentration.10 After initial experiences we currently take samples at 4 
(C4) and 6 h (C6) post dose as well, to be able to determine peak plasma concentrations 
more accurately and to differentiate between delayed absorption and malabsorption. 
After sampling, plasma is separated immediately, frozen to -80 °C, and transported on 
dry ice to the laboratory for bioanalysis of TB drugs by validated high-performance liquid 
chromatographic (HPLC) methods. Previously, plasma concentrations of rifampicin were 
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routinely measured, considering its known concentration-effect relationship.10,17 To limit the 
cost, isoniazid, pyrazinamide and ethambutol concentrations were only determined if the 
rifampicin concentration was below the lower limit of the target range. Now we measure 
rifampicin, isoniazid and pyrazinamide at once in all samples.  
The following target ranges of peak plasma concentrations are used for first-line TB drugs 
that are taken in daily, oral doses: 3-5 mg/L for isoniazid, 8-24 mg/L for rifampicin, 20-50 
mg/L for pyrazinamide, and 2-6 mg/L for ethambutol.10 These ranges represent the normal 
concentrations that can be expected after the standard doses of TB drugs. The ranges are 
based on data that were compiled from all available sources (both healthy volunteers and 
TB patients).5,10 Subsequently the ranges were validated in a range of phase I studies in 
healthy volunteers.9 Since then these target values have been adapted in all subsequent 
pharmacokinetic studies in TB.  In our setting, hospital pharmacists interpret the TDM 
results and respiratory physicians decide on adjusting drug doses.
Results-case series
Patient 1 – relapse TB after previously delayed sputum culture conversion
A 57-year-old Caucasian man with a body mass index (BMI) of 18.6 kg/m2 and a history 
of alcohol abuse and smoking was treated with the standard 2HRZE/4HR for susceptible 
pulmonary TB from January to July 2008. He was on Directly Observed Treatment (DOT) 
during the first 2 months. Sputum culture conversion occurred late: after 11.5 weeks of 
treatment. In April 2009, he presented with relapse pulmonary TB (the Mycobacterium 
tuberculosis (MTB) strain was identical to that of the first episode) which was still 
susceptible to HRZE. High Resolution Computed Tomography (HR CT) showed large 
pulmonary cavities. Treatment with HRZE was started. There was no clinical improvement 
in the first 4 weeks. Considering the slow culture conversion in the first TB episode and the 
fact that it concerned a relapse case, TB drug plasma concentrations were measured. A 
rifampicin peak concentration of 5.6 mg/L at 2 hours post dose (C2) was found. The isoniazid 
peak plasma concentration was undetectable (< 0.025 mg/L) at C2 and the pyrazinamide 
peak plasma concentration was 8.3 mg/L. After dose adjustment of rifampicin from 600 
to 1200 mg, its peak plasma concentration increased to 15.2 mg/L. Dose adjustments 
of isoniazid and pyrazinamide did not lead to peak plasma concentrations within the 
target ranges (0.04 mg/L and 12.2 mg/L, respectively). Nevertheless, within 2 weeks after 
increasing the drug doses, the patient’s productive cough diminished and his appetite 
approved. Sputum culture conversion occurred 6 weeks after dose adjustments. The 
patient did not experience adverse events to the higher dosages of rifampicin, isoniazid and 
pyrazinamide. His clinical condition was excellent at completion of treatment in March 2010 
and remained well during a follow-up period that lasted until October 2010.
Patient 2 – treatment failure in a patient with relapse TB and diabetes mellitus
A 59-year-old Indian man with a history of type II DM and alcohol abuse was diagnosed 
with pulmonary TB in India in November 2006. He was treated until April 2007 and said to 
have been well adherent to treatment. Within 8 months after completing treatment, he 
was diagnosed with active TB in The Netherlands. The HR CT of the chest showed bilateral 
cavernous and endobronchial lesions. Standard treatment with HRZE under DOT was 
started. The MTB strain was susceptible to HRZE. One month after start of treatment, 
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pyrazinamide was stopped because of gastro-intestinal intolerance. There were no signs 
of hepatotoxicity. Sputum remained culture positive for more than 4 months (indicating 
treatment failure according to the Dutch NVALT guidelines).16 Drug susceptibility testing 
showed that the MTB strain was still susceptible to all first-line TB drugs. Rifampicin 
plasma concentrations were determined and revealed a peak concentration of 4.1 mg/L 
at 2 h post dose. Dose adjustment took place (from 600 to 1200 mg), upon which the C2 
plasma concentration increased to 22.4 mg/L, reflecting the nonlinear pharmacokinetics of 
rifampicin.15 Sputum culture conversion occurred 1 month later. The patient gained weight 
and the cough disappeared. Despite gastrointestinal problems at the onset of treatment, 
the patient completed treatment without any further adverse events. The total treatment 
duration was 11 months. After more than 1.5 years of follow-up, there were no signs of 
relapse.
Patient 3 – second relapse TB after gastric surgery in the past 
A 66-year-old Caucasian man with a history of Billroth II gastrectomy (1980), ischemic 
heart failure and chronic obstructive pulmonary disease (COPD, gold III), was successfully 
treated with self-administered 2HRZE/4HR for pulmonary TB in 2004. In December 2007, he 
developed relapse TB caused by an identical, drug susceptible MTB strain. He was treated 
with 2HRZE/4HR again (unsupervised). In December 2008, the patient returned with a 
second relapse of pulmonary TB. He presented with weight loss of 10 kg (BMI 13.7 kg/m2). 
This second relapse was confirmed by identical MTB genotypic fingerprints to those of the 
previous episodes. Treatment with HRZE was started and the patient was admitted to our 
centre. Plasma concentrations of rifampicin and pyrazinamide were obtained considering 
the possibility of drug absorption problems in this patient as a consequence of gastric 
surgery in the past. Peak concentrations were low (4.0 mg/L for rifampicin and 10 mg/L for 
pyrazinamide) and occurred delayed (at 4 h post dose) for rifampicin. Because of the low 
BMI of the patient, protein-unbound (free) concentrations of rifampicin and pyrazinamide 
were measured as well, since a change in the ratio of unbound versus total (bound plus 
unbound) concentrations (i.e. the free fraction) may affect the interpretation of total 
concentrations.18 However, both unbound fractions and plasma albumin levels were normal. 
Therefore, the doses of isoniazid, rifampicin and pyrazinamide were adjusted (H from 200 
to 250 mg, R from 450 to 600 mg, Z from 1250 to 2000 mg). The pyrazinamide peak plasma 
concentration reached the target range (43 mg/L) with this dose adjustment, and the 
rifampicin peak plasma concentration did so after another dose adjustment (to 900 mg; 
C6: 8.5 mg/L). Sputum culture conversion occurred within 8 weeks after the second dose 
adjustment of rifampicin. The higher doses were tolerated well. The patient recovered with 
treatment under DOT in July 2009. Unfortunately, he died of progressive heart failure a few 
months later. 
Patient 4 – relapse TB in a diabetes patient  with extensive cavitary disease 
A 42-year-old Caucasian man with a history of type II DM and schizophrenia completed 
treatment with 2HRZE/4HR under DOT for susceptible pulmonary TB in July 2007. In April 
2008, he presented with relapse pulmonary TB that was susceptible to HRZE. The HR CT 
showed bilateral multiple small consolidations, large cavities in the left upper lobe and 
partial collapse of the right lung, together with traction bronchiectasis. Treatment with 
HRZE was started again. Sputum culture conversion occurred within 6 weeks after start of 
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treatment, but clinical and radiologic response were slow. Rifampicin plasma concentrations 
were measured after 12 weeks of treatment and the peak plasma concentration was 2.3 
mg/L at 2 h post dose. Dose adjustment of rifampicin from 600 to 900 mg took place and 
resulted in an improved peak plasma concentration of 8.2 mg/L. The C4 en C6 plasma 
concentrations however, were 3.6 and 1.6 mg/L respectively, and it was decided to 
increase the dose to 1200 mg in order to achieve higher exposure. Clinically, the patient 
improved from the time of the final dose adjustment. A control CT scan 3 months later 
showed slight improvement, but the large cavities in the left upper lobe were unchanged. 
Positron Emission Tomography (PET) showed little fluorodexoglucose uptake in the lesions 
and therefore, we decided to refrain from surgery. Supervised treatment was continued for 9 
months. No adverse events occurred. After more than 1.5 years of follow-up, the patient did 
not show signs of relapse TB.
Discussion
In our setting, TDM proved to be of help in detecting low TB drug plasma concentrations 
as one of the possible causes of slow treatment response, treatment failure or relapse 
TB, and in monitoring the effects of step-wise increases in drug doses. We presented four 
patients with relapse TB, all of whom appeared to have peak plasma concentrations of TB 
drugs below the target range. In most cases, increased drug doses resulted in peak plasma 
concentrations within the target range and clinical response to treatment, while no adverse 
events occurred. 
Generally, the applicability of TDM depends on the fulfilment of a number of criteria.13,15
First, there should be a large inter individual variation in drug plasma concentrations, which 
is the case in TB treatment.10
Second, there should be a clear relationship between drug plasma concentrations and 
response (which can either be therapeutic or undesirable, toxic response). The association 
between TB drug plasma concentrations and treatment response is incompletely 
understood. A limited number of in vitro and murine studies have shown that the ratio 
between the area under the plasma concentration curve (AUC) and the minimum inhibitory 
concentration (MIC) is the pharmacodynamic index that best explains the effects of 
isoniazid, rifampicin, pyrazinamide and ethambutol.19-24 
Findings from a number of studies in humans pointed towards an association between low 
TB drug concentrations and poor treatment outcome,3,4,25 but this association has been 
questioned by findings from other studies.12,26
As a third criterion for TDM, the drug concentration range in which a drug is effective and 
tolerated well, should be known and narrow. As mentioned previously, the target ranges 
that are currently used represent normal concentrations that can be expected after 
standard doses of TB drugs. As the standard doses are generally effective and tolerable, 
these concentrations seem suitable as target ranges.10
The fourth criterion for the applicability of TDM is that there should be no alternative, 
easier measurable indicator of treatment response available. Although clinical response 
and sputum smear or culture conversion are markers of TB treatment response,27 they 
are typically assessed after weeks of treatment, when the emergence of resistance or 
treatment failure may already have occurred.2 
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Obviously, TB treatment does not fulfill all requirements for TDM, mainly because of gaps in 
knowledge and understanding of the pharmacokinetics and –dynamics of TB drugs. Sharing 
clinical experience of using TDM to individualize TB treatment could help to fill parts of 
those gaps.
We have presented a series of four cases only. The results are therefore not generalizable. 
Nevertheless, we think that this case-series illustrates the value of TDM as a tool to assess 
whether inadequate response to TB treatment can be attributed to suboptimal exposure to 
TB drugs in patients with drug-susceptible TB. More research is needed to evaluate the TB 
drug plasma concentration – response relationship as a basis for TDM in TB treatment.
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Abstract
Concentrations of antimycobacterial drugs are an intermediary link between doses admin-
istered and eventual response to the drugs. Few pharmacokinetic studies have focussed 
on drug treatment for non-tuberculous mycobacterial (NTM) disease, although favourable 
treatment response occurs in just over 50% of patients despite drug treatment for at least 
one year. Purpose of the study: a prospective, descriptive pharmacokinetic study was per-
formed to assess the plasma pharmacokinetics of rifampicin, ethambutol, clarithromycin, 
14-OH-clarithromycin, azithromycin, isoniazid and moxifloxacin. Intensive pharmacokinetic 
sampling was performed in 14 patients with clinically relevant NTM lung disease. Pharma-
cokinetic parameters were assessed and compared with available data from the literature. 
Results: exposure to clarithromycin when combined with rifampicin was very low (geo-
metric mean AUC0-12h: 2.6, range 1.6-3.2 h*mg/L , Cmax: 0.3, range 0.1-0.7 mg/L ). The mean 
parent-to-metabolite ratios were 0.4 and 0.3 for AUC0-12h and Cmax, instead of the typical ratio 
of around 3, probably reflecting increased metabolism of clarithromycin to its (virtually inac-
tive) 14-OH-metabolite. Exposure to rifampicin was relatively high, with all patients having 
a rifampicin Cmax value within the reference range. The majority of ethambutol Cmax values 
were within the reference range. Major conclusion: the current study re-emphasizes the 
relevant pharmacokinetic interaction between clarithromycin and rifampicin. This calls for 
a re-evaluation of the dosing strategies in NTM lung disease, as suboptimal drug exposure 
may contribute to inadequate response to NTM treatment.
1. Introduction
The incidence of Non-tuberculous mycobacterial (NTM) lung infections is increasing 
worldwide due to various factors including improved detection methods, greater 
awareness of clinicians, advancing age, increasing incidence of COPD, the widespread use 
of  immunomodulating drugs and possibly an increasing environmental exposure to these 
bacteria.1,2 In The Netherlands, the incidence of NTM lung disease has also increased in 
the past years.3 The Dutch NTM lung disease patient population differs from that in other 
countries in terms of a predominance of male sex (>60% men), cavitary disease (<10%), 
underlying lung diseases (>75%) and the causative NTM species, among which M. avium is 
predominant.3-4 Successful treatment for NTM infections is hampered by misinterpretation 
of drug susceptibility patterns of the causative mycobacteria, co-morbidities including 
underlying lung disease5 and possibly non-adherence to drug treatment due to adverse 
effects.2 
Unfortunately, there is limited evidence for currently recommended drug treatment 
regimens; these regimens are mostly based on single centre, non-comparative studies and 
only few prospective clinical trials have been performed to compare possible treatment 
combinations.1-2
The relationship between the doses of the drugs applied and the drug concentrations 
achieved in patients (pharmacokinetics, PK) and the relationship between these 
concentrations  and response (pharmacodynamics, PD) are important knowledge gaps in 
NTM lung disease treatment.1,2,6 In NTM lung disease, very few studies have been performed 
to study drug concentrations as an intermediary link between dose and effect.7-11 
In contrast, the PK of drugs in tuberculosis (TB) treatment have been studied extensively 
in the past (reviewed in12-13) and it has become evident that suboptimal exposure to TB 
drugs can result in inadequate response to TB treatment.14-16 In our setting, measurement 
and interpretation of TB drug concentrations (Therapeutic Drug Monitoring, TDM) proved 
helpful in detecting low TB drug plasma concentrations as one of the possible causes of 
slow treatment response, treatment failure or relapse TB, and in monitoring the effect 
of step-wise increases in drug doses.16 Similarly, insight into the pharmacokinetics and 
pharmacodynamics of drugs in NTM infections is urgently required to better comprehend 
how adequate response is achieved and when drug resistance and drug-related toxicity 
emerge. 
In this study, we have determined the plasma pharmacokinetics of rifampicin, ethambutol, 
clarithromycin and its metabolite hydroxy-clarithromycin (OH-clarithromycin, which is far 
less active against M. avium complex than the parent drug), azithromycin, isoniazid and 
moxifloxacin in a series of patients in The Netherlands with clinically relevant NTM lung 
disease and we have compared the results to other series from the literature.
Materials and Methods
1 Subjects
Adult patients with M. avium complex, M. kansasii or M. malmoense pulmonary infections as 
diagnosed according to the American Thoracic Society (ATS) guideline,2  were eligible for the 
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study and were recruited from November 2010 until November 2011. Patients were either 
newly diagnosed or currently receiving treatment. We included patients on daily treatment 
with at least rifampicin and ethambutol and optionally with isoniazid, clarithromycin, 
azithromycin or moxifloxacin. Patients with hepatic or renal dysfunction, pregnancy, cystic 
fibrosis or HIV infection were excluded, as these conditions may affect PK. All patients 
provided written informed consent, the study was approved by the Ethical Review Board 
of University Medical Centre Nijmegen, The Netherlands and was registered under www.
clinicaltrials.gov: NCT01051752.
2 Design and procedures
A prospective, descriptive pharmacokinetic study was performed, using the standard two-
stage approach. With this approach individual pharmacokinetic parameters are estimated 
in the first stage. In the second stage, population characteristics of each parameter are 
derived by obtaining measures of central tendency and spread of the subjects’ individual 
parameters. The patients were treated with approved drugs supplied by our institution 
for at least two weeks to achieve steady state before the pharmacokinetic sampling day. 
Adherence in the two weeks preceding the sampling day was monitored with a medication 
diary in which patients recorded the time of drug intake.
Patients refrained from the intake of food from 00.00 a.m. at the PK sampling day. At 
09.00 h the patients ingested all prescribed drugs on an empty stomach, under supervision 
of study personnel. In the case of clarithromycin, which is dosed twice daily, the second 
dose of 500 mg was taken 12 h later under supervision of the nurse of the hospital ward. 
Patients were allowed to eat, drink and take other medications starting from 12.00 am. A full 
pharmacokinetic curve was recorded. Serial venous blood samples were collected just prior 
to, and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 12.0 and 24.0 h post dose, or until 12.0 h post dose for 
clarithromycin. Plasma was separated immediately, frozen to -80 °C and transported on dry 
ice for bioanalysis.
3 Bioanalysis
Total (protein bound plus unbound) plasma concentrations of rifampicin, ethambutol, 
clarithromycin and its metabolite 14-OH-clarithromycin, and moxifloxacin were assessed by 
validated high performance liquid chromatography (HPLC) methods as described before.17-19 
Isoniazid was measured with liquid-liquid extraction followed by ultra performance liquid 
chromatography (UPLC) with ultraviolet (UV) detection. Accuracy was between 97.8% 
and 106.7%, dependent on the concentration level. The intra- and interassay coefficients of 
variation were less than 13.4 % (dependent on the concentration) over the range of 0.05 
-15.1 mg/L. The lower limit of quantitation for isoniazid was 0.05 mg/L. Isoniazid containing 
samples were stable (<5% loss) for at least 12 months at -80oC. Azithromycin was measured 
with LC-MS/MS. Accuracy was between 98.0 and 101.3%, dependent on the concentration 
level. The intra- and interassay coefficients of variation were less than 7.4% over the range of 
0.1 mg/L to 5.0 mg/L. The lower limit of quantitation was 0.1 mg/L.
4 Pharmacokinetic analysis
Pharmacokinetic parameters were assessed with non-compartmental methods using 
WinNonLin version 5.0 (Pharsight Corp., Mountain View, California). The highest observed 
plasma concentration was defined as Cmax, with the corresponding time as Tmax. If the 
concentration at 24 h post dose (C24) was below the limit of quantitation, it was calculated 
using the formula C24 = Clast* e 
(-β * (24-Tlast), in which β is the first order elimination rate 
constant and Tlast is the time of the last measurable concentration (Clast). β was obtained 
by least squares linear regression analysis on log C versus time, with the absolute slope of 
the regression line being β/2.303. The area under the time-concentration curve (AUC0-24, 
or  AUC0-12 for clarithromycin and OH-clarithromycin) was calculated using the log-linear 
trapezoidal rule from zero up to T=24 u or T=12 h. The apparent clearance of the drug (Cl/F) 
was calculated by dose/AUC0-24 or dose/AUC0-12 for clarithromycin. The volume of distribution 
was calculated by the equation Cl/F/ [β].
5 Statistics
Pharmacokinetic parameters were described by geometric means and range, apart from Tmax 
which was presented as median and range. Based on previously published reference ranges 
or values, Cmax values were dichotomized as either normal or low. Low concentrations were 
defined as <8 mg/L for rifampin,20<2 mg/L for ethambutol,20 <2.5 mg/L for clarithromycin,21 
<0.3 mg/L for azithromycin22 and <3 mg/L for isoniazid20 based on standard weight-adjusted 
dosing. The median peak plasma concentration for moxifloxacin at a daily dose of 400 mg 
as assessed in TB patients in The Netherlands was 2.5 mg/L.23
Where possible in view of patient numbers, the effects of gender, age, body weight and 
BMI on the PK parameters were assessed using the independent sample t-tests on the log-
transformed parameters (or the Wilcoxon rank sum test for Tmax; comparison of subgroups 
e.g. men vs women) or Spearman’s rho on untransformed parameters (correlation of 
parameters). All statistical evaluations were performed with SPSS for Windows version 20 
(SPSS Inc., Chicago). P values of less than 0.05 were considered significant in all analyses.
Results
1 Subjects 
Fourteen patients were included in the study. Their baseline characteristics, drug regimens 
used and doses applied are shown in Table 1. All patients were Caucasians, 10 (71%) were 
males. Four patients had disease caused by M. avium, three M. intracellulare, one M. 
chimaera, three M. malmoense and three by M. kansasii. Two patients had a relapse of M. 
avium infection, all others had their first episode of NTM lung disease. Disease caused by 
M. avium, M. intracellulare and M. chimaera  was treated with rifampicin and ethambutol in 
combination with claritromycin or azitromycin, if the causative bacteria proved susceptible, 
in vitro, to clarithromycin. M. malmoense was treated with rifampicin and ethambutol (n=2), 
combined with moxifloxacin in one case. M. kansasii was treated with isoniazid,  rifampicin 
and ethambutol. In one patient with isoniazid resistant M. kansasii, clarithromycin was 
used. The two patients with recurrent M. avium infection had treatment regimens that 
differed from the regimen recommended by the ATS. One had rifampicin combined with 
clarithromycin because of toxicity of ethambutol. The other did not use clarithromycin 
because of macrolide resistance in vitro.
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Table 1. Characteristics of 14 patients with NTM infection and their drug regimens
Abbreviations: RIF: rifampicin, E: ethambutol, CLR : clarithromycin, AZM: azithromycin,
H: isoniazid, MXF: moxifloxacin, Cfz: clofazimine, AMK: amikacin, Cs: cycloserin
The clarithromycin dose used was 500 mg BID. Azithromycin dose was 250 mg once daily 
in one case and 500 mg once daily in the other. Adherence in the two weeks preceding the 
PK assessment was 100% according to the medication diaries.  All but one patient had a full  
pharmacokinetic curve recorded. This patient had samples taken at 2, 4 and 6 hours post 
dose.
2 Pharmacokinetic analysis
In one out of six patients on clarithromycin, concentrations of clarithromycin and 14-OH-
clarithromycin could not be analyzed as the volume of plasma remaining after analysis of 
rifampicin was not sufficient to analyze other drugs. In another patient on clarithromycin, 
only four subsequent concentrations in the PK curve were measurable at the limit of 
quantitation, which shows a very low exposure to clarithromycin but did not allow the 
calculation of an AUC0-12.
Characteristics
Male, n (%) 10 (71%)
Age (yrs)( median, range) 67.5 (43-85)
Weight (kg)(median, range) 70 (60-83)
BMI (median, range) 23.5 (19-30)
Used drug regimens
RIF, E, CLR 5
RIF, E 2
RIF, E, AZM 2
RIF, E, H 2
RIF, E, MXF 1
RIF, E, Cfz, AMK, Cs 1
RIF, CLR 1
Drug dosages (mg/kg/dose, mean±SD)
RIF (n=14) 8.5 ± 0.7
E (n=13) 16.0 ± 1.9
CLR (n=6) 7.1 ±0.8
AZM (n=2) 5.5 
H (n=2) 3.9
MXF (n=1) 6.2
The resulting PK parameters of rifampicin, ethambutol, clarithromycin, 14-OH-clarithromycin 
and azithromycin are summarized in Table 2. Figure 1 and 2 display the average PK curves of 
rifampicin, ethambutol, clarithromycin and 14-OH-clarithromycin. As to rifampicin, a roughly 
three fold interindividual variability in AUC0-24 and Cmax was observed. All patients reached a 
Cmax value within the reference range of rifampicin (>8 mg/L). With respect to ethambutol, 
one out of 13 patients had an ethambutol Cmax below the reference range (2 mg/L). Cmax 
values of clarithromycin were far below the reference value of 2.5 mg/L in all 5 patients 
in whom clarithromycin could be measured (geometric mean 0.3 mg/L, range 0.1-0.7). 
The parent drug to metabolite ratio for clarithromycin to 14-OH-clarithromycin has been 
described as 3:1, but the mean value was 0.39 (Cmax) and 0.33 (AUC0-12h) in our patients. In 
both patients who used azithromycin, the Cmax reference value (>0.3 mg/L) was not reached. 
The two patients on isoniazid had AUC0-24 values of 8.4 and 11.1 h*mg/L and Cmax values were 
5.0 and 4.9 h* mg/L, i.e. within the reference range. The AUC0-24 and Cmax for moxifloxacin in 
one patient were 20.5 h*mg/L and 2.2 mg/L respectively.
We did not find clear correlations between gender, age, body weight or BMI on the one 
hand and AUC or Cmax of rifampicin, ethambutol and clarithromycin or 14-OH-clarithromycin 
on the other hand, but obviously the numbers of patients were small. 
The AUC0-12 ofclarithromycin and 14-OH-clarithromycin did not correlate with the AUC0-24 of 
rifampicin (r=0.1, p=0.01 and r=0.1, p=0.01 respectively).
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Pharmacokinetic parameter RIF
N=14
E
N = 13
CLR
N=5
14-OH-CLR
N=5
AZM
N=2
AUC0-24 (RIF, E, AZM) or AUC0-12 
(CLR, 14-OH-CLR) 
(h.mg/L)
45.9
27.8-80.6
24.2
12.6-46.7
2.6 b
1.6-3.2
6.6
2.0-12.8
1.9
1.4-2.6
Cmax (mg/L) 12.3
8.6-24.9
3.1
1.5-5.3
0.3
0.1-0.7
1.0
0.4-1.9
0.18
0.17-0.2
Tmax (h) 2.0
1.0-4.0
3.0
1.5-6.0
2.0
2-12
3.0
3-6
5.25
2.5-8.0
Cl/F (L/h) 13.1
7.4-21.6
46.5
25.7-79.3
188.9 b
154.4-308.2
182.0
175.0-189.3
Vd/F (L) 30.4
16.5-45.2
671.6
338.6-1356.4
1207.4 c
602.2-4817.1
2979.6
1913.1-4640.8
t½(h) 1.6
1.2-2.7
10.0
6.6-16.2
4.1 c
2.4-10.8
4.0
2.6-7.2
11.3
7.6-17.0
Table 2. Pharmacokinetic parameters of rifampicin, ethambutol, clarithromycin and 
azithromycin in patients with NTM disease a
Geometric means and range, apart from median and range for Tmax. Abbreviations of pharmacokinetic a. 
parameters: see the text. 
b.  Based on data for n=4 patients 
Based on data for n=3 patients c. 
Abbreviations: RIF: rifampicin, E: ethambutol, CLR : clarithromycin, 14-OH-CLR: 14-OH-clarithromycin, d. 
AZM: azithromycin
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Figure 1. Pharmacokinetics of rifampicin (n=14) and ethambutol (n=13), mean and standard 
deviations
Figure 2. Pharmacokinetics of clarithromycin and its active metabolite 14-OH-clarithromycin 
(n = 5), mean and standard deviations
4 Discussion
This study evaluated the steady-state pharmacokinetics of antimycobacterial drugs, 
obtained by intensive pharmacokinetic sampling, in a series of NTM lung disease patients 
who were typical to the Dutch NTM patient population in terms of race, male sex, age and a 
relatively low body weight.3
The most important finding from this study is that exposure to clarithromycin is low 
when combined with rifampicin. All 5 patients in whom clarithromycin was measured had 
Cmax values far below the reference value of 2.5 mg/L for clarithromycin.
21 In addition, the 
average AUC0-12 for clarithromycin after a dose of 500 mg at steady-state (geometric mean: 
2.6 h* mg/L) was much lower than that described without co-administration of rifampicin 
(circa 20 h*mg/L).21 
The mean parent to metabolite ratio for the Cmax and AUC for clarithromycin were 0.3 
and 0.4, respectively, which is much lower than the typical ratio of 3:1.7,21 This reflects an 
increased metabolism of clarithromycin to its main 14-OH-metabolite. The latter is 10-30 
times less active against M. avium complex, in vitro, than the parent drug.24 These findings 
are in agreement with available data from the literature, summarized in table 3,7-10 previously 
demonstrating low Cmax and AUC levels of clarithromycin in the presence of rifampicin. Most 
probably, these effects are the result of the induction by rifampicin of the metabolic enzyme 
that catalyzes the hydrolysis of clarithromycin.8
Table 3.    Pharmacokinetic studies in NTM disease studying co-administration of 
clarithromycin and rifampicin a,b
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Author
(number of sampling 
points)
Drugs 
(number of patients) Average Dose AverageAUC (h.mg/L)c
Average,
Cmax(mg/L)
Wallace (1995)
(1)
RIF (12) 600 mg QD
NA
NA
CLR (12) 500 mg BID 0.7
14-OH CLR (12) 1.8-1.9
Peloquin (1996)d
(2)
RIF (12) NA
NA
10.3
CLR (21) 10.6 mg/kg QD 0.58
14-OH CLR (21) 1.75
Alffenaar (2010)
(full PK curve)
RIF (8) 8.8 mg/kg QD 25.8 4.9
CLR (8) 7.5 mg/kg QD 2.9 1.0
14-OH CLR (8) 8.6 1.5
Van Ingen (2012)
(2)
RIF (326) 9.6 mg/kg QD 68.4 18.8
CLR (39) 14.3 mg/kg daily 5.3 1.25
14-OH CLR (39) NA NA
This study (2012)
(full PK curve)
RIF (14) 8.5 mg/kg QD 45.9 12.3
CLR (5) 7.1 mg/kg BID 2.6 0.3
14-OH CLR (5) 6.6 1.0
Abbreviations: n: number of patients studied, NA: not available, RIF: rifampicin, CLR: a. 
clarithromycin, 14-OH-CLR: 14-OH-clarithromycin
Measures for central tendency (e.g. mean, median, geometric mean) differ between studiesb. 
AUC data differ from study to study: Alffenaar et al assessed AUCc. 0-24 for RIF, CLR and 14-OH-CLR; 
van Ingen et al assessed AUC0-6/7 for RIF and CLR; and the current study assessed AUC0-24 for RIF 
and AUC0-12 for CLR and 14-OH-CLR
Data are shown for the ‘NJC population’ described in this study, not for the ‘referral patients’d. 
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The low clarithromycin plasma concentrations demonstrated in this study are likely to 
be very relevant  for  treatment outcome. Macrolides exert so called time-dependent 
inhibition, which requires that the drug concentrations should be above the MIC value of 
the bacteria for a certain minimal amount of time (T>MIC).21
The low clarithromycin AUC0-12 and Cmax values upon co-administration of rifampicin will 
inevitably result in a decrease in T>MIC in plasma. For mycobacteria it is not yet clear, 
though, how long this amount of time should be. Furthermore it should be underlined that 
macrolides achieve significantly higher drug concentrations in the epithelial lining fluid (ELF) 
and alveolar macrophages, the potential sites of action of extracellular and intracellular 
replicating respiratory pathogens, respectively.21 There are no actual data to show that the 
macrolide accumulation in tissues in humans is affected by the interaction with rifampicin. In 
a recent study in foals however, the concentrations of clarithromycin in ELF and in alveolar 
macrophages were lowered drastically after co-administration with rifampicin.25 
Clearly, the interaction of clarithomycin with rifampicin may be one of the reasons for 
suboptimal response to drug treatment in NTM lung disease. Consequently there is a 
need for follow-up studies that evaluate the pharmacokinetics, safety/tolerability and 
efficacy of a higher dose of clarithromycin when combined with rifampicin. Alternatively, 
rifabutin may be used instead of rifampicin, as co-administration of this rifamycin has less 
effect on clarithromycin concentrations.7 However, it should be noted that rifabutin and 
clarithromycin show a complex bi-directional interaction which may result in rifabutin-
induced toxicity, including uveitis and polyarthritis.21 
Azithromycin could also be used as an alternative to clarithromycin, as it is generally less 
prone to interactions and can be dosed once-daily. Our data on azithromycin relate to only 
two patients, which precludes firm conclusions. In the absence of follow-up studies at this 
moment, TDM may be used to optimize the exposure to all drugs in individual patients.8,16
Considering rifampicin, our data showed that all patients reached a rifampicin Cmax value 
within the reference range (i.e. > 8mg/L). This may suggest that patients with NTM disease 
reach higher peak plasma concentrations of this pivotal antimycobacterial drug than 
patients with TB. For example, in a study among TB patients in Dutch TB clinics, using a 
similar intensive sampling scheme and the same analytical methods, we observed that 30% 
of the patients had Cmax values below 8 mg/L (Magis-Escurra, et al. submitted). Similarly, an 
intensive PK sampling study of ours in Indonesian TB patients showed 21% of patients with 
rifampicin Cmax values below 8 mg/L.
17 
Using other analytical methods and limited sampling, Van Ingen et al. also found only 5% 
of patients with rifampicin Cmax concentrations below 8 mg/L among Northern American 
patients with NTM (M.avium) lung disease.10  The higher Cmax of rifampicin among patients 
with NTM disease versus TB patients may be due to faster absorption or smaller volumes 
of distribution. Furthermore we can not exclude that co-administration of isoniazid in all 
patients with TB (as compared to few patients with NTM lung disease) may somehow 
affect the pharmacokinetics of rifampicin.  As to the total exposure of rifampicin, the 
current study with intensive sampling allowed for an accurate estimation of AUC0-24 of 
rifampicin (geometric mean: 45.9 h*mg/L) and this appeared to be only slightly higher 
than the geometric mean AUC0-24 in Dutch TB patients (41.1 h*mg/L, Magis-Escurra et al., 
submitted). Of note, most NTM are known to be much less susceptible (i.e. having much 
higher minimum inhibitory concentrations [MIC]) to rifampicin than M. tuberculosis26 but 
there are no clinical data showing what Cmax/MIC or AUC/MIC values should be reached for 
this exposure-dependent drug in NTM disease or TB.  As to ethambutol, only one patient 
had a low Cmax (1.4 mg/mL) and AUC0-24 (12.6 h.mg/L) of ethambutol. Similarly, ethambutol 
Cmax reference values are often reached in TB patients.
17 In contrast, Van Ingen et al. found 
that 48% of patients had ethambutol Cmax values below the reference values (2-6 mg/L) in a 
Northern American population of patients with NTM lung disease.10
The strength of this study compared to the few other pharmacokinetic studies in NTM 
disease was the intensive sampling  of patients, resulting in accurate estimates of 
pharmacokinetic parameters in all individuals. However, the study was limited by the 
small sample size which restricted statistical power to detect possible pharmacokinetic 
differences between patient subgroups. 
In summary, this study confirmed and re-emphasized that exposure to clarithromycin is 
very low when rifampicin is co-administered in patients with NTM disease. In addition, 
results from this study suggest that peak plasma concentrations of rifampicin are higher in 
patients with NTM disease compared to patients with TB. There remains an urgent need to 
re-evaluate dosing strategies in NTM lung disease, to study the pharmacokinetics, safety/
tolerability and efficacy of higher doses of clarithromycin when combined with rifampicin, 
and to evaluate azithromycin and rifabutin as alternative macrolides and rifamycins in 
combatting NTM.
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Background
Tuberculosis (TB) has ravaged humans since ancient times. Signs of the disease could 
already be observed in pharao’s tombs, where mummies showed signs of “Pott’s spine 
disease” leaving mutilating and disabling kyphoscoliosis. Although we dispose of effective 
treatment for TB since the sixties of the last century, not a single country in the world has 
yet managed to eradicate this disease. 
TB is caused by bacteria from the Mycobacterium tuberculosis complex and consists of 
several subtypes. Although the global incidence and mortality is declining still a 9 million 
new TB patients are registered annually with 1.4 million annual deaths. Incidence rates 
vary enormously from 5/100.000 in Scandinavian, some European countries and the United 
States of America to well over 300/100.000 in South Africa. 
Non tuberculous mycobacteria (NTM) are becoming frequently recognized as real 
pathogens. They are culprits of a disease resembling TB with the difference of being a non-
communicable and showing a rising incidence especially in countries where TB incidence 
is declining. This increase is caused by various factors including improved detection 
methods, greater awareness of clinicians, advancing age, increasing incidence of COPD, the 
widespread use of immune modulating drugs and possibly an increasing environmental 
exposure to these bacteria.
This thesis gives an overview of epidemiological, diagnostic and pharmacological research 
from Dekkerswald, a Dutch tertiary referral centre for patients with TB and NTM infections. 
All studies in this thesis deal with mycobacterial infections, mostly tuberculosis but also one 
chapter on NTM infections.
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Summary of the chapters 
Introduction
In the introduction of this thesis (chapter 1) a historical perspective, pathogenesis, diagnosis 
and treatment of TB and NTM are described. Subsequently we zoom in to pharmacokinetics 
of TB treatment helping to understand that TB treatment harbours many possible threats 
for treatment failure, relapse and acquired drug resistance. Finally, an overview of Dutch 
TB control is given, explaining the function of clinical TB consultants and the TB referral 
centers.
Epidemiological studies
The thesis starts with a descriptive study (Chapter 2) of TB patients in our centre, admitted 
during the period 2000-2005, and provides an insight in the demographic, clinical and social 
data of this population. A total of 166 patients with 37 different nationalities were analyzed. 
Tertiary referrals accounted for 98% of all hospitalizations. Most patients (68%) were 
referred for clinical reasons and 32% were referred for social reasons such as homelessness, 
substance misuse and psychiatric diseases. 
Severe hepatotoxicity was the principal clinical reason for referral, followed by delayed 
response to treatment, need of surgical interventions, combined HIV-TB infection, drug 
resistance problems, and need for isolation. Of the drug resistant strains, 94% were isolated 
from patients of foreign origin. Toxicity and side effects of treatment often led to changes in 
treatment (40%). Ten percent of patients were seropositive for HIV and many of them (82%) 
experienced adverse effects, mainly hepatotoxicity. Extrapulmonary TB was diagnosed 
significantly more often in the foreign patient group. 
The median admission period for the total population was 10.1 weeks, showing no 
differences between patients admitted for clinical or social reasons or country of origin. 
Eighty-five percent of the population completed treatment, six percent was lost to follow 
up and TB mortality was five percent. 
In conclusion, the TB population treated in Dekkerswald had excellent treatment success 
rates despite the complexity and diversity of this group. Regarding the increased number of 
admissions to our centre since 2005, we seem to be meeting a considerable demand. When 
TB incidence began to decline, sanatoria were no longer needed at large scale, but TB will 
never be eliminated completely and it is therefore important that some of these specialized 
institutions remain active to preserve and optimize expertise.
The subsequent chapter (chapter 3) describes the retrospective analysis of all 
Mycobacterium bovis TB in The Netherlands during 1993-2007 after our attention was drawn 
by three Dutch patients with M. bovis disease in our Centre. 
We analyzed data from 231 patients for clinical, demographic, treatment, outcome 
characteristics and for risk factors. Disease was mainly extrapulmonary (n=136; 59%). 
Although 95 patients had pulmonary disease, person-to-person transmission did not occur, 
as shown by structural DNA fingerprinting analysis. 
Lymph node TB was more likely to develop in women (p<0.0001), whereas pulmonary M. 
bovis disease developed more frequently in men (p<0.0001). Diagnosis was accurate but 
the determination delay led to inadequate treatment in 17% of the cases. The proportion of 
deaths from M. bovis (5%) was higher than that for M. tuberculosis disease (2%). From this 
study it was concluded that the prevalence of M. bovis disease in The Netherlands (1.4%) 
is comparable to that in other countries in which control programs for M. bovis infection 
are enforced. Gender differences in clinical features and mortality rates were found in our 
cohort of patients. The disease now mainly affects elderly native Dutch citizens (60%) and 
immigrants from Morocco (23%). Anti-TNF-α treatment is an emerging cause of endogenous 
reactivation and M. bovis TB may reactivate slower than M. tuberculosis TB.
Diagnostic studies
In the following chapter (chapter 4) we assessed  the accuracy of registration of culture 
results in the TB register and studied the characteristics of patients notified with non-culture 
confirmed TB and the quality of TB diagnosis. Patient records of patients notified with 
non-culture confirmed TB in the period 2007-2009 were reviewed at the Public Municipal 
Health Services (PMHS). These data were compared to the information in the NTR. Cases 
were subsequently classified according to the TB case definition of the European Centre 
for Disease prevention and Control (ECDC) as; ‘no’, ’possible’, ’probable’ or ’confirmed’ 
TB. Laboratory confirmation data of 6%  of notified TB cases in the NTR were incorrect or 
incomplete and the overall percentage of culture confirmed cases was corrected from 70% 
to 71%. In total 63% of non-culture confirmed cases were ETB. A total of 42% of non-culture 
confirmed TB diagnoses were established with other laboratory evidence such as positive 
Polymerase Chain Reaction or positive Ziehl Neelsen staining, or histology suggestive 
of TB. In total 164 out of 516 (32%) of the non-culture confirmed cases represented early 
diagnosis of extra pulmonary TB due to active case finding by physicians of PMHS, and no 
culture was attempted. In clinical extra pulmonary cases culture was not done because 
biopsy material was not suitable for culture anymore. 56% of non-culture confirmed cases 
was classified (according to the ECDC case definition) as ‘possible TB’, 35% as ‘probable 
TB’, and 6.8% as ‘confirmed TB’. Thirteen cases could not be classified due to missing data.  
Most ‘possible’ TB cases were those with a high likelihood of infection, diagnosed through 
active case finding by physicians of the PMHS. ‘Probable’ TB cases were mostly diagnosed 
in the hospital, culture was attempted in 60% of the cases but remained negative. In 31% 
of the cases the body material was retrieved, but delivered in the wrong condition to be 
cultured. Hospital clinicians should become aware of the importance of their contribution to 
registration and surveillance to control TB. On the other hand, advanced training of public 
municipal health staff may further improve quality of the NTR. 
Another study concerning diagnostics (Chapter 5) provides insight in the patient- and clinical 
characteristics of patients with spinal TB and the course of diagnostic delays of spinal TB 
from 2000-2011 in The Netherlands. We performed a descriptive, retrospective study. Data 
from the Netherlands Tuberculosis Registry (NTR) were studied, completed with basic 
demographic data and data considering patients-, doctors- and total diagnostic delay 
retrieved from the patient records at the public municipal health services. 
A total of 274 cases were studied at the PMHS. We found a median diagnostic delay of five 
months and this remained stable during 2000-2011. Sex and age groups were associated 
with significant differences in diagnostic delay (resp. male 4.5 vs female 5.5 months, 
p=0.004 and 0-34 years 4.5 months, 35-64 years 5.75 months and > 65 years 5.0 months, 
p=0.006). No difference was observed between origin of patients, patients presenting 
with TB risk factors or with neurological symptoms. Typical TB symptoms (back pain, night 
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sweats and weight loss) at presentation surprisingly lead to significantly increased doctors’ 
delay (typical symptoms 4.0 vs no typical symptoms 2.0 months, p=0.05). 
We concluded that refresher courses should be offered continuously both to family physicians 
and clinical specialists in order to raise the awareness and knowledge of TB in the era of declining 
TB incidence in The Netherlands.
Pharmacokinetic studies
To improve outcome of TB treatment, a better understanding of anti-TB drug 
pharmacokinetics is indispensable. Information about drug exposure in fixed dosing 
regimens seems crucial now to understand mechanisms of treatment failure, relapse 
and emergence of drug resistance. In addition, rather than only applying fixed dosing 
regimens, physicians may have drug concentrations measured and may individualize the 
dose based on the measured concentration (Therapeutic Drug Monitoring, TDM). However, 
unawareness of the relevance of drug exposure for response, high patient burden, costs 
and time spent still keep clinicians from performing TDM on a large scale, both for current 
first line and new anti-TB drugs. 
Variability in exposure to anti-TB drugs is one of the main factors related to treatment 
failure and the emergence of resistance. Therefore, total drug exposure, AUC0-24, is the 
pharmacokinetic parameter probably most relevant to the efficacy of TB drugs. High 
patient burden, costs and time spent, still keep clinicians from performing Therapeutic Drug 
Monitoring (TDM) of current first-line drug regimens on a large scale. 
In chapter 6  we assessed population pharmacokinetic data especially concerning AUC0-
24 for first-line TB drugs and moxifloxacin and developed limited sampling strategies. 
Intensive pharmacokinetic sampling was performed  in 41 hospitalized patients from two 
TB referral centers in The Netherlands. Drug concentrations were assessed with validated 
HPLC methods and pharmacokinetic parameters were assessed with non-compartmental 
pharmacokinetic methods. Best subset selection multiple linear regression was performed 
to derive limited sampling equations predictive of the AUC0-24. To assess the predictive 
performances of the models, residuals for each patient were calculated based on models 
fitted to a dataset where that patient was omitted. 
Geometric mean AUC0-24 values for rifampicin, isoniazid, pyrazinamide, ethambutol and 
moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 h*mg/L respectively. Limited sampling at two 
or three fixed sampling points allowed for an accurate and precise estimation of the AUC0-24 
values of all drugs separately and simultaneously. Sampling at 1, 4 and 6 h best predicted 
the AUC0-24 of all drugs together. 
In the absence of clinically validated target values for AUC0-24, the derived average values for 
AUC0-24 from this population could be used as reference values in TDM. Limited sampling of 
AUC0-24 of TB drugs is feasible and allows for TDM at a larger scale in Europe. 
In the next chapter (chapter 7) we provide insight in the current TDM practice in our centre. 
TDM is used in patients with drug-susceptible TB when abnormal TB drug concentrations 
are suspected (e.g. in case of HIV-infection, diabetes, gastro-intestinal abnormalities, 
malnutrition, or renal or hepatic dysfunction), when there is delayed sputum culture 
conversion (i.e. after more than eight weeks of treatment), and in case of relapse TB. We 
present a brief clinical glossary of four relapse TB cases to illustrate the method of TDM and 
the value of individualized TB drug dosing with low TB drug concentrations. 
In the four relapse cases increased doses of the first line TB drugs, especially rifampicin, 
resulted in adequate peak plasma concentrations and subsequently improved clinical 
response to treatment in these patients, while no adverse events occurred. 
As stated before, the mainstay of the thesis remains TB disease, but NTM infections are 
an entity not to be neglected. Last but not least, we therefore shift to a pharmacokinetic 
study in NTM lung disease in the last chapter (chapter 8). Treatment outcomes for NTM 
infections are poor even if recommended regimens are applied. In NTM disease very few 
pharmacokinetic (PK) studies have been performed. We performed a descriptive PK study 
using 11 sampling points, to assess the plasma pharmacokinetics of rifampicin, ethambutol, 
clarithromycin, azithromycin, isoniazid and moxifloxacin and their active metabolites in a 
series of 14 patients with clinically relevant NTM lung disease. We compared our results with 
available data from the literature. 
We learned that exposure to clarithromycin when combined with rifampicin was very low, 
and the mean parent-to-metabolite ratios were low as well. This probably reflects induction 
of metabolic enzymes by rifampicin. Exposure to rifampicin was relatively high, with all 
patients having a rifampicin Cmax value within the reference range of over 8 mg/L. Similarly, 
all ethambutol Cmax values were within the reference range between 2 and 6 mg/L. From this 
study we concluded that the relevant PK interaction between clarithromycin and rifampicin  
calls for a reconsideration of the dosing strategies in NTM lung disease, as suboptimal drug 
exposure may contribute to inadequate response to NTM treatment.
The table on the next page contains highlights of the thesis and their implications for future 
TB management and research.
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Anthology of this thesis’ findings and implications
Query Finding Implication
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Chapter 2
What characterizes patients 
admitted to  a Dutch TB referral 
centre (2000-2005)?
166 patients from 37 different 
nationalities, 68% hospitalized for 
medical reasons.
Drug resistant TB occurs in 23%.
Ten percent is HIV-positive.
Good therapy response with 
interdisciplinary approach at our 
centre.
1. specialized centers meet an 
important demand.
2. TB expertise must be actively 
sustained.
3. consultants specialized in  clinical 
TB care play a pivotal role in 
safeguarding expertise.
4. clinical TB expertise can be applied 
to improve TB care elsewhere in the 
EU/EEA region.
Chapter 3
Which  was the result of screening 
for latent TB before starting TNF 
alfa blocking agents in two patients 
who developed M.bovis TB?
Who is prone nowadays to develop 
bovine TB in The Netherlands?
The two patients will receive TB 
prophylaxis with current guidelines. 
Prevalence bovine TB 1.4%, mainly 
older Dutch (59.7%) and Moroccan 
individuals (23.4%).
Inadequate treatment in 17% of 
cases due to ignorance or slow 
determination and drug susceptibility 
testing.
1.the screen for latent TB is in need 
of a gold standard, evaluation of 
updated national guidelines and 
of a cardinal role for hospital TB 
coordinators. 
2. faster determination and drug 
susceptibility for M.bovis; accessibility 
to advise treatment regimens.
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Chapter 4 
Was the accuracy of registration of 
culture results in the Netherlands 
TB Registry during 2007-2009 
accurate? What characteristics had 
non-culture confirmed TB cases 
and which was their diagnostic 
accuracy?
6%  of notified TB cases in the NTR 
were incorrect. Culture confirmed 
cases was corrected from 70% to 
71%. In total 63% of  non-culture 
confirmed cases were ETB. 32% 
represented active case finding. 56% 
of cases was classified as ‘possible TB’, 
35% as ‘probable TB’, and 6.8% as 
‘confirmed TB’. 
1. awareness to culture biopsy and 
resection material should increase. 
2. false positive diagnosis of TB 
disease in active case finding should 
be considered. 
3. developing standard forms to 
complete NTR data. 
4. advanced training to further 
improve quality of the registered data 
in the NTR.
Chapter 5 
Did diagnostic delay in spinal TB 
worsen in the last decade?
Diagnostic delays remained stable over 
the years. Classical TB presentation 
or likewise risk factors did not reduce 
degree of diagnostic delays.
1.TB expertise needs to be preserved, 
this applies even more so in 
extrapulmonary TB.
2.role of consultants for clinical TB is 
important to maintain this expertise.
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Chapter 6 
Which were the population 
pharmacokinetics of first line anti-
TB drugs and moxifloxacin from 
the two Dutch TB referral centers 
and can limited sampling strategies 
be developed to estimate AUC0-24 
values of these drugs?
AUC0-24 values for rifampicin, isoniazid, 
pyrazinamide, ethambutol and 
moxifloxacin were 41.1, 15.2, 380, 
25.5 and 33.6 h*mg/L respectively. 
Limited sampling at two or three 
fixed sampling points allowed for an 
accurate and precise estimation of the 
AUC0-24 values of all drugs. 
1. TDM with limited sampling and 
less invasive PK methods is needed 
to implement TDM as a standard 
procedure in European TB care. 
Chapter 7 
What happens in a TB referral 
center with patients suspected for 
low serum levels of anti TB drugs?
TDM proved very useful in these 
selected cases with relapseTB. 
All cases showed lowered exposure to 
rifampicin. Higher dosage of rifampicin 
improved clinical status and rapidly led 
to culture conversion and termination 
of further relapses.
1.TDM should become widely 
available in European TB (referral) 
centers. 
2.limited sampling and dried blood 
spot methods facilitate the use at 
larger scale of this valuable tool for 
TB treatment.
Chapter 8 
What can we learn from 
pharmacokinetic data in patients 
with non-tuberculous mycobacterial 
lung infections?
Exposure to clarithromycin with 
rifampicin was very low. Exposure to 
rifampicin was relatively high. The 
majority of ethambutol Cmax values 
were within the reference range.
1. dosing strategies of in NTM lung 
disease need to be reconsidered to 
optimize treatment outcome.
2. evaluation of other treatment 
regimens is necessary
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General discussion on future TB care and research
From this table the implications of our studies for future clinical TB care and prevention 
become evident. Tuberculosis care in an affluent country such as The Netherlands readily 
provides all required resources, yet tuberculosis is still the invincible disease it has 
been since ancient times. Referral centers and clinical TB consultants currently meet a 
considerable demand in The Netherlands and will remain needed at national level. Hospital 
TB coordinators will play an important role in the future. Their knowledge and expertise 
needs to be maintained as they will be the spider in the web of screening, prevention and 
quality monitoring in TB care. Data supply for TB surveillance registry will benefit from 
more actively involved local physicians. From an international and especially European 
perspective, the Dutch level of expertise may serve as an example in optimization of 
drug resistant TB treatment. Adapting more to active case finding policies can decrease 
TB incidence. On the other hand, our study results also nourish further TB research. They 
stress the need of gold standards in latent TB infections (LTBI). Equally important is the 
evaluation of national and European guidelines for screening and treatment of patients 
with LTBI. Clinical TB care would benefit from strategies accelerating M.bovis growth. 
Finally, therapeutic drug monitoring warrants simpler, less invasive and less time consuming 
methods. The considerable outcome variability in different laboratories need quality control 
programs to guarantee its quality in different centers.  In the next paragraphs several of 
these implications are highlighted and discussed more extensively. 
Hospital TB coordinators
In only five years time (2006-2011), the TB population of Dekkerswald has grown 
exponentially to a median population of 80 patients a year [unpublished data]. Migration 
has not increased anymore since 1994 and TB incidence rates have even shown a slight 
decline to a stable 1000 TB cases each year now. It appears the decreasing expertise of the 
health care professionals due to declining incidence rates indeed led to increased transfers 
to TB referral centers as was preluded in an article in 2002.1,2
In 2011 the Netherlands Scientific Board of Respiratory Disease and Tuberculosis Specialists 
(NVALT) adopted the idea of allocating a TB coordinator for each hospital. These 
coordinators will be responsible for all TB related matters in their hospital. By appointing 
TB coordinators, together with the official recognition by the NVALT of the four clinical TB 
consultants, we will probably be able to ensure the quality of TB diagnostics, treatment and 
hygiene in the hospitals in the coming era. 
To consolidate this idea, regular updates for TB coordinators, as organized in 2011 and 2012 
as a master course at the Erasmus Medical Centre, Rotterdam, should be sustained by 
the NVALT. Firstly, TB coordinators will acquire more knowledge of TB and will be trained 
in hospital tuberculosis hygiene measures (chapter 2 and 5). Secondly, the role in latent 
TB infection (LTBI) screening before starting anti-TNF α blocking agents will be discussed 
(chapter 3). Thirdly, updated treatment guidelines are to be discussed, if available. Finally 
their important role in data collection for the National Tuberculosis Registry (NTR), a means 
of surveillance, will be emphasized (chapter 4). During the courses TB coordinators get 
familiar with the clinical TB consultants which will help to consult one of them in case of 
complex TB (chapter 2). All these measures are necessary to preserve TB knowledge and 
experience of respiratory diseases specialists at a national level (chapter 2, 3, 4, 5).
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Drug resistant TB in the European Region
With the interdisciplinary approach to complex and drug resistant TB, Dekkerswald had 
excellent treatment outcomes.3  Contrary to this, the overall treatment success in the 
European Union and European Economic Area (EU/EEA) is currently the lowest in the world 
(67%).4 This is caused by less favorable treatment outcomes in some subregions of the EU/
EEA which are responsible for 86% of all TB cases and 98% of MDR-TB cases of the EU/EEA.5 
A considerable number of these countries form part of the European Union, which allows its 
members free travel - to and from - within its borders.
Especially drug-resistant TB is now posing a real challenge to weak public health care 
systems of mainly former Soviet Union countries and TB is becoming a public health menace 
again in Europe. Problems of therapy errors, nonadherence, pharmacokinetic variability and 
most important nosocomial infections are leading continuously to acquiring drug resistance 
in these subregions. The fight against multi- and extensively drug resistant (MDR/XDR) TB in 
these EU/EEA subregions should become a priority effort.6
Excellent recent initiatives ultimately rely on political readiness to act. In Romania, for 
instance, the allocated budget of 23 million Euros for the next four years is supposed to 
ensure that at least 80% of estimated cases in Romania are diagnosed and treated. Yet 
the entire budget may be spent on a health system upgrade to start with, since treatment 
expenses only for their MDR TB population are much higher.5,7-8 
Drugs cost 2000-6000 Euros per MDR TB patient, and estimated total costs for treatment 
in Romania are 50.000 Euros/ patient, as health care will probably not be as costly as in 
Western Europe.6 Treating 1300 drug resistant TB cases costs Romania at least 65 million 
Euros a year. Apart from this financial investment, 30 physicians with MDR TB expertise are 
required based on a minimum 6 days direct patient contact a year. 
High incidence countries should be offered to transfer drug resistant TB patients to 
countries with a low incidence. By “exporting” these cases, the troubled countries will have 
the time and the finances to strengthen and eventually rebuild their health care systems to 
be able to detect and treat patients in the near future according to the recently published 
EU/EEA standards of TB care.9  Training of doctors and nurses at European standards of 
care with exchange programs may take place at the same time. Especially in case of this 
fastidious disease, this is to provide a moral boost for the health care workers and it will 
lower stigma around drug resistant TB as MDR and XDR TB in these countries generally 
means developing chronic TB or dying. Changing stigma will help patients to come in 
an earlier phase of the disease, will prevent transmissions and will improve treatment 
adherence. Most important, it will give the institutions time to fortify their health care 
systems. Inability to implement the above measures will further increase the problem, 
making it practically insolvable.8-9 
For low incidence countries such as The Netherlands this policy will ensure maintenance 
of familiarity to the various facets of TB (chapter 2) and will also facilitate European TB 
research at high standards.10 A facilitating condition for this plan is that referral TB centers 
have effective and prudent administrative and personal protection measures in place.3-4 
Secondly, negative-pressure ventilation rooms are available.4 Finally, the centers are used 
to language barriers as the major part of TB populations in most low incidence countries are 
immigrants.3 
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Latent tuberculosis infections
Currently, multiple indications for biologic agents – particularly for anti-TNF α agents- are 
under investigation. As blockage of TNF α induces a higher risk of reactivation of TB, 
screening for LTBI becomes more and more important (chapter 3).11-12  Similarly,  in other 
parts of the world, especially where HIV is more prevalent, detection of TB latency is 
becoming increasingly important as recent studies showed again that isoniazid preventive 
therapy reduces the risk of tuberculosis or death by 44-58%, mainly in patients with 
positive TST results.13-14  For these purposes we need a gold standard for LTBI diagnosis. 
Both tuberculin skin testing and interferon gamma release assays (IGRA) have limitations 
detecting LTBI.12,15-18  Furthermore, a positive TST or IGRA, cannot predict reactivation. Future 
research should focus on predictive tests for TB reactivation. 
On the other hand, updated national and European guidelines of LTBI screening in relation 
to the use of anti-TNF α blocking agents need to be evaluated meticulously  in the coming 
years. To distinguish which screening test has the best positive predictive value and which 
is the best treatment regimen, a multi-centre and -country study is needed. A large amount 
of patients using biologic agents are required to study method and outcome of screening, 
prophylactic treatment prescribed, treatment adherence and reactivation of TB during the 
use of biologic agents. Local hospital TB coordinators and/or research nurses may have a 
central role in data collection and follow up in such a study. 
Microbiology of M. bovis
As was shown in our M. bovis study (chapter 3), 17% of all patients did not receive treatment 
in accordance with international guidelines. This was accounted for by the treating 
physicians' unawareness of the fact that M. bovis is always resistant to pyrazinamide. 
A delay in susceptibility testing (DST) of M. bovis, explained by the slow growth of this 
subspecies on Löwenstein Jensen medium, ultimately led to incorrect therapy schemes. The 
majority of the patients in our study were elderly native Dutch individuals in whom we often 
fear increased toxicity or leave ethambutol from the start considering the possibility for 
drug resistant TB negligible. 
In a recent epidemiological study conducted in England, primary resistance in M. bovis 
was found.19  Studying our data again we also observed that six percent of our cases were 
resistant to isoniazid, two were MDR cases and two patients had a poly resistance (isoniazid 
and streptomycin). All of them occurred in immigrants from less affluent countries.
There are several future means to improve the diagnosis and treatment of M. bovis 
infections (chapter 3). First, we need to study the reason of slow growth of M. bovis on 
conventional media and how to accelerate this process. Second, laboratory policy should 
be steered towards providing preliminary DST results from molecular studies in case of M. 
bovis. Third, TB coordinators ought to be educated to change treatment schemes when 
M. bovis is encountered. More specifically, clinicians have to stop using pyrazinamide 
and prolong treatment to nine months. In this way providing preliminary molecular drug 
susceptibility tests and education will prevent suboptimal treatment and acquired drug 
resistance in case of isoniazide resistance, especially in case of drug toxicities.
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Active case finding
Tuberculosis case detection rates still remains low in large parts of the world. With 
the emphasis on passive case finding strategies, as propagated by the World Health 
Organization (WHO) for a long time, we will continue to underestimate the burden of the 
disease. This urges for a change (chapter 4).4,20-21
Active case finding in school children, teachers and army recruits, has been employed in 
The Netherlands from the beginning of the previous century and was abandoned around 
the eighties. Since 1970 active case finding of immigrants from Turkey and Morocco with 
chest X-ray (CXR) was employed again. The extension to high risk groups, with tuberculin 
skin testing (TST) and CXR, has been adopted since 1995 in The Netherlands. To distinguish 
between the exact effects of active case finding and the improved socio-economic welfare 
along with effective drug treatment remains difficult. 
We have a well functioning TB control system and excellent treatment success rates.22  It 
speaks for itself that our country provides many ingredients for success although studies 
from remote areas in Africa also show that active case finding is possible and worthwhile.22-
26 Referring to The Lancet, its article ‘Time to act’ highlights the inappropriateness of the 
ongoing debate on cost (in)effectiveness of active case finding strategies.4,24,27 
Active case finding will allow for more early diagnoses at the expense of bacteriological 
confirmations. However, it boosts case detection rate and early treatments, preventing 
further transmissions, morbidity and mortality.21  Obviously the extent of drug resistant 
mycobacterial strains in high incidence countries is scaled differently from ours and there is 
a risk of misdiagnosis28 and insufficient treatment. But the majority of these countries still 
not have any possibility to determine the strain or perform DST. Upscaling the laboratories 
worldwide is very necessary29 but time consuming and in the meantime we should try to 
diminish the expanding problem and try to reach the most vulnerable patient groups. 
Active case finding relies on certain conditions. First of all enlargement of public awareness 
and education level of latent and active TB. Nowadays, a large part of the world has access 
to internet via computers and smartphones. 
Via these media, advertisers constantly exhaust the public with commercials and it resulted 
quite easy to organize a wild but spontaneous “sweet-sixteen birthday party”, in a remote 
Dutch village via Facebook recently. To reach the world, we need these popular media 
to get to people even in the remotest areas.  I hereby announce an award for the most 
creative spreading initiative!
Another important issue is changing the current worldwide policy of 6 months isoniazid 
prophylactic treatment to an equally effective 3 month regimen of both isoniazid and 
rifampicin.15-16,30-31  Shortened and amplified schemes in fixed dose combinations may solve 
important problems encountered with current prophylaxis, i.e. problems of adherence, 
isoniazid resistancy and acquiring drug resistance in case of treating active TB with mono-
therapy.  To screen contacts and risk groups, countries need solid public TB health care 
systems, ideally integrated into their HIV programs, and sufficient personnel. 
The currently available trucks equipped as ‘mobile-one-stop-shops’ for TB and HIV diagnosis 
are excellent initiatives enormously facilitating the implementation of active case finding in 
remote areas.20,24-26,32-33
TDM at large scale
In an in vitro model, it was recently shown that treatment adherence, is not predicting 
treatment outcome, as was thought frequently. From this hollow-fiber model we 
understand now that pharmacokinetic (PK) variability is crucial in acquiring drug resistance 
and treatment failure.34-35  In our study among TB patients in Dutch referral centers we 
observed large interindividual variability in pharmacokinetics (chapter 6). 
Furthermore, we  observed low drug exposures in patients with treatment failures 
and relapse TB (chapter 7).36  Increasing the dosages of first line TB drugs led to culture 
conversions, clinical improvement and no further relapses. Higher dosages did not lead to 
the increase of adverse effects. For this reason, TDM should be central in patient care and 
drug trials. Very few centers in the world are currently applying TDM in patient care. To 
implement TDM at large scale, patient burden, especially for children, and cost is considered 
too high. The familiarity with the indication and usefulness of TDM of physicians in clinical 
TB care is not very large. 
The first condition to implement TDM at large scale is the availability of accurate and 
precise analytical methods for bio-analysis of TB drugs. These methods should be validated 
and every assay should be accompanied by measurement of internal quality control (QC) 
samples with known drug concentrations. Furthermore an external (inter-laboratory) QC 
program, or proficiency testing program, should be available. Pharmacists involved in the 
two Dutch TB referral centers recently initiated such a program.37 The QC program sends 
samples to laboratories with blinded concentrations of TB drugs to analyze. The program 
alerts the laboratory in case of detected errors to enable them to improve their assays or 
procedures if applicable.
Secondly, we should study simpler, less invasive and less time consuming methods for TDM. 
Intensive venous sampling (chapter 6 and 8) goes along with a high patient burden and high 
costs due to labor intensive sample extraction and processing. In our patient care service, 
we sample at 2h, 4h and 6h post dose to ‘catch’ the peak plasma concentrations (Cmax) of TB 
drugs. Reference values for these peak plasma concentrations are available.38 
This strategy is also applied in TB care in the USA.38 An alternative strategy is to estimate 
the total exposure of TB drugs, the area under the concentration versus time curve (AUC), 
rather than Cmax.  In (chapter 6) we have derived the optimal sampling times that enable 
estimation of the AUC for some TB drugs. This resulted in limited sampling formulas with 
fixed sampling times. Alternatively, individual exposure can be estimated by combining 
measured concentrations at any (non-fixed) sampling time point with population 
pharmacokinetic parameters. Therefore, maximum a posteriori probability Bayesian fitting 
should be used.39 
Less invasive methods imply less patient burden and may be less labor intensive.  Especially 
for children, it would be advantageous to use saliva instead of plasma, as saliva can be 
collected by non-invasive techniques. Until now, only few studies have evaluated the 
correlation between salivary and plasma concentrations of TB drugs,40-41 but more studies 
are currently conducted . The dried blood spot (DBS) technique, with blood from a simple 
finger prick on filter paper, already an established method for measurement of peak levels 
and exposure of several drugs (such as phenytoin, tobramycin, carbamazepine), seems 
promising in TB. 
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In the mentioned examples  a cost-benefit discussion was never evoked, unlike in TB.42 
With ease, DBS recently found its way to patient care in home based intravenous antibiotics 
treatments with measurements of tobramycin levels in our Cystic Fibrosis Centre. The 
patients send the DBS from their homes to the hospital per postal services. 
The first laboratory studies in DBS of first- and second-line TB drugs were recently 
published.43-45 The accuracy of the method still may be affected by many factors, including 
paper type, blood characteristics, analysis method and the characteristics of drugs 
themselves. Clinical validation of this method is required for the interpretation of DBS 
concentrations versus serum or plasma concentrations. Pharmacogenetics can also be 
evaluated via this technique. DBS, which seems promising to perform TDM in TB treatment 
at large scale in less equipped areas, is currently awaiting validation studies.
TDM practice will be continued to individualize TB treatment in our TB referral centre 
(chapter 7). PK studies in fixed dose regimens will be evaluated in the near future in 
Dekkerswald and we will continue to perform PK studies abroad ( in Tanzania and South 
Africa) as conducted in the last few years from our centre. A pharmacokinetic study, 
planned to be undertaken in Paraguayan native Indians, will compare conventional two time 
points venous sampling with DBS to evaluate exposure. Although no PK data are available 
from this geographic region, we do have data from Asia, Africa and Europe. An earlier study 
in Paraguay has shown that most native Indians from Paraguay are superstitious about 
blood extractions and therefore are more difficult to include in trials.46 We will evaluate the 
correlation of the dried blood spots with conventional sampling, the exposure of native 
Paraguayan Indians to first line TB drugs and the patient burden. Likewise, children will be 
studied in the same hospital in Paraguay.
NTM research
The important interaction between rifampicin and clarithromycin leading to very low 
serum concentrations of clarithromycin demands re-evaluation of dosing schemes in NTM 
infections (chapter 8). Low plasma concentrations in TB treatment can lead to acquired 
drug resistance as was shown with the hollow-fiber model.34-35,42 In a study testing drug 
susceptibility of NTM isolates, acquired clarithromycin resistance occurred in 22/237 (9%) 
of cases with serial isolates. It either occurred during therapy or was discovered when the 
patient relapsed.47 Outcome of treatment for NTM is often disappointing. The interaction of 
rifampicin with macrolides is one of the possible reasons. 
It is not clear whether this interaction plays a role in the observed discrepancies of 
the influence of macrolides on the outcome of treatment between American studies 
and the studies from the British Thoracic Society in 2008.48-49  Increasing the dose of 
clarithromycin to compensate for the effect of rifampicin and to improve clarithromycin 
plasma concentrations should be evaluated in PK studies. The use of rifabutin instead of 
rifampicin might overcome this important interaction and a study is needed to evaluate the 
pharmacokinetics and tolerability in an HIV negative population. Azithromycin, a newer and 
better tolerated macrolide in a once-daily dose, is increasingly used in NTM treatment. In 
our study the effect of rifampicin on exposure to this macrolide was less pronounced. 
The efficacy of azithromycin has never been studied in a randomized trial for NTM 
infections. For a randomized controlled trial that compares the efficacy of clarithromycin 
versus azithromycin or a treatment scheme without macrolides, large homogenous patient 
groups need to be studied to prove superiority. To include a large homogenous group of 
patients with NTM disease is very challenging. Hollow-fiber models might serve as surrogate 
markers for response and proof of concept. The in vivo response to treatment in clinical 
trials may prove to be a lot more capricious however.
The current thesis provides building blocks to fortify the defense against TB. The foundation 
is formed by practical recommendations for future Dutch (hospital) TB care, a possible 
short term solution for the increasing problems with drug resistant TB in the EU/EEA region 
and a call for adaption of active case finding policies for better global TB control. These 
recommendations evolved from epidemiologic, diagnostic and pharmacological studies in 
our relatively small scale TB population. Yet especially pharmacological PK studies do not 
necessarily need large numbers and can be done in centers as ours. 
The currently conducted pharmacological (international) studies are important and 
innovative and may lead to changes in TB treatment and good clinical practice. Intervention 
studies in TB treatment, as for example the phase II High Dosage of Rifampicin Study 
from our centre performed in Moshi, Tanzania, are more pioneering and might become 
revolutionary in the near future.  Promising building blocks will be added to the foundation 
in the years to come- but the cornerstones for improving TB care have been laid.
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Achtergrond
Tuberculose (TB) teistert de mens al sinds de oudheid. Tekenen van deze ziekte worden 
gezien in graven van de farao’s, waar mummies tekenen vertonen van "werveltuberculose" 
met invaliderende en mutilerende krommingen in de wervelkolom. Hoewel we sinds de 
jaren zestig van de vorige eeuw over een effectieve behandeling voor TB beschikken, is het 
geen enkel land in de wereld tot nu toe gelukt deze ziekte helemaal uit te roeien.
TB wordt veroorzaakt door bacteriën van het Mycobacterium tuberculosis complex. Dit 
complex bestaat uit verschillende subtypes die allen de ziekte TB veroorzaken. Hoewel 
de wereldwijde incidentie en sterfte nog steeds afneemt, worden ieder jaar nog zo’n 9 
miljoen nieuwe TB patiënten geregistreerd met jaarlijks  1,4 miljoen doden. De incidentie 
van TB varieert enorm van 5 : 100.000 in Scandinavische, sommige Europese landen en de 
Verenigde Staten tot meer dan 300 : 100.000 in Zuid-Afrika.
Non-tuberculeuze mycobacteriën (NTM) worden de laatste jaren steeds vaker herkend 
als echte ziekteverwekkers. Ze zijn de verwekkers  van een ziekte die lijkt op TB met als 
verschil dat het een niet-overdraagbare ziekte betreft en er nu sprake is van een stijgende 
incidentie, vooral in landen waar de TB incidentie afneemt. Deze stijging wordt veroorzaakt 
door verschillende factoren, waaronder verbeterde detectiemethoden, een groter 
bewustzijn van artsen, de toegenomen leeftijd van patiënten, de toegenomen incidentie 
van COPD, het wijdverbreide gebruik van immuunmodulerende geneesmiddelen en 
mogelijk een toegenomen blootstelling van het milieu aan deze bacteriën.
Dit proefschrift geeft een overzicht van epidemiologische, diagnostische en 
farmacologische studies vanuit Dekkerswald, een tertiair TB referentiecentrum voor 
patiënten met TB en NTM-infecties. De studies in dit proefschrift gaan over mycobacteriële 
infecties; over TB en  één hoofdstuk over NTM-infecties.
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Introductie
De inleiding van het proefschrift (hoofdstuk 1) geeft een overzicht van de historie, de 
ontstaanswijze, de diagnosestelling en behandeling van TB en NTM. Vervolgens zoomen 
we in  op de farmacokinetiek van de TB behandeling om te kunnen begrijpen dat de TB 
behandeling vele mogelijke bedreigingen kent voor het falen van de therapie, het optreden 
van recidieven en het verwerven van resistentie tegen geneesmiddelen. Tot slot wordt een 
overzicht gegeven van de Nederlandse TB bestrijding, waarin de rol van de klinische TB 
consulenten  en de TB referentiecentra wordt verduidelijkt.
Epidemiologische studies
Dit proefschrift begint met een beschrijvende studie (hoofdstuk 2) van TB patiënten in 
Dekkerswald in de periode 2000-2005. Het geeft inzicht in de demografische, klinische en 
sociale gegevens van de populatie van ons centrum. Een totaal van 166 patiënten, met 37 
verschillende nationaliteiten, werden geanalyseerd. In 98% van de gevallen was er sprake 
van een tertiaire verwijzing. De meeste patiënten (68%) werden verwezen om klinische 
redenen. 32% werd verwezen om sociale redenen, zoals dakloosheid, drugsmisbruik en 
psychiatrische toestandsbeelden. Ernstige levertoxiciteit was de meest voorkomende 
klinische reden voor verwijzing, gevolgd door een trage respons op de behandeling, de 
noodzaak tot chirurgisch ingrijpen, een combinatie van HIV en TB, resistentie tegen 1e 
lijnsgeneesmiddelen en de noodzaak tot isolatie van de patiënt. 94% van de resistente 
stammen werden geïsoleerd bij patiënten van buitenlandse afkomst. Toxiciteit en 
bijwerkingen leidden vaak tot veranderingen in de behandeling (40%). Tien procent van de 
patiënten was seropositief voor HIV en velen van hen (82%) hadden last van bijwerkingen 
van de behandeling, vooral levertoxiciteit. Extrapulmonale TB werd significant vaker 
gediagnosticeerd in de buitenlandse patiëntengroep. De mediane opnameduur voor de 
totale populatie was 10,1 weken. Deze liet geen verschillen zien tussen klinische- of sociale 
redenen voor opname of land van herkomst. Vijfentachtig procent van de patiënten 
voltooide de behandeling, zes procent werden uit het oog verloren bij follow-up en de 
mortaliteit was vijf procent. We concludeerden dat de TB populatie van Dekkerswald een 
uitstekend slagingspercentage van de behandeling heeft, ondanks de complexiteit van de 
ziektebeelden en de diversiteit van deze groep patiënten. Gezien de toename van het aantal 
opnames in Dekkerswald sinds 2005 lijken we te voldoen aan een behoefte in Nederland. 
Na het beschikbaar komen van een effectieve behandeling vanaf de zestiger jaren waren 
sanatoria al gauw niet meer nodig op grote schaal. TB zal echter nooit volledig verdwijnen 
en het is daarom van belang dat er enkele gespecialiseerde instellingen actief blijven om 
deze specifieke expertise te behouden en zelfs verder uit te bouwen op het gebied van 
resistente TB. Het volgende hoofdstuk (hoofdstuk 3) is een retrospectieve analyse van 
alle Mycobacterium bovis TB in Nederland van 1993-2007. We startte deze analyse nadat 
we kort na elkaar drie patiënten in Dekkerswald opgenomen hadden met M. bovis TB. We 
analyseerden de gegevens van 231 M. bovis TB patiënten en bestudeerden klinische- en 
demografische gegevens, behandelschema’s, behandeluitkomsten en risicofactoren. De 
ziekte was voornamelijk extrapulmonaal van aard (n = 136; 59%). Hoewel 95 patiënten een 
pulmonale bovis TB hadden traden er geen besmettingen op van persoon tot persoon, 
zoals bleek uit structurele DNA-analyse. Vrouwen hadden meer kans een lymfeklier TB te 
ontwikkelen (p <0,0001), mannen ontwikkelden vaker pulmonale ziekte (p <0,0001). De 
diagnose werd juist gesteld, maar de vertraging in de determinatie van de stam leidde 
frequent tot inadequate behandeling (17% van de gevallen). Het aantal sterfgevallen door M. 
bovis (5%) was hoger dan die voor M. tuberculosis (2%). Uit deze studie werd geconcludeerd 
dat de prevalentie van M. bovis ziekte in Nederland (1,4%) vergelijkbaar is met die in andere 
landen waar ook controleprogramma's voor rundertuberculose werden ingesteld. Sexe 
verschillen in klinische kenmerken en sterftecijfers werden gevonden in ons cohort van 
patiënten. De ziekte wordt heden ten dage vooral aangetroffen bij oudere autochtone 
Nederlanders (60%) en immigranten uit Marokko (23%). Anti-TNF-α behandeling is een 
recente oorzaak van endogene reactiveringen waarbij  M. bovis TB trager reactiveert dan M. 
tuberculosis.
Diagnostische onderzoeken
In hoofdstuk 4 werd de reden onderzocht van een daling van de kweek bevestigde TB 
diagnoses (72 % in 2007 tot 66% in 2009) in Nederland. Een Mycobacteriële kweek is de 
gouden standaard voor de diagnose TB en is nodig om de gevoeligheid van de bacterie voor 
de medicatie te bepalen. In deze studie hebben we studie gemaakt van de validiteit van de 
registratie van kweekresultaten in het Nederlands Tuberculose Register (NTR). Daarnaast 
hebben we de patiënten karakteristieken van de niet met kweek bevestigde TB diagnoses 
bestudeerd en hebben we gekeken naar de juistheid van de diagnoses. We bestudeerden 
de gegevens van patiëntendossiers van niet kweek bevestigde TB patiënten in de dossiers 
bij de GGD-tuberculosebestrijding. In het geval van ontbrekende informatie zochten we 
contact met de behandelaar van het ziekenhuis of het laboratorium. De resultaten werden 
vergeleken met de gegevens van het NTR. Volgens de criteria van  het Europees Centrum 
voor ziektepreventie en ziektebestrijding (ECDC) werden alle niet met kweek bevestigde 
TB gevallen ingedeeld als 'bevestigd', 'waarschijnlijk', 'mogelijk' en 'geen' TB. Volgens de 
ECDC classificatie werd uiteindelijk 56% van de 516 onderzochte patiënten geclassificeerd als 
‘mogelijk TB’, 35% als 'waarschijnlijk TB', en slechts 6,8% als 'bevestigde TB'. Van de niet met 
kweek bevestigde gevallen was 36% een vroege diagnose in de screening van risicogroepen 
(of contact onderzoek). Deze vroege diagnoses werden voornamelijk gesteld door artsen 
van de GGD-tuberculosebestrijding en gaan soms ten koste van kweek bevestiging. Een 
totaal van 37% werd niet geheel correct geregistreerd in het NTR, maar slechts 2,5% was 
uiteindelijk kweek positief. Specialisten in het ziekenhuis moeten zich bewust worden 
van het belang van hun bijdrage aan de Nederlandse TB registratie voor surveillance. Aan 
de andere kant kan extra scholing van de GGD’en de kwaliteit van de registratie van het 
NTR nog verder verbeteren. Een andere studie die betrekking heeft op de diagnostiek 
(hoofdstuk 5) geeft inzicht in de patient karakteristieken en de tijd tot aan diagnose van 
spinale TB in Nederland van 2000-2011. We voerden een beschrijvende, retrospectieve studie 
uit met gegevens van het NTR en patiëntendossiers van de GGD tuberculosebestrijding. We 
onderzochten 274 patienten dossiers en vonden een mediaan diagnostisch traject van vijf 
maanden (variatie 0 tot 76 maanden). Geslacht én leeftijdsgroepen werden geassocieerd 
met significante verschillen in diagnostische vertraging (resp. man 4,5 maanden vs. vrouw 
5,5 maanden, p = 0,004 en 0 tot 34 jaar 4,5 maanden, 35-64 jaar 5,75 maanden en> 65 
jaar 5,0 maanden, p = 0,006) . Opvallend genoeg werd er geen verschil waargenomen 
tussen de oorsprong van patiënten, patiënten die  risicofactoren voor TB hadden of zich 
presenteerden met neurologische symptomen. Typische TB symptomen bij presentatie 
(pijn in de rug, nachtzweten en gewichtsverlies) leidden verrassend genoeg tot een sterk 
135
10
Chapter 10
136
patiënten die  risicofactoren voor TB hadden of zich presenteerden met neurologische 
symptomen. Typische TB symptomen bij presentatie (pijn in de rug, nachtzweten en 
gewichtsverlies) leidden verrassend genoeg tot een sterk toegenomen doctors’ delay 
(typische symptomen 4,0 versus geen typische symptomen 2,0 maanden, p = 0,05). Om TB 
hoog in de differentiaal diagnose van dokters te houden moet bijscholing steeds opnieuw 
worden aangeboden aan huisartsen en klinisch specialisten. 
Farmacokinetiek studies
Om de resultaten van behandeling te optimaliseren is een beter begrip van de 
farmacokinetiek van TB medicatie noodzakelijk. Informatie over de precieze blootstelling 
aan een geneesmiddel lijkt van cruciaal belang om mechanismen als therapie-falen, 
het optreden van recidieven en de verwerving van resistentie beter te kunnen 
begrijpen. In plaats van het toepassen van alleen vaste doseerschema, kunnen de 
geneesmiddelconcentraties worden gemeten en kan de dosis op basis van de vastgestelde 
concentratie (Therapeutic Drug Monitoring, TDM) worden geïndividualiseerd. Echter, 
omdat de relatie van de totale blootstelling aan het geneesmiddel en het effect op de 
uitkomt van de behandeling nog niet goed bekend is, wordt TDM slechts op beperkte 
schaal toegepast. Bovendien zijn de belasting voor patiënt, de kosten en de hoeveelheid tijd 
gemoeid met het meten van de bloedspiegels ook nog belemmerende factoren. Dit geldt 
voor TDM binnen de patiëntenzorg als ook bij de evaluatie van nieuwe TB medicijnen in 
onderzoeksverband.
Hoofdstuk 6 is een beschrijvende farmacokinetische studie van de anti-TB medicijnen 
binnen een serie van opgenomen patiënten uit de twee Nederlandse TB referentiecentra. 
Eenenveertig kweek bevestigde TB patiënten participeerden in de studie. Bij hen werd 
een 24-uurs farmacokinetische curve afgenomen na het bereiken van ‘steady state’. Grote 
inter-individuele variatie in de farmacokinetiek van de geneesmiddelen werd aangetoond 
en 32% bereikte niet de minimale referentie plasma piek concentratie voor rifampicine. De 
reeds eerder beschreven interactie van rifampicine en moxifloxacine werd ook in deze 
studie gevonden. We voerden een lineaire regressie analyse uit om te kunnen adviseren 
over de tijdstippen van bloedafname na het innemen van het medicijn die het beste 
correleren met de totale blootstelling aan het geneesmiddel. De tijdstippen 1, 4 en 6 uur 
na inname waren de beste tijdstippen. Beperking van het aantal bloedafnames van 11 naar 
3 om de totale blootstelling te kunnen bepalen, zal TDM binnen routine patiëntenzorg of 
onderzoek vergemakkelijken. In het volgende hoofdstuk (hoofdstuk 7) bieden wij inzicht 
in de huidige TDM praktijk van Dekkerswald. TDM wordt gebruikt bij patiënten met een 
normaal gevoelige TB waarbij abnormale TB concentraties van het geneesmiddel worden 
vermoed (bijvoorbeeld in het geval van HIV-infectie, diabetes, gastro-intestinale chirurgie 
in het verleden, ondervoeding, of nier- of leverinsufficiëntie), wanneer er sprake is van 
een vertraagde sputumkweek conversie ( dat wil zeggen na meer dan acht weken van 
de behandeling), en in het geval van een recidief tuberculose. We presenteren een korte 
klinische samenvatting van vier  TB patiënten met een recidief TB om daarmee de methode 
van TDM en de waarde van geïndividualiseerde therapiedosering te illustreren.
In de vier gevallen resulteerde verhoogde doses van de eerste lijn  TB middelen, in het 
bijzonder rifampicine, in adequate plasma piekconcentraties en uiteindelijk een goede 
klinische respons op de behandeling. Er traden geen bijwerkingen op. Zoals reeds eerder 
vermeld is TB de belangrijkste pijler van dit proefschrift, maar NTM infecties zijn een 
entiteit die niet langer kunnen worden genegeerd. Last but not least, verschuiven we 
ons focus daarom van TB naar een (farmacokinetische) studie bij NTM in hoofdstuk 8 
van dit proefschrift. In het algemeen zijn behandelresultaten voor NTM-infecties slecht, 
zelfs wanneer de aanbevolen doseringen van geneesmiddelen worden toegepast. In 
NTM populaties zijn zeer weinig farmacokinetiek studies uitgevoerd. Wij voerden een 
uitgebreide PK studie uit en hebben de plasma farmacokinetiek beoordeeld van rifampicine, 
ethambutol, claritromycine, azitromycine, isoniazide en moxifloxacine en de actieve 
metabolieten in een reeks van 14 patiënten met klinisch relevante NTM longziekten. We 
vergeleken onze resultaten met de beschikbare literatuurgegevens.
We leerden dat blootstelling aan claritromycine in combinatie met rifampicine zeer laag 
was en de gemiddelde medicijn-metaboliet ratios ook laag waren. Dit komt waarschijnlijk 
door de inductie van metabole enzymen door rifampicine. De totale blootstelling aan 
rifampicine was relatief hoog in vergelijking tot een TB populatie. Alle patiënten hadden 
een rifampicine Cmax waarde boven de referentiewaarden van 8 mg / L.  Ook alle ethambutol 
Cmax-waarden lagen binnen de referentiewaarden (2 en 6 mg / L). Uit deze studie hebben we 
geconcludeerd dat de relevante interactie tussen claritromycine en rifampicine vraagt  om 
een  heroverweging van de doseringsstrategieën in NTM longziekten, omdat suboptimale 
blootstelling aan geneesmiddelen zouden kunnen bijdragen aan de matige respons op 
therapie. Hoofdstuk 9 geeft een samenvatting van de studies en de implicaties voor verdere 
patiëntenzorg en onderzoek. Uit de tabel in hoofdstuk 9 worden de implicaties van onze 
studies voor toekomstige TB zorg en preventie verduidelijkt. De zorg voor TB patiënten in 
een welvarend land als Nederland biedt alle noodzakelijke middelen. Daarentegen blijft TB 
nog steeds de onoverwinnelijke ziekte die het al is sinds de oudheid. TB referentiecentra en 
klinische TB consulenten voorzien op dit moment in een behoefte in Nederland en zullen 
nodig blijven in de toekomst. Ziekenhuis TB coördinatoren zullen een belangrijke rol gaan 
spelen in de toekomst. Hun kennis en expertise moet gegarandeerd zijn daar ze de spin 
in het web zullen zijn in screening, preventie en kwaliteitsbewaking van de TB zorg in de 
ziekenhuizen. Het TB surveillance register zal nog verder kunnen verbeteren door een meer 
actieve betrokkenheid van specialisten in het ziekenhuis. 
De kennis van de Nederlandse TB centra zouden gebruikt kunnen worden om 
probleemgebieden binnen Europese regio (EU/EEA) te gaan helpen bij de behandeling van 
grote aantallen patiënten met resistente TB.  Anderzijds hebben onze studies ook voer 
voor verder tuberculose onderzoek gegeven. Er blijft een grote behoefte bestaan aan een 
gouden standaard voor latente TB infecties (LTBI). Ook is het belangrijk de nationale en 
Europese richtlijnen voor screening en behandeling van patiënten met LTBI in de toekomst 
te evalueren. Voor de directe patiëntenzorg is het versnellen van de groei van  M.bovis TB 
stammen voor determinatie en gevoeligheidsbepalingen belangrijk. 
Tot slot, de huidige manier van therapeutic drug monitoring, de spiegel bepalingen van 
TB medicijnen,  rechtvaardigt eenvoudigere, minder invasieve en minder tijdrovende 
methoden.  Dit proefschrift heeft een aantal bouwstenen in de strijd tegen TB 
opgeleverd; praktische aanbevelingen die volgen uit epidemiologische, diagnostische 
en farmacokinetiek studies in een Nederlandse TB populatie. Nieuwe, minder invasieve 
technieken in de bloedspiegelbepalingen van TB medicatie kunnen gaan leiden tot 
veranderingen in onze huidige TB behandeling en ‘ good clinical practice’.  Van de kennis die 
we hebben opgedaan kunnen wetenschappers die zich bezighouden met medicijnstudies in 
de toekomst profiteren.
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